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Background: The ARTISTIC (A Randomised Trial In Screening To Improve Cytology) trial originally reported
after two rounds of primary cervical screening with human papillomavirus (HPV). Extended follow-up of
the randomised trial cohort through a third round could provide valuable insight into the duration of
protection of a negative HPV test, which could allow extended screening intervals. If HPV primary
screening is to be considered in the national programme, then determining its cost-effectiveness is key,
and a detailed economic analysis using ARTISTIC data is needed.
Aims/objectives: (1) To determine the round 3 and cumulative rates of cervical intraepithelial neoplasia
(CIN) grade 2 or worse (2+) and CIN grade 3 or worse (CIN3+) between the revealed and concealed arms
of ARTISTIC after three screening rounds over 6 years. (2) To compare the cumulative incidence of CIN2+
over three screening rounds following negative screening cytology with that following negative baseline
HPV. (3) To determine whether or not HPV screening could safely extend the screening interval from 3 to
6 years. (4) To study the potential clinical utility of an increased cut-off of 2 relative light unit/mean control
(RLU/Co) for Hybrid Capture 2 (HC2) and HPV genotyping in primary cervical screening. (5) To determine
the potential impact of HPV vaccination with Cervarix™ in terms of preventing abnormal cytology and
CIN2+. (6) To determine the cost-effectiveness of HPV primary screening compared with current practice
using cervical cytology in England.
Design: The ARTISTIC study cohort was recalled for a third round of screening 3 years after round 2 and
6 years following their enrolment to the study. Both arms of the original trial used a single protocol during
round 3.
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Setting: ARTISTIC study cohort undergoing cervical screening in primary care in Greater Manchester, UK.
Participants: Between July 2007 and September 2009, 8873 women participated in round 3; 6337 had
been screened in round 2 and 2536 had not been screened since round 1.
Interventions: All women underwent liquid-based cytology and HPV testing and genotyping. Colposcopy
was offered to women with moderate dyskaryosis or worse and with HPV-positive mild dyskaryosis/
borderline changes. Women with negative cytology or HPV-negative mild dyskaryosis/borderline changes
were returned to routine recall.
Main outcome measures: Principal outcomes were cumulative rates of CIN2+ over three screening
rounds by cytology and HPV status at entry; HPV type speciﬁc rates of CIN2+; effect of age on outcomes
correlated with cytology and HPV status; comparison of HC2 cut-off RLU/Co of both 1 and 2; and
cost-effectiveness of HPV primary screening.
Results: The median duration of follow-up was 72.7 months in round 3. Over the three screening rounds,
there was no signiﬁcant difference in CIN2+ [odds ratio (OR): 1.06, 95% conﬁdence interval (CI) 0.89 to
1.26, p = 0.5)] or CIN3+ (OR: 0.90, 95% CI 0.72 to 1.14, p = 0.4) rates between the trial arms (revealed vs.
concealed). Overall, 16% of women were HC2 positive at entry, decreasing from 40% in women aged
20–24 years to around 7% in women aged over 50 years. Abnormal cytology rates at entry were 13% for
borderline+ and 2% for moderate+ cytology. Following positive cytology at entry, the cumulative rate of
CIN2+ was 20.5%, and was 20.1% following a HPV-positive result at baseline. The cumulative CIN2+ rate
for women who were HPV negative at baseline was only 0.87% (95% CI 0.70% to 1.06%) after three
rounds of screening, signiﬁcantly lower than that for women with negative cytology, which was 1.41%
(95% CI 1.19% to 1.65%). Women who were HPV negative at baseline had similar protection from CIN2+
after 6 years as women who were cytology negative at baseline after 3 years. Women who were HPV
positive/cytology negative at baseline had a cumulative CIN2+ rate at 6 years of 7.7%, signiﬁcantly higher
than that for women who were cytology positive/HPV negative (3.2%). Women who were HPV type 16
positive at baseline had a cumulative CIN2+ rate over three rounds of 43.6% compared with 20.1% for any
HPV-positive test. Using a HC2 cut-off of RLU/Co≥ 2 would maintain acceptable sensitivity and result in 16%
fewer HPV-positive results. Typing data suggested that around 55–60% of high-grade cytology and CIN2+,
but less than 25% of low-grade cytology, would be prevented by HPV vaccine given current rates
of coverage in the UK national programme. For the cost-effectiveness analysis, most of the primary HPV
strategies examined where HPV was used as the sole primary test were cost saving in both unvaccinated and
vaccinated cohorts under baseline cost assumptions, with a 7–18% reduction in annual screening-associated
costs in unvaccinated cohorts and a 9–22% reduction for vaccinated cohorts. Utilising partial genotyping at
the primary screening stage to identify women with HPV 16/18 and referring them to colposcopy was the
most effective strategy (barring co-testing, which is signiﬁcantly more costly than any other strategies
considered), resulting in 83 additional life-years per 100,000 women for unvaccinated women when
compared with current practice, and similar life-years saved compared with current practice for vaccinated
women. In unvaccinated cohorts, however, this genotyping strategy is predicted to result in a 20% increase
in the number of colposcopies performed in England, although in vaccinated cohorts the number of
colposcopy referrals was predicted to be lower than in current practice. For all strategies in which HPV is
used as the sole primary screening test, decreasing the follow-up interval for intermediate-risk women from
24 to 12 months increased the overall effectiveness of primary HPV screening. In exploratory analysis,
strategies for which cytology screening was retained until either age 30 or 35 years, and for which HPV
testing was used at older ages, were predicted to be of higher costs and intermediate effectiveness than
those associated with full implementation of primary HPV screening from age 25 years. However, this ﬁnding
should be interpreted with caution as it depends on assumptions made about screening behaviour and
compliance with recommendations at the ‘switch over’ point.
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Conclusions: HPV testing as an initial screen was signiﬁcantly more protective over three rounds (6 years)
than the current practice of cytology and the use of primary HPV screening could allow a safe lengthening
of the screening interval. A substantial decrease in high-grade cytology and CIN2+ can be expected as a
consequence of the HPV vaccination programme. A HC2 cut-off of 2RLU/Co instead of the manufacturer’s
recommended cut-off of 1 would be clinically beneﬁcial in terms of an optimal balance between sensitivity
and speciﬁcity. Modelled analysis predicts that primary HPV screening would be both more effective and
cost saving compared with current practice with cervical cytology for a number of potential strategies in
both unvaccinated and vaccinated cohorts. Compliance with surveillance and optimal management of
HPV-positive/cytology-negative women after primary HPV screening is of key importance. Limitations
of the economic investigation included the need to make assumptions around compliance with screening
attendance and follow-up for longer screening intervals in the future, assumptions regarding maintenance
of current uptake vaccination in the future, and assumptions regarding the stability of cost of HPV and
cytology tests in the future. Detailed sensitivity analysis across a range of possible assumptions was
conducted to address these issues. This study and the economic evaluation lend support to convert from
cytology to HPV-based screening. Future work should include researching (i) the attitudes of women who
test HPV positive/cytology negative, (ii) the value of complementary biomarkers and (iii) activities relevant
to primary HPV screening in unvaccinated and vaccinated populations from the point of view of
QALY assessment.
Study registration: Current Controlled Trials ISRCTN25417821.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 18, No. 23. See the NIHR Journals Library
programme website for further project information.
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FIGURE 55 Strategy 2, 12-monthly follow-up: Relative difference in the cost of
the strategy compared with current practice for each of the sensitivity analysis
assumptions are shown on the left-hand side as the black bars. Relative differences
in the life-years are shown on the right-hand side as the green bars. a, ‘Worst-case
scenario’ (with respect to HPV testing) assumed that cytology had higher sensitivity
to CIN2+ (79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best-case
scenario assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV testing
has a higher CIN2+ sensitivity rate (97.4%). b, Doubling the progression rate from
CIN3 to undetected FIGO1 resulted in a decrease in the incremental cost but an
increase in the incremental life-years saved 172
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in the life-years are shown on the right hand side as the green bars. a, ‘Worst-case
scenario’ (with respect to HPV testing) assumed that cytology had higher sensitivity
to CIN2+ (79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best-case
scenario assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV testing
has a higher CIN2+ sensitivity rate (97.4%). b, No further follow-up for women
not complying to colposcopy and follow-up referral would result an increase in
the incremental cost but a decrease in incremental life-years saved. c, Doubling the
progression rate from CIN3 to undetected FIGO1 resulted in a decrease in the
incremental cost but an increase in the incremental life-years saved 173
FIGURE 57 Strategy 1: Relative difference in the cost of the strategy compared
with current practice for each of the sensitivity analysis assumptions are shown
on the left-hand side as the black bars. Relative differences in the life-years
are shown on the right-hand side as the green bars. a, ‘Worst-case scenario’
(with respect to HPV testing) assumed that cytology had higher sensitivity to CIN2+
(79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best-case scenario
assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV testing has
a higher CIN2+ sensitivity rate (97.4%). b, Note that, although the graph shows
no decrease in life-years when cytology test sensitivity is increased and HPV test
sensitivity is simultaneously decreased, the strategy is actually less effective than
current practice (the strategy is predicted to have 0.001–0.002% fewer life-years
than current practice). c, Both doubling and halving the progression rate from CIN3
to undetected FIGO1 resulted in a decrease in the predicted incremental life-years 174
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the strategy compared with current practice for each of the sensitivity analysis
assumptions are shown on the left-hand side as the black bars. Relative differences
in the life-years are shown on the right-hand side as the green bars. a, ‘Worst-case
scenario’ (with respect to HPV testing) assumed that cytology had higher sensitivity
to CIN2+ (79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best case
scenario assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV
testing has a higher CIN2+ sensitivity rate (97.4%). b, Note that, although the
graph shows no decrease in life-years when cytology test sensitivity is increased
and HPV test sensitivity is simultaneously decreased, the strategy is actually less
effective than current practice (the strategy is predicted to have 0.001–0.002%
fewer life-years than current practice). c, Both lower and higher compliance to
colposcopy and follow-up referral increase the predicted incremental screening
associated cost and incremental life-years 175
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FIGURE 59 Strategy 1, 5-yearly screening: Relative difference in the cost of the
strategy compared with current practice for each of the sensitivity analysis
assumptions are shown on the left-hand side as the black bars. Relative differences
in the life-years are shown on the right-hand side as the green bars. a, ‘Worst-case
scenario’ (with respect to HPV testing) assumed that cytology had higher sensitivity
to CIN2+ (79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best case
scenario assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV
testing has a higher CIN2+ sensitivity rate (97.4%). b, Note that, although the
graph shows no decrease in life-years when cytology test sensitivity is increased
and HPV test sensitivity is simultaneously decreased, the strategy is actually less
effective than current practice (the strategy is predicted to have 0.001–0.002%
fewer life-years than current practice). c, No further follow-up for women not
complying to colposcopy and follow-up referral would result in an increase in the
incremental cost but a decrease in incremental life-years saved 176
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on the left-hand side as the black bars. Relative differences in the life-years are
shown on the right-hand side as the green bars. a, ‘Worst-case scenario’ (with
respect to HPV testing) assumed that cytology had higher sensitivity to CIN2+
(79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best-case scenario
assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV testing has a
higher CIN2+ sensitivity rate (97.4%). b, Note that, although the graph shows no
decrease in life-years when cytology test sensitivity is increased and HPV test
sensitivity is simultaneously decreased, the strategy is actually less effective than
current practice (the strategy is predicted to have 0.001–0.002% fewer life-years
than current practice). c, No further follow-up for women not complying to
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assumptions are shown on the left-hand side as the black bars. Relative differences
in the life-years are shown on the right-hand side as the green bars. a, ’Worst-case
scenario’ (with respect to HPV testing) assumed that cytology had higher sensitivity
to CIN2+ (79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best-case
scenario assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV
testing has a higher CIN2+ sensitivity rate (97.4%). b, Note that, although the graph
shows no decrease in life-years when cytology test sensitivity is increased and HPV
test sensitivity is simultaneously decreased, the strategy is actually less effective than
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FIGURE 62 Strategy 2, 5-yearly screening: Relative difference in the cost of the
strategy compared with current practice for each of the sensitivity analysis
assumptions are shown on the left-hand side as the black bars. Relative differences
in the life-years are shown on the right-hand side as the green bars. a, ‘Worst-case
scenario’ (with respect to HPV testing) assumed that cytology had higher sensitivity
to CIN2+ (79%) while HPV test has a lower CIN2+ sensitivity (94.2%). The best-case
scenario assumed cytology had a lower CIN2+ sensitivity rate (53%) while HPV
testing has a higher CIN2+ sensitivity rate (97.4%). b, Note that, although the graph
shows no decrease in life-years when cytology test sensitivity is increased and HPV
test sensitivity is simultaneously decreased, the strategy is actually less effective
than current practice (the strategy is predicted to have 0.001–0.002% fewer
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the number of women who entered the trial in the respective age group and
trial arm 186
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List of abbreviations
ARTISTIC A Randomised Trial In Screening
To Improve Cytology
CI conﬁdence interval
CIN cervical intraepithelial neoplasia
CIN2+ (any lesion of) CIN grade 2 or
worse
CIN3+ (any lesion of) CIN grade 3 or
worse
CONSORT Consolidated Standards of
Reporting Trials
DNA deoxyribonucleic acid
FIGO International Federation of
Gynaecology and Obstetrics
GP general practitioner
HC2 Hybrid Capture 2
HCHS Hospital and Community Health
Service
HPV human papillomavirus
HR high-risk (HPV type)
HTA Health Technology Assessment
LA Linear Array®
LBA Line Blot Assay®
LBC liquid-based cytology
LLETZ large loop excision of the
transformation zone
NATSAL National Survey of Sexual
Attitudes and Lifestyles
NHSCSP National Health Service Cervical
Screening Programme
OR odds ratio
PCR polymerase chain reaction
PPV positive predictive value
PSA probabilistic sensitivity analysis
QA quality assurance
QALY quality-adjusted life-year
RLU relative light unit
RLU/Co relative light unit/mean control
TPM test probability matrix
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Scientiﬁc summary
Background
The ARTISTIC (A Randomised Trial In Screening To Improve Cytology) trial, published in 2009, randomised
women undergoing cervical screening with liquid-based cytology (LBC) to either human papillomavirus
(HPV) testing, which was revealed and acted upon if cytology was negative, or concealed at entry and at
the next screening round 3 years later. The study demonstrated that LBC and HPV testing combined was
not superior to LBC alone, over either the initial or two consecutive rounds of cervical screening. Other
trials of HPV testing, which demonstrated that HPV testing was more sensitive than cytology in an initial
prevalence round, used conventional cytology and not LBC. Data from ARTISTIC conﬁrm the very high
negative predictive value of HPV status, and an economic analysis suggested that initial screening for HPV
triaged by cytology would be less costly than cytology-based screening, which relies on repeat cytology for
low-grade abnormalities. One of the key attributes of HPV testing could be prolongation of screening
intervals, as suggested by data from other studies. A particular strength of the ARTISTIC study was an
extensive programme of HPV genotyping in rounds 1 and 2. This extension of the ARTISTIC study to a
third round of screening was performed under two broad headings: the clinical effectiveness and
cost-effectiveness of HPV primary screening.
Clinical effectiveness
1. The cumulative cervical intraepithelial neoplasia (CIN) grade 2 or worse (2+) rates over three
screening rounds.
2. The cumulative rates of CIN2+ in women who were HPV negative at baseline and cytology negative
at baseline.
3. The potential for HPV testing to extend the screening interval.
4. The inﬂuence of genotyping on cumulative CIN2+.
5. The potential beneﬁt of using a Hybrid Capture 2 (HC2) cut-off value of 2 rather than 1 relative light
unit (RLU) in maintaining sensitivity but increasing speciﬁcity of HPV testing.
6. The potential impact of the UK national HPV vaccination programme on the results of
cervical screening.
Cost-effectiveness
1. To use clinical results from the ARTISTIC trial to inform an evaluation of the cost-effectiveness of various
options for primary HPV screening in England compared with current practice with cervical cytological
screening. The predicted long-term outcomes following the implementation of strategies involving
primary HPV screening were compared with those associated with current screening using
cervical cytology.
Methods
Clinical study
This study comprised an extension of follow-up of the ARTISTIC study cohort into a third screening round,
3 years following round 2. All women were screened with LBC, and HC2 testing for HPV was performed
on LBC residues. HPV genotyping was performed on HC2-positive samples. In round 3, colposcopy was
performed on all women with HPV-positive results and borderline or mild dyskaryosis, and women with
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moderate dyskaryosis or worse. Women with negative cytology, or HPV negative and borderline or mild
dyskaryosis, were returned to routine recall in line with the so-called NHS Sentinel Site protocol for HPV
triage. Colposcopic-guided biopsy was performed in the presence of a colposcopic abnormality and if
CIN2+ was detected the transformation zone was excised by loop excision. In screening round 3, there
was no difference in the management of screening results between the original arms of the trial.
Economic study
The economic analysis utilised a pre-existing, pre-calibrated and validated modelling platform that has
been previously used to evaluate outcomes in Australia, New Zealand, the UK and China. This platform was
then further validated against clinical results from the ARTISTIC trial, after setting up a simulation of the
ARTISTIC cohort at trial entry which reﬂected the observed age and test outcome distribution in the cohort.
The model was then used to perform a larger simulation of HPV transmission, the natural history of CIN and
cancer, and cervical screening and HPV vaccination in England. Cervical screening, HPV triage, diagnosis
and HPV test-of-cure were modelled using compliance data from registries and NHS HPV Sentinel Sites.
A range of assumptions for HPV and cytology characteristics were used. HPV transmission was simulated
using the second National Survey of Sexual Attitudes and Lifestyles (NATSAL II) survey of sexual behaviour,
and vaccination coverage data since 2008 was incorporated (84% coverage in 12- to 13-year-olds).
Extensive validation was performed against a number of observational data sets. This model was then used
to simulate lifetime outcomes after the introduction of primary HPV screening on a population-wide basis in
England, in unvaccinated cohorts and in cohorts offered vaccination. Several potential triaging strategies
were considered for HPV-positive women: (strategy 1) reﬂex cytology with triage-negative women followed
in 12 (or 24) months with HPV testing; (strategy 2) as for strategy 1 but women followed up at 12 or
24 months have a HPV test with partial genotyping, and women positive for types 16/18 are referred to
colposcopy; (strategy 3) HPV 16/18 referred to colposcopy at primary screening; and (strategy 4) HPV and
cytology performed adjunctively or ‘co-testing’. In addition, a range of variants on each strategy were
considered, which included consideration of different recommended screening intervals and follow-up
times for triage-negative women. We evaluated the cost-effectiveness of these screening strategies, and
their variants, against a comparator of current screening practice, incorporating detailed data-driven
modelling of compliance to current recommendations. Cross-sectional outcomes, including estimated
rates and case numbers of cervical cancer cases and deaths, biopsies, detected high-grade abnormalities,
colposcopies, and numbers of screening tests, were predicted, after incorporating information on the
population age structure. Detailed sensitivity analyses using one-way and probabilistic sensitivity analysis
were performed on a wide range of input parameters used in the model.
The economic evaluation of primary HPV screening in England took a health services perspective, taking
into account the health services costs associated with population-based screening, management,
diagnosis, and follow-up and treatment of CIN and invasive cancer. A discount rate of 3.5% was used for
costs and effects. Life-years was considered as the primary outcome of the analysis, as supplementary
analysis for quality-adjusted life-years (QALYs) outcomes found substantial variations in outcomes when
alternate health utility weight sets (QALY weights) were considered.
Results
Clinical results
Between January 2006 and June 2009, eligible samples were collected from 8873 women, of whom 71%
had been screened in round 2 and 29% had not been screened since round 1. The median duration of
follow-up was 72.7 months. The proportion with cytological abnormalities was around 5% in round 3,
similar to round 2. The HPV-positive rate, which was 16% in round 1, had fallen to 11% in round 3.
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1. The CIN2+ rate in round 3 was 0.74% compared with 2.39% in round 1 and 0.78% in round 2.
The cumulative rate of CIN2+ over three screening rounds was 3.9% [95% conﬁdence interval
(CI) 3.6% to 4.3%] in the revealed arm and 3.7% (95% CI 3.2% to 4.3%) in the concealed arm.
– The cumulative CIN2+ rate for women who were HPV negative at baseline was 0.87% (95% CI
0.70% to 1.06%) after three rounds of screening. This was signiﬁcantly lower than that for women
with negative cytology: 1.41% (95% CI 1.19% to 1.65%).
– Women who were cytology negative and HPV positive at round 1 continued to develop CIN2+ over
rounds 2 and 3 (3.67% and 2.77%, respectively) at rates twice those of the cohort overall and had a
cumulative CIN2+ rate at 6 years of 7.7%, signiﬁcantly higher than women who were cytology
positive/HPV negative (3.2%).
– Women who had not been screened in round 2 had a higher CIN2+ rate than those who had been
screened (1.34% and 0.50%, respectively).
2. For women who were HPV positive at baseline, the cumulative CIN2+ rate was 20.1%. The cumulative
rate of CIN2+ over three rounds and 6 years of follow-up in HPV-negative women (0.87%) was similar
to that for women with negative baseline cytology after round 2 and 3 years (0.78%), clearly
demonstrating an extended period of protection by a negative HPV result compared with a negative
cytology report.
3. The inﬂuence of different genotype groups in terms of cumulative CIN2+ after three rounds is clearly
shown by signiﬁcant differences between 16 alone, 16/18, 31/33/45/52/58, and other high-risk types.
Women who were HPV-type 16 positive at entry had a cumulative CIN2+ rate over three rounds of
43.6%, compared with 20.1% for all HPV-positive tests. Repeat detection of a speciﬁc genotype, that is
to say true persistence, was associated with a higher CIN2+ rates than HC2-positive persistence with
different type-speciﬁc infection in different rounds.
4. If screening were HPV-based [HC2 relative light unit/mean control (RLU/Co 1)] with cytology triage,
4.9% would be referred for borderline+ based on ARTISTIC data. If women with negative cytology
were referred based on reﬂex typing for 16, 18, 31, 33, 45, 52, 58, then 87% of CIN2+ would be
detected but the colposcopy referral rate would almost double.
5. Using a HC2 cut-off of RLU/Co ≥ 2 would maintain acceptable sensitivity and result in 16% fewer
HPV-positive results.
6. By combining data from the published randomised trial of Cervarix™, the vaccine used in the UK
vaccination programme (until 2012), with genotyping data from ARTISTIC, it can be estimated that
70% of CIN2+ would be prevented in vaccinated women and this is seen in all three rounds. At current
rates of vaccination coverage (∼80%) in 12- to 13-year-olds, there would be a reduction in CIN2+ of
about 55%. A far smaller proportion of low-grade cytological abnormalities would be prevented by
vaccination, as these are associated with lower rates of underlying HPV 16/18.
Economic results
Most of the primary HPV screening strategies examined were cost saving in both unvaccinated and
vaccinated cohorts, and many of the strategies also resulted in an increase in predicted life-years saved in
the population. Overall, the cost savings compared with current practice were predicted to be slightly
higher in vaccinated cohorts, varying from 9% (strategy 4) to 22% (strategy 1) in vaccinated cohorts and
from 7% (strategy 4) to 18% (strategy 1) in unvaccinated cohorts. The most effective strategy involving
HPV as the sole primary screening test incorporated partial genotyping for HPV 16/18 at the primary
screening step, and direct referral of women positive for these types to colposcopy (strategy 3). In
unvaccinated cohorts, the genotyping strategy is predicted to result in a 20% increase in the number of
colposcopies performed in England due to the immediate referral of HPV-16/18 women at the primary
screening step, but in vaccinated cohorts the number of colposcopy referrals is predicted to be lower than
current practice. The increase in colposcopies in unvaccinated cohorts for the partial genotyping strategy
S3 suggests that using cytology as a reﬂex triage test for oncogenic HPV positive women may be, in
practice, more feasible in England.
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In general, strategies for which HPV is used as the sole primary screening test were found to be both cost
and life-years saving, if attention was paid to the optimal combination of screening interval (5- or 6-yearly)
and follow-up interval (12 or 24 months) for HPV-positive, cytology-negative (‘intermediate risk’) women.
For all strategies in which HPV is used as the sole primary screening test, decreasing the follow-up interval
for HPV-positive/cytology-negative risk women from 24 to 12 months increased the overall effectiveness of
primary HPV screening. If 24-month follow-up is retained, the (relative) loss of effectiveness can be partly
compensated for by decreasing the screening interval from 6-yearly to 5-yearly, although this was generally
a less effective approach than optimising the follow-up of intermediate risk women by decreasing the
follow-up interval. Having a recommended follow-up of 12 months in intermediate risk women resulted
in between 73–113 and 37–41 additional life-years saved per 100,000 women in unvaccinated and
vaccinated cohorts, respectively, when compared with the corresponding strategy with 24-month
follow-up. Having a recommended routine screening interval of 5 years was the next most effective
variation, and resulted in 40–45 and 20–21 additional life-years saved per 100,000 women in
unvaccinated and vaccinated cohorts, respectively, when compared with the corresponding strategy
with 6-yearly screening.
In exploratory analysis, strategies for which cytology screening was retained until either age 30 or 35 years,
and for which a switch to primary HPV screening was implemented in older women, were predicted to be
of somewhat higher costs and intermediate effectiveness than those associated with full implementation
of primary HPV screening from age 25 years, even for unvaccinated cohorts. This exploratory ﬁnding
suggests that implementation from age 25 years of the appropriate strategy for primary HPV screening has
the potential to optimise cost and life-year savings in England. However, this ﬁnding should be interpreted
with caution as it depends on assumptions made about screening behaviour and compliance with
recommendations at the ‘switch over’ point, particularly in relation to management of women already
undergoing follow-up at the time of the ‘switch’. Further analysis, using detailed protocols for the
proposed recommendations underpinning such ‘switching’, would be required to conﬁrm this ﬁnding.
The most inﬂuential factors in sensitivity analysis were test characteristics and compliance with follow-up
for HPV-positive, cytology-triage-negative (‘intermediate risk’) women.
Probabilistic sensitivity analysis for the range of potential costs of screening, diagnosis and treatment was
conducted. In vaccinated cohorts, strategies 1–3 (but not strategy 4) were cost saving under all sets of cost
assumptions and strategy variants considered; in unvaccinated cohorts, strategy 1 and strategy 2 were
cost saving under most sets of assumptions but strategy 3 (and strategy 4), with 12 months’ follow-up of
HPV-positive, triage-negative women, were more costly than current practice under some, but not all, sets
of cost assumptions. In supplementary analysis, calculated QALYs were widely divergent depending on the
health-state utility weight set used, but under some conditions these weights modiﬁed the calculated
effectiveness (in terms of quality-adjusted life-years saved) of HPV screening.
Conclusions
The extended ARTISTIC study has provided valuable insights into several key areas. The ﬁrst is the longer
interval of protection by a HPV-negative result than that of a cytology-negative result (6 rather than
3 years), as evidenced by the lower cumulative rate of CIN2+. The data also provide evidence that
HPV-negative women aged 50 years could be safely rescreened after 10 years rather than 5. This is an
important consideration in relation to HPV testing as a replacement for cytology as the initial screening
test. The risk of cumulative CIN2+ following a HPV-positive/cytology-negative result means that optimal
strategies will balance the need for surveillance with the potential beneﬁt of immediate intervention.
The genotyping data are also relevant to the possible use of HPV typing to select women, for example
HPV 16/18 positive, for colposcopic assessment followed by return to routine recall if colposcopy negative.
A HC2 cut-off of 2RLU/Co instead of the manufacturer’s recommended cut-off of 1 would be clinically
beneﬁcial in terms of an optimal balance between sensitivity and speciﬁcity.
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The extended ARTISTIC data indicate that HPV vaccination with Cervarix™ at the current rates of
vaccination in 12- to 13-year-olds could be expected to prevent the majority of CIN2+ lesions resulting in
an eventual two-thirds reduction in CIN2+.
Modelled analysis predicts that primary HPV screening would be both more effective and cost saving
compared with current practice with cervical cytology for a number of potential strategies in both
unvaccinated and vaccinated cohorts. Compliance with surveillance and optimal management of
HPV-positive/cytology-negative women after primary HPV screening is of key importance. This study and
the economic evaluation lend support to convert from cytology to HPV-based screening, piloting of which
commenced in the English programme in the second quarter of 2013.
Study registration
This trial is registered as ISRCTN25417821.
Funding
This project was funded by the NIHR Health Technology Assessment programme and will be published in
full in Health Technology Assessment; Vol. 18, No. 23. See the NIHR Journals Library programme website
for further project information.
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Chapter 1 Introduction
The ARTISTIC (A Randomised Trial In Screening To Improve Cytology) trial was a randomised comparisonof human papillomavirus (HPV) testing in combination with liquid-based cytology (LBC) versus LBC
alone in primary cervical screening. It was based on outcomes over two rounds of screening and which
have been published recently in a Health Technology Assessment (HTA) monograph1 and other
peer-reviewed publications,2–6 including analyses of clinical outcomes, psychosocial outcomes, health
economics and other HPV typing and testing data.
The following summarises the principal ﬁndings of ARTISTIC based on the two screening rounds:
1. Detection of high-grade disease was not signiﬁcantly increased by LBC combined with HPV testing
compared with LBC alone, in either the ﬁrst round of screening or both rounds combined.1,2 Other trials
of HPV testing, which showed that HPV testing was more sensitive than cytology, used conventional
cytology and not LBC.7–9
2. Prevalence of high-risk (HR) HPV infection [Hybrid Capture 2 (HC2) test] by age: 28% in women aged
25–29 years, falling to 6.5% in women aged 50–64 years.1,3,4
3. Prevalence of type-speciﬁc HPV infection by cytology grade: HPV 16 and/or HPV 18 were detected in
10% of borderline, 22% of mild dyskaryosis and over 50% of moderate/severe dyskaryosis.1,3
4. The use of HPV testing did not signiﬁcantly increase psychosocial distress engendered by
cervical screening.5
5. Combined testing (LBC and HPV) was more expensive and, with an incremental cost-effectiveness of
£38,771 per additional case of cervical intraepithelial neoplasia (CIN) grade 3 or worse (3+) detected,
could not be justiﬁed. The mean cost of primary LBC triaged with HPV testing, or primary HPV testing
with cytology, was less than the routine NHS Cervical Screening Programme (NHSCSP) protocol of
repeat cytology for low-grade abnormalities.1
6. A HC2 HPV test result cut-off of relative light unit/mean control (RLU/Co) 2 is superior in terms of
clinical utility than the manufacturer’s recommended cut-off of RLU/Co 1.6
Those conclusions will inform future consideration of HPV testing as a primary screening test. ARTISTIC
data have also been used in validating models for evaluating the cost-effectiveness of HPV vaccination,
which will help inform any decision to implement a national programme.10 One of the key attributes
of HPV testing could be the potential to lengthen screening intervals as suggested by data from
other studies.11
We have extended the follow-up of the trial cohort to October 2009 (up to 8 years after entry) to provide
data from a third round of screening. This would offer valuable insight into the predictive ability of HPV
testing compared with LBC as negative baseline tests, and for women who tested cytology negative/HPV
positive. In the event of considering HPV testing as an initial screen, it would be important to understand
what length of protection could be obtained from a negative HPV test and, in the event of a HPV-positive/
cytology-negative result, what degree of risk existed over what period of time, and whether or not the
type of HPV was important.
With HPV vaccination having been established in the UK in 2008, it would be possible using genotyping
data to estimate how much disease would be prevented over a 6-year period by the prevention of HPV
infection by the vaccine. We have then undertaken cost-effectiveness analysis of HPV primary screening,
triaged with cytology, compared with current screening based on cytology triaged with HPV testing.
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Hypotheses
1. A negative HPV test at baseline would provide a greater duration of protection against CIN grade 2
or worse (2+) when compared with a negative cytology result, and would allow extended
screening intervals.
Research questions:
– What are the round 3 and cumulative rates of CIN2+ and CIN3+ between the revealed and concealed
arms of ARTISTIC after three screening rounds over 6 years?
– What is the cumulative incidence of CIN2+ over three screening rounds following negative screening
cytology with that following negative baseline HPV?
– Could the screening interval be safely extended from 3 to 6 years (continued hypothesis)?
2. Genotyping HPV to identify certain HR types could be clinically useful in terms of rapid referral to
colposcopy following reﬂex cytology.
Research question:
– What are the differential rates of disease associated with various HR genotypes?
3. Increasing the HC2 cut-off from 1RLU/Co to 2RLU/Co could maintain sensitivity and improve speciﬁcity
of HPV testing.
Research question:
– What is the effect of HC2 cut-off on the proportion of women with CIN2+?
4. The impact of the national vaccination programme against HPV types 16/18 will lead to a major
reduction in the incidence of CIN2.
Research question:
– What is the proportion of disease and cytological abnormalities associated with types 16/18?
5. Conversion from cytology-based screening to HPV-based screening would, through increased ability to
predict future risk of CIN2+ and CIN3+, save life-years and by increasing the screening interval,
save costs.
Research question:
– What is the cost-effectiveness of moving from cytology- to HPV-based cervical screening?
Aims
The two principal aims of the trial extension were:
1. to determine, over a 6-year period, the predictive signiﬁcance of a positive or negative HPV test, and
speciﬁc HPV types with respect to the development of CIN, and to compare this with cytology, in order
to determine the impact of HPV testing on cervical screening recall intervals
2. based on the ARTISTIC data, to model cost-effectiveness of changing cervical screening nationally from
cytology triaged by HPV testing to HPV testing triaged by cytology.
INTRODUCTION
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Other outcomes were:
(a) the round 3 and cumulative incidence of CIN2+ and CIN3+ in the original randomised arms of the trial
(b) CIN2+ rates in relation to HPV type-speciﬁc persistence
(c) the predicted impact of prophylactic HPV 16/18 vaccination on cervical screening outcomes in
the NHSCSP
(d) the potential beneﬁt of using a HC2 cut-off value of 2 rather than 1 RLU in maintaining sensitivity but
increasing speciﬁcity of HPV testing.
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Chapter 2 Methods
ARTISTIC study extension
Study design
The original ARTISTIC study design has been previously described in detail. Brieﬂy, 25,410 women aged
20–64 years undergoing routine cervical cytology screening in Greater Manchester between July 2001 and
September 2003 underwent co-testing for HPV. They were randomised 3 : 1 to have the test either
revealed and acted upon or concealed so as not to affect management. The intervention in the revealed
arm was in those women who were cytology negative but HPV positive. Such women were invited back at
12 months and, if persistently HPV positive, were offered the choice between either colposcopy or a repeat
HPV test at 24 months. If still positive at that time, all were offered colposcopy. In the event, two-thirds of
those who chose selected colposcopy.
Women who had abnormal cytology at baseline were managed according to national guidance irrespective
of HPV status. The hypothesis was that the addition of HPV testing would add sensitivity to detection of
high-grade CIN in the ﬁrst round and result in a reduction of high-grade CIN in round 2. The original
primary outcome was therefore the incidence of detected high-grade CIN in round 2.
This extension of ARTISTIC involved extending follow-up of the study cohort through a third round of
screening (Figure 1). All ARTISTIC women were invited to participate in a third round of screening 3 years
following round 2. All women who participated in round 3 had LBC and HPV testing; however, for reasons
explained below, a HPV-positive result only affected the management of those women with borderline
changes or mild dyskaryosis who were then offered colposcopy, and this applied to both of the original
arms. In all other respects routine clinical care applied.
As was the case throughout the ARTISTIC study, all colposcopy was performed by practitioners accredited
in colposcopy through the British Society of Colposcopy and Cervical Pathology. Equally, all cytology
procedures were done according to NHSCSP Quality Assurance (QA) standards and HPV testing was
performed in a Clinical Pathology Accreditation-approved laboratory.
Setting and ethics committee approval for the extension
The original protocol did not include continued HPV testing after the second screening round. The trial
extension with a further (third) round of HPV testing in addition to cytology was initially approved by the
North West Multicentre Research Ethics Committee (ref 00/8/30) on the basis that there were no
signiﬁcant changes to the management of women involved in the 6-year follow-up and that all
participants were reconsented to the study. It was anticipated by the investigators that this would be
difﬁcult to achieve. The patient information leaﬂets are included in Appendix 5 and Appendix 6 and
consent forms are included in Appendix 7.
General practitioner and family planning involvement
The original primary care practices and family planning clinics maintained their involvement in the trial
extension. As all clinics had been participating since 2001, and LBC roll-out and update training across the
region had been completed, it was deemed unnecessary to hold any information or training sessions. All
practices involved were sent information about the trial extension and spare copies of the patient literature
to keep in the clinic rooms.
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Reconsenting procedures
All previously enrolled women were sent a letter to their last known address, detailing the aims and
procedures of the trial extension. The appropriate patient information leaﬂet and consent form were also
included. Women were given stamped addressed envelopes to return the consent form to the trial ofﬁce.
Women who did not wish to continue their participation in the trial were asked to return their consent
forms blank with just their unique trial number included to allow identiﬁcation. Women who withdrew
from the extension did not receive any further correspondence from the trial ofﬁce. Non-responders to the
initial information were sent a repeat letter containing the same information to give them an additional
opportunity to reconsent.
General practitioners (GPs) and family planning clinics were sent lists of all ARTISTIC women so that they
were able to check whether or not the women were still participating when they attended for screening.
A reimbursement of £5 was offered to sample-takers to reconsent women at the clinics who had failed to
respond to the letters from the trial ofﬁce. As some women had changed GPs since the ﬁrst round of
screening in the trial began, practices that were not originally part of the trial were sent additional
information about the trial and its extension, if they had ARTISTIC women registered with them.
Concealed arm (1)
ThinPrep/HC2Baseline
36 months
National guidelines
ThinPrep/HC2
Revealed arm (3)
ThinPrep/HC2
Cytology–ve/HPV+ve Cytology–ve/HPV–veCytology+ve
ThinPrep/HC2
HPV+veHPV–ve
Patient choice
Repeat HPV Colposcopy
Repeat HPV testing at 12 months
ThinPrep/HC2
Second round protocol – both arms used control group protocol in round 1 except (a) colposcopy referral
after two rather than three consecutive borderline results; and (b) colposcopy offered to cytology-negative
women if persistently HPV+ve over two rounds without prior colposcopy
Third round protocol – both arms used control group protocol in round 1 except colposcopy referral
for all HPV+ve borderline or mild and return to routine recall for HPV–ve borderline/mild as used in
NHSCSP Sentinel Sites protocol
FIGURE 1 ARTISTIC protocol for rounds 1, 2 and 3.
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Protocol amendments
Throughout the course of the third round extension, two major protocol amendments were necessary:
1. An amendment was submitted to the ethics committee to seek approval for triaging all ARTISTIC
women on the basis of reﬂex HPV testing for low-grade abnormalities in line with the NHSCSP Sentinel
Sites protocol. This amendment was approved on the basis that to deny the women participating in the
trial access to the triage would have provided them with inferior management than that received by
other women attending for routine screening in the Greater Manchester area.
2. Within 9 months of the process of reconsenting for the third round extension of ARTISTIC, it became
clear, as had been anticipated, that this was not viable. Fewer than one-quarter of women had
returned consent forms, and not all of these women actually underwent screening. It was obvious that
this would result in insufﬁcient data to allow any useful conclusions to be drawn. A substantial
amendment was submitted to the ethics committee, who agreed that under the circumstances it was
in the public interest for approval to be given to the use of unconsented samples to be tested for
HPV and recommended the following:
i. to obtain samples of residual material from routinely performed cytology (ARTISTIC participants)
ii. to ensure that the HPV test result would not generate any non-routine clinical action
iii. to ensure that data were anonymised by removing the use of the patient NHS number on the study
database and instead use the unique study identiﬁer to make it impossible for researchers to link
HPV data to named individuals.
This amendment meant that colposcopy could not be offered to cytology-negative women who were
HPV positive at the third screening round. Consequently, the positive and negative predictive values
could be affected by the lack of colposcopy veriﬁcation in cytology-negative/HPV-positive women.
On the other hand, the triage of low-grade abnormalities would have resulted in rapid colposcopic
veriﬁcation of underlying CIN. The impact of the protocol amendments on the management of women
in the trial is summarised in Table 1. Round 3 management was based on the post-amendments
management recommendations.
Impact of the NHS Cervical Screening Programme sentinel sites
for human papillomavirus triage
On 1 March 2008, the Manchester Cytology Centre became one of six sentinel sites for HPV triage in
England. The aim of the sentinel sites project was to evaluate the roll-out of HPV triage of low-grade
cytological abnormalities. Women who tested HPV positive were referred to colposcopy, while those who
were negative were returned to routine recall. This process expedited the referral to colposcopy for those
who were at risk of an underlying abnormality, while women who were negative, and therefore at low
risk, were spared repeat cytological testing.
TABLE 1 Summary of third round management protocol amendments
Pre-amendments Post-amendments
Both arms
High-grade cytology – colposcopy High-grade cytology – colposcopy
Low-grade cytology Low-grade cytology/HPV+ve – colposcopy
Mild dyskaryosis – colposcopy
Borderline changes – repeat and refer if abnormal
Negative cytology – colposcopy HPV+ve second and third round
(revealed arm only)
Negative cytology – routine recall
+ve, positive.
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In order to keep the management of the ARTISTIC women in line with local policies as required by the
ethics committee, women in both revealed and concealed arms were entered into the triage protocol.12
Women entered into the triage protocol received both a combined cytology/HPV result letter from the
screening agencies as well as a results letter from the trial ofﬁce. The changes in the HPV testing protocol
were explained in the patient information leaﬂets. Women living in the Stockport area were also sent a
leaﬂet explaining HPV triage, as this would not have been sent to them by their local screening agency.
The trial protocol originally meant that only the HPV result in women with negative cytology inﬂuenced
management in the revealed arm and differentiated the effect of HPV testing between the two arms. The
maintenance of the revealing and concealment of HPV results in round 3 was rendered impossible by
the consequences of the ethics committee’s decision.
Clinical samples
All samples were collected as previously described.1 Samples that were reported as showing low-grade
abnormalities were HPV tested as part of the sentinel sites protocol. All HPV triage testing was carried out
at the Manchester Virology laboratory alongside the ARTISTIC HPV testing. Samples were reported as
positive and acted upon at the recommended cut-off of 1 RLU/Co. During the course of the ARTISTIC
study, the following QA measures were followed: retesting of every 50th sample and participation in
external QA schemes when they became available. External QA schemes included National External Quality
Assessment Service (NEQAS), Quality Control for Molecular Diagnostics (QCMD) and samples sent from the
Scottish HPV Reference laboratory.
Reading of cytology slides and samples
All samples were read and reported in line with current laboratory and NHSCSP guidelines as previously
reported.1 Samples were reported blind to both the allocation of the sample within the trial and the HPV
test results, with the exception of slides showing low-grade abnormalities which were sent for HPV testing
as part of the NHSCSP Sentinel Sites project.
Human papillomavirus testing
Hybrid Capture 2 cut-off values
Unless otherwise stated, HC2 results have been reported using a cut-off RLU/Co of 1 or greater.
The alternative cut-off of 2 RLU/Co has been calculated for the purposes of comparison with a cut-off of
RLU/Co of 1 or greater and these cut-offs have been clearly identiﬁed where relevant.
Changes to human papillomavirus genotyping protocol
Three typing assays for HPV detection were considered during the study to genotype HC2-positive
samples. All of the HC2-positive samples accrued during the original trial were genotyped using the
prototype Roche Line Blot Assay® (LBA) as previously described.1
In order to compare typing assays, two-thirds of HC2-positive round 1 archived samples were also tested
by the Greiner Bio-One PapilloCheck® assay (Greiner Bio-One GmbH, Frickenhausen, Germany). In
round 2, one-third of archived HC2-positive samples were tested by the Roche Linear Array® (LA) (Roche
Molecular Diagnostics, Pleasanton, CA, USA). As a result of the prototype LBA being replaced with the
commercially available LA assay during the extension period of this study, only 34% of HC2 positive
samples in round 3 were actually tested by the LBA. The remainder were tested using PapilloCheck® only
(23%), LA only (15%) or both PapilloCheck® and LA (28%). In order to present as many genotyping data
as possible, typing results using the PapilloCheck® assay have been included. Any type detected by any of
the assays used on a particular sample in all rounds were considered in the analysis.
Human papillomavirus genotyping by the Greiner Bio-One PapilloCheck® test
The PapilloCheck® HPV test is a polymerase chain reaction (PCR)-based assay designed to simultaneously
detect and genotype 24 mucogenital HPV types including the 13 HR types targeted by the HC2 test
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(Qiagen, Gaithersberg, MD, USA). The PapilloCheck® test uses a consensus primer set targeting the
E1 region of the HPV genome followed by HPV-type speciﬁc product detection using a micro-array
hybridisation system.
Deoxyribonucleic acid (DNA) extraction for the PapilloCheck® assay was carried out using the Nuclisens
easyMAG automated extraction system (bioMérieux, Inc., Durham, NC, USA). Storage samples (4) were
thawed and 50 µl was added to the appropriate well in the easyMAG carrier strip. Twenty-four samples
were extracted at a time. The puriﬁed total nucleic acid was eluted in 100 µl of extraction buffer, which
was transferred to a 2-ml vial for storage at −70 °C prior to ampliﬁcation.
A 350-bp fragment within the E1 region of the HPV genome was ampliﬁed by PCR using a
broad-spectrum consensus primer set. In addition, a fragment of the human ADAT1 gene was ampliﬁed
and ﬂuorescently labelled with Cy5 in the same reaction. This acted as an internal control to assess the
quality of DNA. The ampliﬁed products were then hybridised to HPV type-speciﬁc oligonucleotide probes
immobilised onto a DNA chip and were detected by the binding of a Cy5-dUTP labelled oligonucleotide.
After hybridisation and subsequent washing, the PapilloCheck® DNA chip was scanned using the
CheckScanner apparatus (Greiner Bio-One GmbH, Frickenhausen, Germany) at excitation wavelengths of
532 and 635 nm. Evaluation and analysis of the DNA chip was carried out using the CheckReport
analysis software.
Human papillomavirus detection by the M2000 Abbott real-time high-risk
human papillomavirus assay
During the course of the ARTISTIC trial the virology laboratory was invited to participate in the Abbott HPV
early access evaluation programme. The Abbott test was performed on archived samples for which women
had consented to further testing. None of the Abbott results were acted upon clinically.
The recently introduced highly automated Abbott real-time HR HPV assay is a PCR-based real-time assay
designed to detect 14 HR HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). By
the use of different dyes, the assay identiﬁed infection with types 16 and 18 singly while the 12 remaining
types were detected as a group. Following extraction of DNA from the LBC sample using the Abbott
M2000sp extraction robot (Abbott Molecular, Maidenhead, UK), any HR HPV DNA present in the sample
was ampliﬁed and detected simultaneously using the Abbott M2000rt sequence detection system. The
system also co-ampliﬁed and detected a portion of human DNA which acted as a sample integrity control.
A 400-µl aliquot of ThinPrep® Medium (Hologic, Inc., Bedford, MA, USA) was added to 100 µl of
archived sample prior to DNA extraction using the M2000sp as per the Abbott protocol. Following DNA
extraction, any HR HPV DNA was ampliﬁed and detected using the M2000rt system as per the
recommended protocol.
Statistical analysis
Definitions
Women were eligible if they were aged 20–64 years when they provided a round 1 sample which was
deﬁned as the ﬁrst cytologically adequate sample after randomisation at entry that gave a satisfactory HPV
result. Many women attended their next routine screen earlier or later than the scheduled 3-year recall.
Originally, ARTISTIC round 2 was deﬁned as 30–48 months after entry. This resulted in CIN2+ lesions
being excluded and, in the HTA ARTISTIC report,1 the broader deﬁnition of 26–54 months was also used.
This latter deﬁnition, which was used in the Lancet Oncology manuscript,2 was employed in this current
report. Alternative results are shown in Appendix 3 of this report deﬁning round 2 as the ﬁrst sample
30–48 months after the round 1 entry smear. The round 3 sample was deﬁned as the ﬁrst cytologically
adequate sample at least 54 months after the round 1 smear, and at least 24 months after the round 2
smear (if there was one). Women were classiﬁed histologically at round 1, round 2 and round 3 on the
DOI: 10.3310/hta18230 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 23
9
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
basis of the highest grade of histology within 30 months of the round 1, round 2 or round 3 cytology.
Women with CIN2 histology or worse (CIN2+) were excluded from subsequent rounds.
Women were followed for cytology until the end of June 2009 and for histology to October 2009.
Follow-up was based on cytology and histology reports received by the laboratories in Manchester and
Stockport. Cytology and histology taken outside these areas were not available.
Persistent infection at round 2 was deﬁned as detection of one or more of the same HPV types also found
at round 1. Persistent infection at round 3 was deﬁned as detection of one or more of the same types also
found at round 1 (any round 2 result was ignored for this analysis). Positive HPV results at round 2 or 3
were thus considered to be either ‘new’ or ‘persistent’. Additionally, these HPV positive results were
split by HPV type present (according to the previously deﬁned hierarchy and groupings) at round 2 or 3.
CIN2+ and CIN3+ rates have been presented for new and persistent infections. HC2-positive results where
no HR type was detected have been considered to be ‘new’ infections; hence, no exclusions were made
in the analysis.
Data collection
Data were collected as described in the original HTA monograph.1 For round 3, all patient identiﬁers,
bar the unique trial identifying number, were removed from the database on the advice of the
ethics committee.
Data analysis
Human papillomavirus prevalence, cytological abnormality and CIN2+ rates were tabulated by
combinations of round, age at round, randomisation arm and HPV status at entry or at round. HPV status
was split further by main HPV type identiﬁed: (1) HPV 16 or HPV 18, (2) HPV 31, HPV 33, HPV 45, HPV 52
and HPV 58 and (3) other HC2 positive, including HC2-positive samples where none of the 13 types was
identiﬁed. The rationale behind these groupings was that 16/18 are the types targeted by the Cervarix™
vaccine (GlaxoSmithKline Biologicals, Rixensart, Belgium), which was used in the UK vaccination
programme until September 2012, after which it was switched to Gardasil® (Merck Sharp & Dohme Corp.,
Merck & Co., Inc., Whitehouse Station, NJ, USA). The Cervarix™ vaccine has also been reported to exhibit
a degree of cross-protection against types 31/33/45/52/58. According to published efﬁcacy data,
Cervarix achieved 98% efﬁcacy against 16/18 related CIN2+, 68% efﬁcacy against 31/33/45/52/58
related to CIN2+ and 70% against CIN2+ of any HR type in females who were HPV naive prior
to vaccination.13
Cumulative CIN2+ and CIN3+ rates were estimated as P = 1 – (1 – P1)(1 – P2)(1 – P3), where Pi denotes
the proportion with disease (Di/Ni) in round i. Conﬁdence intervals were calculated from Greenwood’s
formula for the standard error: √(1 – P)2Σi{Di/[Ni(Ni –Di)]}14 (sufﬁx numbers refer to screening round).
Comparisons using two-sided Fisher’s exact test were also based on these binomial proportions.
Between-round differences in rates of abnormal cytology and histology were estimated by unconditional
logistic regression adjusted for age and HPV status at round, cytology (for comparing CIN2+ rates) and
randomisation. All analyses were programmed in Stata 11 (StataCorp LP, College Station, TX, USA).
Economic analysis
Overview of model platform used for the evaluation
An existing model platform was adapted for the economic analysis, and the components of this platform
are summarised in Figure 2. This model platform has been previously used to evaluate changes to the
cervical screening interval in Australia and the UK,15,16 the role of alternative technologies for screening in
Australia, New Zealand and England,17–19 the role of HPV triage testing for women with low-grade
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cytology in Australia and New Zealand,20 and the cost-effectiveness of alternative screening strategies,
combined screening and vaccination approaches in China.21,22 The model platform has three
main components:
i. A dynamic model of sexual behaviour and HPV transmission (and vaccination as appropriate) in
England. This incorporates other data from local sexual behaviour surveys,23 and information on
vaccination catch-up and coverage rates in England.24
ii. A multitype Markov cohort model of the natural history of CIN and invasive cervical cancer (referred to
as the ‘natural history model’). The natural history model takes into account differing clearance and
progression rates associated with HPV 16 and HPV 18, compared with other oncogenic types.
The model also explicitly simulates post-treatment recurrence in women previously treated for
high-grade lesions.
iii. A cohort and multicohort model of screening, diagnosis, treatment and post-treatment management.
Methods for model validation against ARTISTIC data
Reanalysis of ARTISTIC was used to support validation of the existing model platform. The steps involved in
ARTISTIC validation can be summarised as follows:
1. Set up and simulate a ‘virtual’ cohort based on the age distribution and screening behaviour of the
ARTISTIC trial cohort.
2. Run a multicohort simulation (i.e. a subsimulation for each age group in the cohort) to predict the
number of screen-detected low- and high-grade cervical abnormalities that would be observed in each
age group and overall, over the duration of trial follow-up.
3. Validate the predictions obtained from the model with the data from the ARTISTIC trial.
The model platform used for the main evaluation has three main components. These three
components consider:
1. HPV transmission and vaccination
2. the natural history of cervical CIN and cancer in HPV-infected women; and
3. cervical screening.
The methods by which the model components two and three above were adapted for modelling the
ARTISTIC cohort are described below.
Vaccination
Model of HPV
transmission
HPV incidence
Invasive cancer
incidence
Model of the natural
history of HPV
infection and CIN
Model of screening,
diagnosis and
treatment
Model of invasive
cancer survival
FIGURE 2 Schematic diagram of model platform.
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Human papillomavirus transmission and dynamic modelling
Age-speciﬁc pre-vaccination HPV incidence was obtained from a dynamic model of HPV transmission.
As the model is a dynamic transmission model, the effects of herd immunity are taken into account.
Data on sexual behaviour from the UK’s National Survey of Sexual Attitudes and Lifestyles II (NATSAL II)25
(data collected between 2000 and 2001) were incorporated into the model. (See Appendix 16 on
sexual behaviour data for the population model for more details on the simulation of sexual behaviour
in England.)
Model of the natural history of cervical intraepithelial neoplasia and cancer
The model assumes that once a woman becomes infected with HPV, the virus can be cleared, or can
persist and eventually cause CIN or cancer of the cervix. Six different health states in which a woman can
exist were considered: well (or uninfected with HPV); HPV; CIN1 (persistent HPV infection); CIN2; CIN3;
and cancer. The cancer state was further divided into stages to reﬂect International Federation of
Gynecology and Obstetrics (FIGO) clinical stage at diagnosis and for each stage, diagnosed and
undiagnosed cancer. Women who are diagnosed with invasive cervical cancer have an increased,
stage-speciﬁc rate of death. Women who have survived cervical cancer for over 5 years are considered
cancer survivors in the model, and their rate of survival is assumed to be the same as that of the normal
population. Women who had HPV, CIN1, CIN2 or CIN3 were further categorised into three pathways
associated with HPV 16, 18 or other HR types. The initial prevalence of each HPV type for each CIN state
and for each age group was weighted to be consistent with the type-speciﬁc prevalence observed at
enrolment in the ARTISTIC trial.
The natural history aspect of the model captures the rates at which women in different health states can
progress to a more advanced stage (e.g. CIN2 to CIN3), remain in the same health state (e.g. remain in the
CIN2 state), or regress (e.g. CIN2 to CIN1). This was captured in a HPV-type-speciﬁc matrix of progression,
regression and stasis rates between HR HPV infection, CIN1, CIN2, CIN3 and invasive cervical cancer.
The model captured the higher rates of disease progression and lower rates of regression in women
infected with HPV 16 and 18 compared with other HR HPV types.
The rates of progression, regression and stasis between the different health states have been calibrated
and validated previously. However, the ARTISTIC data were used to further validate the natural
history model.
Modelling screening
The natural history aspect of the model dealt with modelling the actual underlying health state distribution
of women in the population. However, the ARTISTIC trial reported histology results from women who
attended screening and were referred for colposcopy and biopsy. Thus, in order to compare the natural
history model results with ARTISTIC results, screening behaviour as observed in the trial was simulated.
Management of the two different screening arms of the trial were simulated, and the ARTISTIC data were
used to determine the rates of non-attendance, early rescreening and late rescreening.
We then compared model predictions for histology detected CIN cases with observed data from the trial.
Fitting test characteristics for cytology and the underlying health state in
the ARTISTIC cohort
In order to simulate the ARTISTIC cohort, the actual underlying health states of women entering the trial
were estimated. To do this, we also needed to estimate the test characteristics of LBC and HPV testing in
the ARTISTIC trial.
The test characteristics for LBC describe the probability of receiving any test result for each possible health
state. For each underlying health state (of which there were six: well, HPV, CIN1, CIN2, CIN3 and cancer),
there were ﬁve possible LBC test results (given an adequate test result): negative, borderline, mild,
moderate and severe. The probabilities of receiving each test result for each possible health state form a
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table called the ‘test probability matrix’, or TPM. The TPM gives complete information on test
characteristics and the test parameters for sensitivity, speciﬁcity and positive predictive value (PPV).
Negative predictive value can be secondarily derived for thresholds at any health state [such as high-grade
lesions (CIN2+) or all CIN lesions] and for any testing threshold (such as borderline or mild dyskaryosis
for cytology).
A Gibbs sampler was used to simulate the posterior distribution of the health state and LBC test
probability parameters using the cytology and HPV data observed at baseline in ARTISTIC.26 Multiple chains
were run and the mixing of the different sequences was monitored. The sampler was stopped when the
potential scale reduction was near one for all the estimated parameters. The LBC TPM determined from
this sampling procedure was further modiﬁed to match histology outputs from the ARTISTIC trial
(see Appendix 9 for more information on the Gibbs sampling and ﬁtting procedure).
Construction of the virtual ARTISTIC cohort and validation of model
outcomes to ARTISTIC data
The procedure for simulating the ARTISTIC cohort can be summarised in the following steps:
1. A ‘virtual’ ARTISTIC cohort was conﬁgured to represent the trial population as at ARTISTIC enrolment.
The enrolled virtual cohort represented the actual ARTISTIC cohort in terms of age proﬁle and HPV test
positive (type-speciﬁc) rates at baseline. We assumed that all women attended their baseline screen at
the same time, and so screening events are synchronised (as opposed to simulating the actual date of
attendance, in line with the way such trial and cohort data are routinely reported). All women had a
baseline cytology and HPV test, with follow-up management dependent upon their trial arm, baseline
test results and compliance with guidelines as observed in the ARTISTIC trial. The actual rates of
colposcopy referral, delays in colposcopy attendance and screening attendance rates that occurred
throughout ARTISTIC were captured in the model.
2. Each woman’s true underlying health state was updated at 6-monthly intervals throughout the
simulation according to the parameters from the natural history model and the HPV transmission
model. The number of women attending routine screening, follow-up screening or colposcopy was also
updated at 6-monthly intervals.
3. For the modelled cohort, for woman with histologically detected CIN2+, any subsequent screening visits
were censored, and this group were removed from the simulation. If the histology result was less than
CIN2 (‘< CIN2’: CIN1 or histological manifestations of HPV effect), women remained in the simulation.
The simulation predicted the number of histology-detected CIN cases at 6-monthly intervals, and these
model predictions were compared with the data from the ARTISTIC trial at 6-monthly intervals. As the
natural history simulated in the model captured disease progression and regression at various rates, the
actual underlying health states of women throughout the trial changes over time. Thus, the model outputs
at later times in the trial give an indication of how well the natural history model captured the rates of
disease progression, regression and stasis (after taking into account the ‘overlay’ of screening, i.e. the
inﬂuence of screening behaviour and test characteristics on the observed outcomes in the trial).
Methods for the evaluation of primary human papillomavirus
screening in England
The validated natural history model of CIN and invasive cervical cancer was then used to evaluate health
outcomes under different screening strategies on a population basis for England. The cost-effectiveness of
various HPV primary screening strategies were evaluated against a comparator of current screening
practice, and cross-sectional outcomes, including estimated rates and case numbers of cervical cancer
cases and deaths, detected high-grade abnormalities, colposcopies and numbers of screening tests, were
predicted after incorporating information on the population age structure. Data from local sexual
behaviour surveys, screening compliance information, and information on vaccination catch-up and
coverage rates were also incorporated into the England-wide model.
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A health-services perspective was used for the collection of costs. The economic evaluation also took a
health-services perspective, taking into account the health-services costs associated with population-based
screening, management, diagnosis, follow-up, and CIN and cancer treatment. A discount rate of 3.5%
was used for costs and effects (the 3.5% discount rate for both costs and effects is recommended
by the National Institute for Health and Care Excellence based on the recommendations of the
UK Treasury, 2008 guide).27
Primary human papillomavirus screening strategies considered
in the evaluation
A number of potential future primary HPV screening strategies were simulated. These are described and
detailed diagrammatically in the following pages. Many of the strategies chosen were thought to represent
possible candidates for effective, and cost-effective, strategies in England. Other, more exploratory,
strategies (as noted) were included for comparative purposes.
Comparator strategy (current screening practice)
The comparator for the evaluation is current screening practice, with and without the effects of HPV
vaccination, and is depicted in Figure 3.
The comparator strategy involves cytology-based screening with LBC and HPV triage testing of low-grade
abnormalities (borderline changes and mild dyskaryosis). The recommended screening interval is 3 years for
women aged 25–49 years and 5 years for women aged 50–64 years.
Primary human papillomavirus screening strategies
We assumed that strategies two and three are carried out using a HPV test that has the ability to
separately output information on HPV 16 and 18, that is to say a ‘partial genotyping’ test [note that one
technology also provides information on type 45 but for the purposes of this analysis we did not model
differential management based on detection of type 45, assuming that, even if this output was available,
women with type 45 were managed as for women with other oncogenic types (not 16/18)].
‘Real-world’ screening compliance was assumed. Screening attendance was informed by a previous
analysis performed for the UK,19 and updated to reﬂect the most recent data on the age-speciﬁc
percentage of eligible women who attended at least once in a 5-year period in England (2009–10). This
analysis allowed the model to take into account non-attendance, early rescreening, late rescreening, and
Inadequate
Recall for
repeat test
Comparator 1:
3-yearly primary screening with LBC
cytology (5-yearly after 50 years)
HPV testing for any
oncogenic types
Refer to
colposcopy
Back to routine
screening
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dyskaryosis
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Back to routine
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severe
FIGURE 3 Comparator strategy (current screening practice).
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screening in ages outside the target age range for screening. Attendance rates for colposcopy and post
treatment were based on those used in a prior model of HPV test-of-cure in England.28
For all strategies, colposcopy management was assumed to be as detailed later (see Figure 8).
Post-treatment management was assumed to use HPV as a test-of-cure as per the protocol used in the
NHS Sentinel Sites evaluation.12
The following primary HPV screening strategies were considered.
Basic strategies
Strategy 1 (Figure 4)
The strategy can be summarised as follows: women positive for any oncogenic infection receive reﬂex
cytology triage testing. Cytology-positive women (borderline dyskaryosis or worse) are referred to
colposcopy. Cytology-negative women are sent for repeat HPV testing with cytology triage in 24 months,
and any women who are HPV positive and borderline dyskaryosis or worse are referred to colposcopy at
that point. HPV-positive, triage-negative women are sent for a repeat HPV testing in another 24 months,
and HPV-positive women at that point are referred to colposcopy. HPV-negative women are returned to
routine screening at each stage.
Strategy 1:
Primary HPV screening for HR HPV
Reflex cytology
Back to routine
screening
Negative Positive 
NegativeInadequate
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FIGURE 4 Screening and follow-up management of primary HPV screening for strategy 1. a, At the second 24-month
follow-up, women negative for HPV are returned to routine screening and HPV-positive women are referred
to colposcopy.
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Strategy 2 (Figure 5)
The strategy can be summarised as follows: women with any oncogenic HPV-positive infection have reﬂex
cytology triage. Cytology-positive women (borderline dyskaryosis or worse) are referred to colposcopy.
HPV-positive, cytology-negative women have repeat HPV and reﬂex cytology in 24 months with partial
genotyping and any HPV 16/18 positive or borderline dyskaryosis or worse are referred to colposcopy at
that point. Cytology-negative women and/or women negative for HPV 16/18 are sent for a repeat
HPV test in another 24 months, with any HPV-positive women referred to colposcopy at that point.
HPV-negative women are returned to routine screening.
Strategy 3 (exploratory) (Figure 6)
The strategy can be summarised as follows: a primary screening test with partial genotyping is used and
women with HPV 16/18 are referred directly to colposcopy. Cytology triage is performed on other
oncogenic HPV-positive women, with those cytology-positive (borderline dyskaryosis or worse) referred to
colposcopy. Other oncogenic HPV-positive women who are cytology negative are then followed up as
in strategy 2.
Strategy 2:
Primary HR HPV screening
Reflex cytology
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16/18
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FIGURE 5 Screening and follow-up management of primary HPV screening for strategy 2. a, Using a HPV test that has
HPV 16/18 partial genotyping. b, At the second 24-month follow-up, any oncogenic HPV positive is referred to
colposcopy. HPV negatives return to routine screening. OHR, other high risk.
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Strategy 4 (exploratory) (Figure 7)
This ‘co-testing’ exploratory strategy can be summarised as follows: women receive HPV and cytology
co-testing. Women with moderate or severe dyskaryosis are referred to colposcopy. Women who are HPV
positive with a cytology result of borderline or mild dyskaryosis are also referred to colposcopy. Women
who are HPV positive with a normal cytology result have repeat testing in 24 months, and are thereafter
managed as in strategy 2. Women who are HPV negative with a cytology result of mild dyskaryosis also
have repeat testing in 24 months, and are thereafter managed as in strategy 2. Women who are HPV
negative with a cytology result of borderline dyskaryosis or normal are returned to routine screening.
Strategy variations
Screening interval
We considered three different screening interval scenarios for each strategy:
1. a 6-yearly screening interval for women aged 25–64 years (used in basic strategies)
2. a 6-yearly screening interval in women aged 25–49 years and a 10-yearly interval in women
aged 50–64 years
3. a 5-yearly screening interval for women aged 25–64 years.
Strategy 3:
Primary HR HPV screeninga
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16/18
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FIGURE 6 Screening and follow-up management of primary HPV screening for strategy 3. a, Using a HPV test that has
HPV 16/18 partial genotyping. b, At the second 24-month follow-up, any oncogenic HPV positive is referred to
colposcopy. HPV negatives return to routine screening. OHR, other high risk.
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Combined primary cytology and primary human papillomavirus
strategies (exploratory analysis)
For each of strategies 1 and 2, we also modelled the following combined screening options where
cytology was retained as the primary screening test for younger women and then primary HPV screening
was used in older women, assuming that:
1. cytology screening according to current recommendations was performed in women 25–29 years, with
primary HPV screening in women > 30 years
2. cytology screening according to current recommendations was performed in women 25–34 years, with
primary HPV screening in women > 35 years.
For these strategies, we assumed that a woman would ‘switch’ primary screening tests at the ﬁrst screen
attendance after the ‘switching’ age (which may be several years later in the case of underscreened
women). We assumed that women who had been screened prior to the ‘switch’, and who were in
follow-up management at the time of the switch, completed that cycle of management until discharged
back to routine screening. However, it should be noted that detailed recommendations for how
underscreened women and women under follow-up management should be handled after the ‘switch’
would require review, and the nature of such recommendations would have the potential to change these
ﬁndings. Therefore, these strategies should be considered exploratory.
Follow-up of human papillomavirus-positive/cytology-negative women
Each strategy was modelled under alternate assumptions about follow-up for HPV-positive women who
were not referred immediately to colposcopy (e.g. because the triage cytology test was negative):
1. Women were assumed to be followed up at 24 months (used in basic strategies).
2. Women were assumed to be followed up at 12 months.
Strategy 4:
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FIGURE 7 Screening and follow-up management of primary HPV screening for strategy 4. a, Using a HPV test that has
HPV 16/18 partial genotyping. b, At the second 24-month follow-up, any oncogenic HPV positive is referred to
colposcopy and HPV negatives return to routine screening. OHR, other high risk.
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Modelling human papillomavirus vaccination
Each strategy was modelled under alternate assumptions about vaccination status:
1. Women were assumed to be unvaccinated.
2. Women were assumed to be part of a cohort who were offered vaccination as pre-adolescents
(12–13 years). The effects of the national HPV vaccination programme were modelled (2010–11
coverage rates24). The vaccination catch-up programme (with appropriate coverage rates obtained from
Sheridan and White24) was also simulated, as this would have some effect on the cohorts offered
routine vaccination via the effects of herd immunity.
Each cost and effectiveness calculation was performed for the primary HPV screening strategy, compared
with current practice, in both vaccinated and unvaccinated cohorts. The effect of vaccination on the
incidence of the vaccine-included types was modelled using the dynamic transmission model (which took
into account the effects of prior exposure to HPV on vaccine effectiveness and also herd immunity); these
differences in HPV incidence were then input to the CIN natural history model and this difference thus
impacted the rate of development of HPV 16- and 18-associated CIN and cervical cancer in the model.
We assumed that the HPV 16/18 vaccine was 100% effective in preventing future HPV 16 and HPV 18
infections in HPV-naive women at the time they were vaccinated and who completed all three doses of the
vaccine course. This protection was assumed to be life-long. We made these assumptions so that the most
generous estimate of vaccine effectiveness can be taken into account when considering new options for
cervical screening, when compared with unvaccinated scenarios. No protection was conferred in the model
in women with a prevalent infection at the time of vaccination, or who are immune (due to a naturally
acquired previous infection) from infection at the time of vaccination. The model assumed that the vaccine
conferred no therapeutic effect in women with a prevalent HPV infection, or with pre-existing CIN. In this
case, the risk of viral clearance, progression, or regression from CIN in the model remains the same as that
in an unvaccinated woman. It was also assumed that an incomplete vaccine course offered no protection;
however, the possibility of higher ‘effective’ vaccine coverage in England due to effective two-dose or
one-dose vaccination was examined in sensitivity analyses (see Appendix 17).
We did not consider the effects of cross-protection against non-vaccine HPV types, nor, as we were
carrying out a cost-effectiveness evaluation of cervical screening (as opposed to vaccination), did we
consider the effects of vaccination on anogenital warts. Thus, the results of our analysis are applicable
to situations where either bivalent or quadrivalent vaccines have been used.
The screening evaluations in vaccinated women involved a modelled cohort of women born in 1998 who
were offered vaccination as 12-year-olds in 2010. Herd immunity effects on the modelled cohort from
vaccination delivered to both older birth cohorts (born 1990–7; included in the catch-up programme) and
younger birth cohorts (1999 or later) were fully taken into account by the dynamic transmission model.
Thus, the effects of the catch-up cohort were included in our analysis through the herd immunity effects
they provided to the cohort we investigated for screening. The overall clinical effectiveness of the vaccine
administered to the catch-up cohorts was expected to be lower because some of these women will have
had prior exposure to HPV; however, for HPV-naive women in the catch-up cohorts, the vaccine is
assumed to be clinically effective, and these effects were taken into account in the dynamic transmission
model. The outcomes for catch-up cohorts are, therefore, expected to be intermediate to those predicted
and presented here for HPV-naive vaccinated cohorts and unvaccinated cohorts.
In the model, we used a hierarchical approach to lesion type-assignment when ﬁtting the model to
observed data (ﬁtting HPV 16-positive ﬁrst, then HPV 18-positive, then other oncogenic types). Because of
the potential for multiple infections, this method may result in underestimation in the model of the
prevalence of other oncogenic-type infections. However, in our model, women who are vaccinated against
HPV types 16 and 18 are available to contract other HR HPV types, partially reducing the effects of this
modelling assumption in vaccinated populations.
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Diagnosis and treatment procedures
The diagnosis and treatment procedures simulated in the model are detailed in Figures 8–10.
Data sources
Screening and diagnostic test characteristics
Liquid-based cytology
With regard to the sensitivity of LBC, in the base case it was assumed that test positivity rates for CIN2+
were equivalent to those from a multicentre screening study conducted in UK (the HART study).29
Colposcopy if referred by
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Adequate and
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and normal
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Excisional treatment for
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Excisional treatment for
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FIGURE 9 Colposcopy management for women referred with moderate/severe cytology. a, Immediate in women over
50 years; delay 12 months in women younger than 50 years. b, Women diagnosed with invasive cancer undergo
cancer treatment. Women treated for CIN undergo HPV and cytology testing 6 months post treatment. If both
cytology and HPV negative, women are returned to routine screening. Women with abnormal cytology or
positive HPV result are referred to colposcopy and are subsequently followed up under current practice
post-treatment management.
Colposcopy if referred by borderline/mild
cytology and/or HPV positive test
Cytology follow-up
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normal
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FIGURE 8 Colposcopy management for women referred with borderline/mild cytology and/or a HPV positive test.
a, Women diagnosed with invasive cancer undergo cancer treatment. Women treated for CIN undergo HPV and
cytology testing 6 months post treatment. If both cytology and HPV negative, women are returned to routine
screening. Women with abnormal cytology or positive HPV result are referred to colposcopy and are subsequently
followed up under current practice post-treatment management. b, At the 12-month follow-up, any abnormal
cytology result is referred to colposcopy. Women with normal cytology are referred to routine screening.
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ARTISTIC cytology test characteristics were not assumed for the national evaluation [although they were
used for the validation exercise reported in Chapter 3 of this report (see Economic analysis validation
results)] because ARTISTIC did not recruit nationally, and it is possible that cytology in the baseline round
of ARTISTIC was inﬂuenced by the retraining associated with the recent introduction of LBC to the
NHSCSP at the time of the trial commencement.2
Although HART was conducted a number of years prior to ARTISTIC, and did not involve LBC, it did recruit
across a wider range of centres and thus is more likely to be representative of the performance of cytology
across England. The use of HART data to represent LBC test accuracy was considered to be appropriate
because the sensitivity of LBC and conventional cytology for detection of CIN2+ have been shown in
meta-analysis to be close to equivalent,30 and the inadequate smear rate for LBC (which is known to be lower
than the rate for conventional cytology in England) was speciﬁcally modelled using other data sources. In the
current analysis, the inadequate rate of LBC was assumed to be 3% in the analysis base case.19
The test positivity rates derived from HART data for cytology for CIN2+ and CIN3+ were 76.7% and
75.9%, respectively, at a borderline dyskaryosis smear threshold; and 70.1% at both CIN2+ and CIN3+,
at a mild dyskaryosis smear test threshold. With regard to the speciﬁcity of LBC, the positivity rate for CIN1
was assumed to be 37.6% at a borderline dyskaryosis smear threshold and 28.0% at a mild dyskaryosis
smear threshold. Alternative sets of test characteristics for LBC, encompassing the test characteristics
derived for ARTISTIC, were investigated in the sensitivity analysis (see Appendix 11 for more details).
Human papillomavirus testing
The HPV test positivity rate used in the base-case analysis and its range for sensitivity analysis was
informed by a previous meta-analysis of international literature,31 and also ﬁndings from the ATHENA
trial32 and the HART study.29 The accuracy of HPV testing was based on extensive data in the literature on
HC2 testing, which were used in ARTISTIC and HART. The use of these test characteristics does not
necessarily assume that the speciﬁc platform was used, but assumes that HC2 or alternative platforms with
close-to-equivalent performance were used. For some strategies, the use of new automated test platforms
with partial genotyping for HPV 16/18 was assumed (sometimes referred to as ‘genotyping’ here).
Biopsy
CIN1a or lessCIN 2/3
Cytology follow-up
at 6 months
Excisional treatment for precancerous
lesion and follow-up at 6 months as per
Sentinel Sites test of cureb
Normal
cytology
Routine recall
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Cytology follow-up
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FIGURE 10 Management for women undergoing biopsy. a, A small proportion of CIN1 are assumed to be treated
along with CIN2+. b, Women undergo HPV and cytology testing 6 months post treatment. If both cytology and HPV
negative, women are returned to routine screening. Women with abnormal cytology or positive HPV result are
referred to colposcopy and are subsequently followed up under current practice post-treatment management.
c, At the 12-month follow-up, any abnormal cytology result is referred to colposcopy. Normal cytology is referred to
routine screening.
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With regard to the sensitivity of HPV test, in the base case it was assumed that the test positivity rates for
CIN2 and CIN3 were 95.5% and 95.7%, respectively. With regard to speciﬁcity, the test positivity rate for
CIN1 was assumed to be 84.2% (see Appendix 11 for more details).
The base-case assumptions assumed that the HPV test threshold was such that the test performance was
equivalent to HC2 at a 2 pg/ml threshold. However, the sensitivity analysis encompassed the possibility that
a test with performance equivalent to that of HC2 with a threshold of 1 pg/ml performance was used.
Colposcopy
The test characteristics and unsatisfactory rate of colposcopy were based on those used in previous
modelling work performed in the UK and Australian context.12,18,20 The test positivity rate for colposcopy
was assumed in the base case for CIN1 and CIN2+ to be 79.2% and 90.8%, respectively. Colposcopy was
assumed to be capable of detecting abnormalities of the cervix in all women with undiagnosed cervical
cancer at the time of examination (see Appendix 11 for more details).
Compliance with screening and management recommendations
For strategies that simulate current practice, we used registry data from Oxfordshire to estimate the
cumulative rescreened proportion at various times after a negative smear for women who appeared on the
register.33 We used age-speciﬁc data on the percentage of eligible women who attended at least once in a
5-year period in England (2007–8)12,34 to adjust these data and derive age- and interval-speciﬁc
probabilities of women attending for routine screening. This allows the model to take into account
non-attendance, early rescreening, late rescreening, and screening in ages outside the target age range
for screening.
For the primary HPV screening strategies involving a recommended 6-yearly interval, the proportion of
women rescreened at the sixth year after the last negative test was assumed to be the same as the
observed proportion for current practice after the third year following a negative cytology test, or ﬁfth year
in women older than 50 years.
Compliance with follow-up recommendations for HPV-positive, cytology-triage-negative women was
assumed to be 80% by the recommended follow-up interval (either 24 or 12 months) in the base case.
This is higher than the compliance rate observed in the ARTISTIC trial, although ARTISTIC was not
nationally representative. Currently, women are either referred for colposcopy (if they have a cytology
result of borderline or mild dyskaryosis and a positive HPV test, or if they have moderate or severe
dyskaryosis) or referred back to routine screening after their primary screening test. Therefore, there is no
directly analogous situation for the NHSCSP from which we can take up-to-date data on compliance for
the future scenario in which HPV-positive, triage-negative women are referred for follow-up. However, the
NHS Sentinel Site experience has shown that compliance with colposcopy referral in women with a
cytology low-grade result who were HPV positive was 90.2% (with a range of 81.4–96.2% depending on
the region). Although this relates to colposcopy referral rather than to follow-up compliance, the Sentinel
Site experience is more representative nationally than ARTISTIC. The use of two alternate recommended
follow-up intervals in this group effectively also assessed the sensitivity of the ﬁndings to compliance
assumptions (as our modelled simulation of 80% compliance to follow-up at a recommended 24 months
is analogous to a situation where the recommended follow-up was 12 months with poor compliance to
that interval and in which late attendance between 12 and 24 months occurred in the remaining women).
Compliance to referral for colposcopy and compliance for follow-up at intervals of either 6 months or
12 months in the new strategies were assumed to remain the same as current practice (see Appendix 12
for more details).
Cost and utilities (quality-adjusted life-year weights)
The costs of HPV testing both for general HR types and speciﬁcally for genotypes 16/18 were obtained
from the manufacturers of four HPV tests: the Abbott® RealTime High Risk HPV test (Abbott Molecular,
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Maidenhead, UK), the Cobas 4800 HPV test (Roche®), Cervista® HPV HR and Cervista® HPV 16/18
Cervista™ HPV (Hologic®) and the Digene HC HR HPV DNA test and the HPV Genotyping PS test, which
can test for HPV 16, 18 and also HPV 45 if required (Qiagen, Gaithersberg, MD, USA). The average cost
across the manufacturer-supplied prices was used as the baseline estimate for the unit cost of HPV testing.
In the base case, we assumed partial genotyping would be obtained at no extra cost (based on the
emergence of systems that provide this information as standard) but the effects of this assumption were
assessed in sensitivity analysis.
The cost of LBC was based on reanalysis of the cost data from the MAVARIC study19 and the costs of
diagnosis and treatment for CIN and cancer were based on the ﬁndings of Martin-Hirsch et al.35 and
Sherlaw-Johnson et al.36 All costs for the ﬁnal model inputs were adjusted using the Hospital and
Community Health Service (HCHS) pay and price index to the year 201037 (see Appendix 13 for details on
the costs used in the model). Probabilistic sensitivity analysis (PSA) was performed to access the robustness
of the results to the input costs.
For this evaluation the primary outcome for effectiveness was considered to be life-years saved, because
there is a paucity of data to inform the choice of quality-adjusted life-year (QALY) weights (health-state
utilities) for HPV testing when it is used as a primary screening test, and for the subsequent referral and
management processes. However, as a supplementary analysis and as a secondary outcome of the
evaluation, two sets of QALY weights were used to examine the potential impact of considering QALYs,
and to assess the sensitivity of the ﬁndings to the particular choice of QALY weights. These were
as follows.
Quality-adjusted life-year weights set 1
The ﬁrst set of weights used for the current analysis was from a study recently conducted speciﬁcally
to assess health-state utilities relevant to primary HPV screening and subsequent triage testing and
management. This study was conducted in metropolitan Sydney, NSW, Australia, and measured QALY
weights via a two-stage standard gamble.38 The QALY weights for patients diagnosed with invasive cervical
cancer were obtained from published studies.39,40 Based on the study ﬁndings, this set of weights assigned
some disutility to the experience of being screened, even if the test result was negative.
Quality-adjusted life-year weight set 2
Previously published weights were used,40,41 although these were not obtained in the context of health-state
preference assessment speciﬁcally for primary HPV testing. This set of weights did not assign any disutility
to the experience of being screened per se.
Details of QALY weight assumptions used in the model are provided in Appendix 14. The impact of
the choice of QALY weights was assessed via comparison of the ﬁndings using the two different sets
of weights.
Human papillomavirus vaccination coverage rates
The screening evaluations in vaccinated women involved a modelled cohort of women born in 1998 and
offered vaccination as 12-year-olds in 2010. In the base case it was assumed that the HPV vaccination
coverage rate was as reported in 2010–11 by the Department of Health (84.2% three-dose coverage rate
in routinely vaccinated 12- to 13-year-old girls).42 As vaccination is an ongoing activity and it is possible
that this level of coverage is not constant over time, and as emerging data on two-dose efﬁcacy suggest
the possibility of relatively high effectiveness for two doses (meaning that the ‘effective’ coverage in
England may be higher than the reported three-dose coverage), lower and higher coverage rates for
vaccination were investigated in sensitivity analysis (see Appendix 15 for details of the age-speciﬁc
vaccination coverage used in the model).
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Demographic data and cancer survival
The rate of death from causes other than cervical cancer was calculated by subtracting the rate of cervical
cancer death43 from all-cause mortality rate.44 The rate of benign hysterectomy was obtained from a
published study conducted in England and Wales.45 The invasive cancer survival rates used in the model
were based on the previous work.19
Sensitivity analysis
Probabilistic sensitivity analyses were performed separately for cost assumptions for selected strategies.
Strategies for which full PSAs were performed included all basic strategies and the strategy variants
associated with the most favourable outcomes.
One-way sensitivity analyses were also performed to determine how sensitive the outcomes were to
various model assumptions. The following assumptions were varied over a feasible range of
possible values:
1. screening attendance rate
2. compliance to colposcopy referral
3. test characteristics for HPV testing
4. test characteristics of LBC (accuracy and inadequate rate)
5. test accuracy of colposcopy
6. assumptions regarding CIN progression and regression
7. the proportion of new oncogenic HPV infections attributable to HPV 16/18
8. vaccination coverage.
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Chapter 3 Results
ARTISTIC STUDY EXTENSION
Follow-up characteristics and compliance through the
three rounds of screening
The Consolidated Standards of Reporting Trials (CONSORT) diagram (Figure 11) shows that, of the
24,510 women who entered the trial, 15,790 (64.4%) were screened in round 2 and 8873 (36.2%) were
screened in round 3 between January 2006 and June 2009, including 6337 who had also been screened
in round 2.
The numbers of women screened, median duration of follow-up and lesions detected in rounds 2 and 3
are shown in Table 2, according to the deﬁnitions of rounds 2 and 3 used in this report (deﬁnition 1:
round 2, 26–54 months; round 3, > 54 months after entry and > 24 months after round 2), and the
original deﬁnition of round 2 used in the initial ARTISTIC HTA report1 (deﬁnition 2: round 2, 30–48 months;
round 3, > 48 months after entry and > 24 months after round 2). Whichever deﬁnition is used, the
numbers of lesions detected in rounds 2 and 3 combined are similar, but deﬁnition 1 increases the number
of lesions in round 2.
Table 3 shows the characteristics at entry of women attending at round 2, rounds 2 and 3, and round 3
but not round 2. Attendance was unrelated to allocated arm, and the apparently lower round 2
attendance rates in women who were HPV-positive or had moderate+ cytology at entry are due to the
exclusion of round 1 CIN2+ cases in round 2. Their round 2 attendance rates when these are ignored are
76.1% (102 out of 134) for moderate+ cytology and 63.5% (2070 out of 3262) for HPV positive.
Cumulative follow-up (Kaplan–Meier analysis of time to next cytology or HPV test) up to 8 years after entry
in women with normal cytology at entry was identical in the randomised arms: 79.7% [95% conﬁdence
interval (CI) 77.3% to 82.0%] concealed and 79.7% (95% CI 79.0% to 80.5%) revealed. Cytology
outside the study area could not be ascertained reliably, so these long-term rates probably underestimate
the proportion with any subsequent cytology.
The cumulative follow-up to next cytology or HPV test within 24 months in women who were HPV positive
and cytologically normal at each screening round indicates the proportion of women complying with
allocated recall. This proportion was 62.4% by 24 months after round 1 and 58.3% by 24 months after
round 2 in the revealed arm.
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25,078 women agreed to
participate and randomised 1 : 3
HPV concealed HPV revealed
430 outside age range
or inadequate samples
453 CIN2+ detected and
treated within 30 months
of round 1 sample and
4165 with no known
cytology after round 1
88 CIN2+ detected and
treated within 30 months
of round 2 sample and
7015 with no known
cytology after round 2
138 outside age range
or inadequate samples
134 CIN2+ detected and
treated within 30 months
of round 1 sample and
1432 with no known
cytology after round 1
35 CIN2+ detected and
treated within 30 months
of round 2 sample and
2315 with no known
cytology after round 2
6262 18,816
6124 18,386
2208 6665
11,862
24,510 with adequate
cytology and HPV
tests at round 1 (entry)
15,790 with adequate
cytology at round 2
8873 with adequate
cytology at round 3
3928
630 1578 19064759
FIGURE 11 Consolidated Standards of Reporting Trials diagram.
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TABLE 2 Study numbers and exclusions by alternative deﬁnitions of rounds 2 and 3
Round (R) and grades of CIN detected
Deﬁnition 1 (this report):
R2, 26–54 months after entry;
R3, > 54 months after entry
and > 24 months after R2
Deﬁnition 2 (previous report):
R2, 30–48 months after entry;
R3, > 48 months after entry
and > 24 months after R2
R2
n 15,790 14,336
Follow-up (months) 26–54 (median 36.6) 30–48 (median 36.6)
CIN2 70 57
CIN3+ 53 45
CIN2+ 123 102
R3
n 8873 9781
Follow-up (months) 54.1–95.3 (median 72.7) 48.1–95.3 (median 71.8)
CIN2 35 43
CIN3+ 31 39
CIN2+ 66 82
R2 + R3
CIN3+ 84 84
CIN2+ 189 184
Excluded CIN2+ by this deﬁnition onlya One CIN3 Five CIN2, one CIN3
a In addition, another six CIN+ were excluded by both deﬁnitions: ﬁve CIN2 and one CIN3.
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Relationship between age, cytology and human papillomavirus
by round of screening
The HPV prevalence by round and age at that round is shown in Table 4, using a RLU/Co of 1. The
advancing age of the cohort meant that in round 3 there were HPV data for a small number of women
aged 65 years and older. It is interesting to note that the HPV prevalence according to age did not change
a great deal between rounds, except that between rounds 1 and 2 there was a fall among women aged
over 40 years, and between rounds 2 and 3 there was a rise of similar magnitude. In the previous
ARTISTIC HTA report,1 the high population of ‘false positive’ HR results in older women was noted, but
this should not change between rounds in similarly aged quinquennia.
In women aged between 25 and 64 years, the HPV rate did fall from 12.7% in round 1 to 8.3% in round
2 and increased to 10.6% in round 3. This fall is probably explained by treatment of CIN which cleared
infection, and also the natural clearing of infection within the ageing cohort. The reason for the small
increase in round 3 is unclear but may be due to newly acquired infection in women over 40, among
whom the increased rate has occurred. It could be due in part to the higher false-positive rate with HC2 in
older women as reported in the original ARTISTIC HTA report.1 We have looked at the possibility that
those attending in round 3 selected, for some reason, women with a higher HPV prevalence in round 1,
but this was not the case. The age-standardised HPV prevalence at round 1 for those women who
attended in rounds 1, 2 and 3, and rounds 1 and 3 only, were 10.9% and 9.1%, respectively, compared
with 10.6% for the entire cohort at round 1.
TABLE 3 Percentage of women with round 2 and round 3 cytology by characteristics at entry (HC2 cut-off
RLU/Co ≥ 1)
Characteristics at entry
Round 1,
n (%)
Round 2,
n (%)
Round 3 and round 2,
n (%)
Round 3, no round 2,
n (%)
Arm
Revealed 6124 (100) 3928 (64.1) 1578 (25.8) 630 (10.3)
Concealed 18,386 (100) 11,862 (64.5) 4759 (25.9) 1906 (10.4)
HPV status
Negative 20,697 (100) 13,720 (66.3) 5382 (26.0) 2170 (10.5)
Positive 3813 (100) 2070 (54.3) 955 (25.0) 366 (9.6)
Cytology
Normal 21,380 (100) 13,930 (65.2) 5450 (25.5) 2349 (11.0)
Mild/borderline 2667 (100) 1758 (65.9) 816 (30.6) 176 (6.6)
Moderate+ 463 (100) 102 (22.0) 71 (15.3) 11 (2.4)
Age at entry (years)
20–24 2600 (100) 1292 (49.7) 656 (25.2) 350 (13.5)
25–29 2589 (100) 1349 (52.1) 729 (28.2) 342 (13.2)
30–39 7633 (100) 4858 (63.6) 2698 (35.3) 893 (11.7)
40–49 6096 (100) 4311 (70.7) 1890 (31.0) 557 (9.1)
50–64 5592 (100) 3980 (71.2) 364 (6.5) 394 (7.0)
All women 24,510 (100) 15,790 (64.4) 6337 (25.9) 2536 (10.3)
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Whether or not round 3 women were screened in round 2 is shown in Table 5. Twenty-nine per cent
of round 3 women had not been screened in round 2, a ﬁgure which was similar between the arms.
A higher proportion of moderate+ cytology was seen in women who did not attend for an intermediate
round of screening (0.9% vs. 0.4%).
The proportion with abnormal cytology was 12.8%, 5.0% and 4.6% in rounds 1, 2 and 3, respectively
(Table 6). Figures 12 and 13 show the proportion of HPV positive results by cytology grade in each of the
arms and Table 6 shows the cytology results in rounds 1, 2 and 3, respectively. The proportions of women
who were HPV positive remained broadly similar in the two arms of the trial and within each grade
of abnormality.
Relationship between human papillomavirus, cytology and age
over three rounds
Figure 14 depicts the comparable proportion of women who tested cytology negative and HPV positive
according to their age at that round, and the proportions of low-grade and high-grade cytology, according
to age at round 1, 2 and 3, are shown in Figures 15 and 16, respectively. The numbers of abnormalities in
round 3 are small due to the effect of previous screening and the reduced proportion of the original
cohort being screened. The number of women under age 25 years fell as the cohort became older, with
almost none by round 3. By contrast, the number of women aged over 64 years increased.
As has been found elsewhere, the proportion of HPV-positive women overall fell rapidly with age.
This is most obvious in women with normal cytology, where HPV prevalence decreased from around 25%
in those under 25 years to around 5% in those over 50 years; this remained relatively unchanged over
the rounds. There was also a marked fall in the HPV positivity rate by age among women with abnormal
cytology in round 1. In rounds 2 and 3, the proportion of women with cytological abnormalities was much
lower and the data by age became sparse.
The numerical data (see Tables 62–71 in Appendix 8) allow an indication of primary screening with HPV
triaged with cytology to be shown over repeated rounds of screening. The round 1 data are broadly
representative of what would happen in routine population-based screening, and rounds 2 and 3 reﬂect
the impact of the detection of disease in the ﬁrst (prevalent) round.
TABLE 4 Human papillomavirus prevalence by round and age at round (HC2 cut-off RLU/Co ≥ 1)
Round 1 Round 2 Round 3
HPV+/total (%) HPV+/totala (%) HPV+/totala (%)
Age at round (years)
20–24 1036/2600 (39.85) 139/418 (33.25) 4/14 (28.57)
25–29 717/2589 (27.69) 246/972 (25.31) 198/754 (26.26)
30–39 1161/7633 (15.21) 433/3567 (12.14) 314/2504 (12.54)
40–49 533/6096 (8.74) 248/4428 (5.60) 263/3330 (7.90)
50–59 290/4351 (6.67) 143/3319 (4.31) 93/1462 (6.36)
60–64 76/1240 (6.13) 47/1112 (4.23) 13/287 (4.53)
65–70 N/A (N/A) 12/416 (2.88) 6/77 (7.79)
Total 3813/24,510 (15.56) 1268/14,232 (8.91) 891/8428 (10.57)
N/A, not applicable.
a Total = non-missing HPV results.
DOI: 10.3310/hta18230 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 23
29
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 6 Cytology results by arm and round
Cytology
Round 1, n (%) Round 2, n (%) Round 3, n (%)
Revealed Concealed Revealed Concealed Revealed Concealed
Negative 16,042 (87.3) 5338 (87.2) 11,282 (95.1) 3715 (94.6) 6355 (95.4) 2106 (95.4)
Borderline 1343 (7.3) 446 (7.3) 350 (3.0) 138 (3.5) 150 (2.3) 51 (2.3)
Mild 643 (3.5) 235 (3.8) 183 (1.5) 59 (1.5) 115 (1.7) 37 (1.7)
Moderate 204 (1.1) 67 (1.1) 28 (0.2) 11 (0.3) 16 (0.2) 8 (0.4)
Severe+ 154 (0.8) 38 (0.6) 19 (0.2) 5 (0.1) 20 (0.3) 6 (0.3)
Total 18,386 6124 11,862 3928 6665 2208
TABLE 5 Characteristics for women with round 3 cytology by presence of round 2 cytology
Characteristics at round 3 With round 2, n (%) Without round 2, n (%)
Arm
Revealed 4759 (75.1) 1906 (75.2)
Concealed 1578 (24.9) 630 (24.8)
HPV status
–ve 5403 (89.5) 2134 (89.3)
+ve 635 (10.5) 256 (10.7)
Not done 299 146
Cytology
Normal 6056 (95.6) 2405 (94.8)
Mild/borderline 255 (4.0) 107 (4.2)
Moderate+ 26 (0.4) 24 (0.9)
Age at round 3 (years)
24–29 478 (7.6) 318 (12.5)
30–39 1835 (29.0) 804 (31.7)
40–49 2751 (43.4) 757 (29.9)
50–59 1072 (16.9) 464 (18.3)
60–64 155 (2.4) 154 (6.1)
≥ 65 44 (0.7) 39 (1.5)
All women 6337 (100) 2536 (100)
–ve, negative; +ve, positive.
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FIGURE 14 Proportion of normal cytology with a positive HPV result according to age at round. R, round.
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FIGURE 12 Proportion of HPV-positive results by cytology grade and round in the concealed arm.
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FIGURE 13 Proportion of HPV-positive results by cytology grade and round in the revealed arm.
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Patterns of any lesion of CIN2+ over three rounds of screening
The impact of screening in the initial (prevalence) round is shown in Table 7, with a marked fall in the
proportion of women with CIN2+ between rounds 1 and 2, but not between rounds 2 and 3. The
cumulative risk of CIN2+ was 3.9% (95% CI to 3.6% to 4.3%) in the revealed arm and 3.7% (95% CI
3.2% to 4.3%) in the concealed arm. There was no signiﬁcant difference between the arms [odds ratio
(OR) 1.1, 95% CI 0.9 to 1.3; p > 0.1]. The corresponding ﬁgures for CIN3+ were 2.1% (95% CI 1.7% to
2.6%) in the revealed arm and 1.9% (95% CI 1.7% to 2.2%) in the concealed arm (OR: 0.9, 95% CI 0.7
to 1.2, p > 0.1).
Logistic regression analysis of abnormality rates adjusted for age and randomisation arm for HPV and
cytology (also adjusting for HPV) is shown in Table 8. Both HPV and cytology showed a signiﬁcant decrease
between rounds 1 and 2. HPV was signiﬁcantly more prevalent in round 3 than in round 2.
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FIGURE 16 Proportion of moderate+ cytology with a positive HPV result according to age at round. R, round.
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FIGURE 15 Proportion of borderline/mild cytology with a positive HPV result according to age at round. R, round.
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Those who had negative cytology but were HPV positive at entry continued to develop CIN2+ at a higher
rate than the overall proportion of CIN2+ in round 1, and at a higher rate than women with abnormal
cytology who were HPV negative (Table 9).
CIN2+ detected in rounds 1, 2 and 3 according to HPV status and cytology grade in the corresponding
round is shown in Table 9. Although the numbers are smaller, the relationship between HPV, cytology and
CIN2+ remain essentially the same when compared with the round 1 data. Around 20–30% of women
with abnormal cytology who are HPV positive had CIN2+ detected in each of the rounds.
TABLE 7 CIN2 and CIN3+ by randomisation arm and round
Round
Randomisation arm
Total, n (%)Concealed, n (%) Revealed, n (%)
Round 1 (entry)
CIN2 53 (0.86) 220 (1.20) 273 (1.11)
CIN3+ 81 (1.32) 233 (1.27) 314 (1.28)
CIN2+ 134 (2.19) 453 (2.46) 587 (2.39)
Total women 6124 18,386 24,510
Round 2
CIN2 18 (0.46) 52 (0.44) 70 (0.44)
CIN3+ 17 (0.43) 36 (0.30) 53 (0.34)
CIN2+ 35 (0.89) 88 (0.74) 123 (0.78)
Total women 3928 11,862 15,790
Round 3
CIN2 7 (0.32) 28 (0.42) 35 (0.39)
CIN3+ 8 (0.36) 23 (0.35) 31 (0.35)
CIN2+ 15 (0.69) 51 (0.77) 66 (0.74)
Total women 2208 6665 8873
Rounds 1+ 2
CIN2 71 (1.32) 272 (1.64) 343 (1.55)
CIN3+ 98 (1.75) 269 (1.57) 367 (1.62)
CIN2+ 169 (3.06) 541 (3.19) 710 (3.16)
Rounds 1+ 2+ 3
CIN2 78 (1.64) 300 (2.06) 378 (1.94)
CIN3+ 106 (2.11) 292 (1.92) 398 (1.97)
CIN2+ 184 (3.72) 592 (3.93) 776 (3.88)
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TABLE 8 Logistic regression analysis comparing abnormality rates over screening rounds
Screening round Adjusteda OR 95% CIs
HC2+ve (adjusted for age and arm)
1 1.00
2 0.73 (0.68 to 0.78)
3 0.87 (0.81 to 0.95)
Borderline/mild cytologyb (adjusted for age, HPV and arm)
1 1.00
2 0.45 (0.40 to 0.49)
3 0.38 (0.34 to 0.43)
Moderate+ cytology (adjusted for age, HPV and arm)
1 1.00
2 0.32 (0.23 to 0.42)
3 0.42 (0.31 to 0.58)
+ve, positive; NS, not signiﬁcant.
a Variables were age at round, cytology result, HPV result (16/18, 31/33/45, other, –ve) and randomisation arm
(NS in all models).
b Moderate+ cytology excluded from this model.
TABLE 9 CIN2+ rate by round and HPV status/cytology at entry (round 1) (% with CIN2+)
Cytology
Concealed arm Revealed arm
HPV–ve HPV+ve Subtotal HPV–ve HPV+ve Subtotal
Round 1
Normal 0/4787 (–) 1/551 (0.18) 1/5338 (0.02) 0/14,367 (–) 32/1675 (1.91) 32/16,042 (0.20)
Abnormal 7/384 (1.82) 126/402 (31.34) 133/786 (16.92) 29/1159 (2.50) 392/1185 (33.08) 421/2344 (17.96)
Total 7/5171 (0.14) 127/953 (13.33) 134/6124 (2.19) 29/15,526 (0.19) 424/2860 (14.83) 453/18,386 (2.46)
Round 2
Normal 7/3124 (0.22) 13/331 (3.93) 20/3455 (0.58) 25/9471 (0.26) 36/1004 (3.59) 61/10,475 (0.58)
Abnormal 1/284 (0.35) 14/189 (7.41) 15/473 (3.17) 4/841 (0.48) 23/546 (4.21) 27/1387 (1.95)
Total 8/3408 (0.23) 27/520 (5.19) 35/3928 (0.89) 29/10,312 (0.28) 59/1550 (3.81) 88/11,862 (0.74)
Round 3
Normal 4/1745 (0.23) 8/207 (3.86) 12/1952 (0.61) 25/5189 (0.48) 16/660 (2.42) 41/5847 (0.70)
Abnormal 1/148 (0.68) 2/108 (1.85) 3/256 (1.17) 2/472 (0.42) 8/346 (2.31) 10/818 (1.22)
Total 5/1893 (0.26) 10/315 (3.17) 15/2208 (0.68) 27/5659 (0.48) 24/1006 (2.39) 51/6665 (0.77)
–ve, negative; +ve, positive.
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The abnormality rates in the concealed arm in terms of histopathology, cytology and HPV detection over
the three rounds are shown in Table 10. Largely similar falls proportionately were seen with CIN2+ rates
and high-grade cytology and low-grade cytology, all of which reﬂect to some extent treatment of detected
disease and the reduced prevalence of disease in serial rounds of screening. The rate of HPV infection also
fell reﬂecting both treatment of CIN and the ageing cohort.
The impact of being screened or not in round 2 on round 3 outcomes is shown in Table 11. Among the
round 3 women who had not attended in round 2, the overall proportion of women with CIN2+ was
1.11% and 1.42% in the concealed and revealed arms, respectively, compared with 0.5% for both arms
in round 3 women who had been screened in round 2. The same effect was seen whether HPV
positive or HPV negative at entry to the study. This conﬁrms the protective effect of regular repeated
rounds of screening.
TABLE 10 Rates of positive test results in the concealed arm over rounds 1, 2 and 3 (%)
Round Histopathology (CIN2+)
Abnormal cytology
HPV+ve rateHigh grade Low grade
Round 1 2.19 1.7 11.1 15.6
Round 2 0.89 0.4 5.0 9.0
Round 3 0.69 0.6 4.0 10.0
+ve, positive.
TABLE 11 Round 3 CIN2+ rate by presence of round 2 cytology and HPV status/cytology at entry (%)
Round 3 cytology
Concealed arm Revealed arm
HPV–ve HPV+ve HPV–ve HPV+ve
Normal
With round 2 2/1230 (0.16) 5/134 (3.73) 13/3636 (0.36) 3/450 (0.67)
Without round 2 2/515 (0.39) 3/73 (4.11) 12/1551 (0.77) 13/210 (6.19)
Abnormal
With round 2 1/130 (0.77) 0/84 1/386 (0.26) 7/287 (2.44)
Without round 2 0/18 2/24 (8.33) 1/86 (1.16) 1/59 (1.69)
Total
With round 2 3/1360 (0.22) 5/218 (2.29) 14/4022 (0.35) 10/737 (1.36)
Without round 2 2/533 (0.38) 5/97 (5.15) 13/1637 (0.79) 14/269 (5.20)
–ve, negative; +ve, positive.
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Cumulative detection of any lesion of CIN2+ over three screening
rounds according to baseline human papillomavirus test and
cytology results
The cumulative risk of being diagnosed with CIN2+ over approximately 6 years is shown in Tables 12–16.
The cumulative rate of CIN2+ was 0.67% (95% CI 0.51% to 0.87%) for women who were both cytology
negative and HPV negative at baseline compared with 37.4% (95% CI 34.91% to 40.04%) for women
who were cytology positive/HPV positive (see Table 14). The cumulative risk in the HPV-positive group
[20.12% (95% CI 18.68% to 21.61%)] is identical to that in the abnormal cytology group [20.12%
(95% CI 19.04% to 22.08%)]. This reinforces the relative similarity in sensitivity between LBC and HPV
testing already reported in the ARTISTIC study.1 There is, however, a signiﬁcantly lower cumulative risk
TABLE 12 Cumulative CIN2+ rate by HPV status and cytology at entry
Cytology HPV
Round 1,
CIN2+/n (%)
Round 2,
CIN2+/n (%)
Round 3,
CIN2+/n (%)
Cumulative CIN2+ rate,14 %
(95% CI)
Normal − 0/19,154 32/12,595 (0.25) 29/6932 (0.42) 0.67 (0.51 to 0.87)
Abnormal − 36/1543 5/1125 (0.44) 3/620 (0.48) 3.24 (2.32 to 4.38)
Normal + 33/2226 (1.48) 49/1335 (3.67) 24/867 (2.77) 7.73 (6.29 to 9.36)
Abnormal + 518/1587 (32.64) 37/735 (5.03) 10/454 (2.20) 37.44 (34.91 to 40.04)
All women 587/24,510 (2.39) 123/15,790 (0.78) 66/8873 (0.74) 3.88 (3.59 to 4.17)
−, negative; +, positive.
TABLE 13 Cumulative CIN3+ rate by HPV status and cytology at entry
Cytology HPV
Round 1,
CIN3+/n (%)
Round 2,
CIN3+/n (%)
Round 3,
CIN3+/n (%)
Cumulative CIN3+ rate,14 %
(95% CI)
Normal − 0/19,154 11/12,595 (0.09) 10/6932 (0.14) 0.23 (0.14 to 0.36)
Abnormal − 9/1543 (0.58) 1/1125 (0.09) 1/620 (0.16) 0.83 (0.40 to 1.52)
Normal + 11/2226 (0.49) 25/1335 (1.87) 15/867 (1.73) 4.05 (2.98 to 5.36)
Abnormal + 294/1587 (18.53) 16/735 (2.18) 5/454 (1.10) 21.18 (19.03 to 23.45)
All women 314/24,510 (1.28) 53/15,790 (0.33) 31/8873 (0.35) 1.96 (1.76 to 2.17)
−, negative; +, positive.
TABLE 14 Cumulative CIN2+ rate by cytology and HPV status at entry
Round 1,
CIN2+/n (%)
Round 2,
CIN2+/n (%)
Round 3,
CIN2+/n (%)
Cumulative CIN2+ rate,14 %
(95% CI)
Cytology
Normal 33/21,380 (0.15) 81/13,930 (0.58) 53/7799 (0.68) 1.41 (1.19 to 1.65)
Abnormal 554/3130 (17.70) 42/1860 (2.26) 13/1074 (1.21) 20.53 (19.04 to 22.08)
HPV
− 36/20,697 (0.17) 37/13,720 (0.27) 32/7552 (0.42) 0.87 (0.70 to 1.06)
+ 551/3813 (14.45) 86/2070 (4.15) 34/1321 (2.57) 20.12 (18.68 to 21.61)
−, negative; +, positive.
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(p = 0.0002) of developing a CIN2+ lesion following a negative HPV test [0.87% (95% CI 0.70% to
1.06%)] compared with a negative cytology result [1.41% (95% CI 1.19% to 1.65%)] (see Table 14).
An important group is women who were HPV positive/cytology negative at entry. This group had a
cumulative CIN2+ rate over 6 years of 7.73% (CI 6.39% to 9.36%), signiﬁcantly higher than that of those
with abnormal cytology/HPV negative at entry at 3.24% (CI 2.32% to 4.38%) and twice that of the
screened population overall (3.9%). It is quite clear that the risk to these women persists, presumably due
to the proportion who develop long-standing persistent infection.
Table 16 shows cumulative CIN2+ rates over three rounds by both HPV status and age. Within the three
age bands of 20–34, 35–49 and 50–64 at entry, there was a 13-, 33- and 40-fold difference, respectively,
between women who were HPV positive and those who were HPV negative at entry. Women who were
HPV positive and aged between 20–34 years at entry had a cumulative CIN2+ rate of 23.95%, whereas
women who were HPV negative and aged 50–64 years at entry had a cumulative rate of only 0.16%.
TABLE 15 Cumulative CIN3+ rate by cytology and HPV status at entry
Round 1,
CIN3+/n (%)
Round 2,
CIN3+/n (%)
Round 3,
CIN3+/n (%)
Cumulative CIN3+ rate,14 %
(95% CI)
Cytology
Normal 11/21,380 (0.05) 36/13,930 (0.26) 25/7799 (0.32) 0.63 (0.48 to 0.80)
Abnormal 303/3130 (9.68) 17/1860 (0.91) 6/1074 (0.56) 11.01 (9.87 to 12.23)
HPV
− 9/20,697 (0.04) 12/13,720 (0.09) 11/7552 (0.15) 0.28 (0.18 to 0.40)
+ 305/3813 (8.00) 41/2070 (1.98) 20/1321 (1.51) 11.19 (10.05 to 12.40)
−, negative; +, positive.
TABLE 16 Cumulative CIN2+ rate by HPV status and age group at entry
Age group
(years) HPV
Round 1,
CIN2+/n (%)
Round 2,
CIN2+/n (%)
Round 3,
CIN2+/n (%)
Cumulative CIN2+ rate,14 %
(95% CI)
20–34 − 19/6439 (0.30) 25/3633 (0.69) 24/2900 (0.83) 1.80 (1.39 to 2.30)
35–49 − 14/9032 (0.16) 8/6338 (0.13) 8/3953 (0.20) 0.48 (0.31 to 0.72)
50–64 − 3/5226 (0.06) 4/3749 (0.11) 0/699 0.16 (0.07 to 0.34)
20–34 + 408/2437 (16.74) 71/1238 (5.74) 27/872 (3.10) 23.95 (22.03 to 25.94)
35–49 + 127/1010 (12.57) 14/601 (2.33) 6/390 (1.54) 15.92 (13.53 to 18.55)
50–64 + 16/366 (4.37) 1/231 (0.43) 1/59 (1.69) 6.40 (3.12 to 11.47)
−, negative; +, positive.
DOI: 10.3310/hta18230 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 23
37
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
The impact of human papillomavirus genotyping on
screening outcomes
The inﬂuence of HPV genotype can also be examined. Tables 17 and 18 show CIN2+ and CIN3+
cumulative rates, respectively, according to the following groupings: HPV 16 alone, HPV 16/18, HPV 31/33/
45/52/58 or other HR types. Compared with a baseline HPV-negative test, HPV 16/18, HPV 31/33/45/52/58
and other HR types generated a 44-, 29- and 8-fold rate of CIN2+, respectively, over three rounds. There
was a signiﬁcant difference between 16/18 and 31/33/45/52/58 and both were signiﬁcantly greater than
other HR types (all p < 0.0001). HPV 16/18 was associated with a signiﬁcantly greater cumulative rate of
CIN3+ compared with 31/33/45/52/58 and both groups were signiﬁcantly greater than other HR types
(all p < 0.0001). Compared with HPV negative at baseline the CIN3+ rates over three rounds were
92-, 40- and 10-fold for HPV 16/18, 31/33/45/52/58 and other HR types, respectively.
Because of the difﬁculty in assigning a lesion to a speciﬁc HPV genotype in the presence of multiple types,
we chose to assign a multiple type lesion to the individual type highest in a hierarchy based on single type
associated lesions in round 1. These data are shown in Appendix 8 (see Tables 62–64).
The CIN2+ and CIN3+ rates by HPV results in rounds 2 and 3 are shown in Table 19 in relation to HPV
result at entry, thus estimating rates in new and persistent infection. In round 2 there was a greater than
threefold difference in CIN2+ rate between those with ‘new’ HPV infection and those with persistent HPV
(6.21% vs. 21.01%, respectively). In round 3, this difference was almost twofold (7.91% vs. 14.74%).
In both rounds, the CIN2+ rate was similar for women with new HPV infection. There is a similar pattern
for CIN3+ rate, although the numbers are small.
TABLE 18 Cumulative CIN3+ rate by HPV type at entry
HPV at round 1
Round 1, CIN3+/
n (%)
Round 2, CIN3+/
n (%)
Round 3, CIN3+/
n (%)
Cumulative CIN3+ rate,14 %
(95% CI)
Negative 9/20,697 (0.04) 12/13,720 (0.09) 11/7552 (0.15) 0.28 (0.18 to 0.40)
16 191/827 (23.10) 20/339 (5.90) 8/213 (3.76) 30.35 (26.70 to 34.24)
16/18 213/1098 (19.40) 23/487 (4.72) 11/312 (3.53) 25.91 (22.90 to 29.09)
31/33/45/52/58 67/895 (7.49) 11/480 (2.29) 4/338 (1.18) 10.68 (8.46 to 13.23)
Other 25/1820 (1.37) 7/1103 (0.63) 5/671 (0.75) 2.73 (1.86 to 3.85)
TABLE 17 Cumulative CIN2+ rate by HPV type at entry
HPV type at
round 1
Round 1, CIN2+/
n (%)
Round 2, CIN2+/
n (%)
Round 3, CIN2+/
n (%)
Cumulative CIN2+ rate,14 %
(95% CI)
Negative 36/20,697 (0.17) 37/13,720 (0.27) 32/7552 (0.42) 0.87 (0.70 to 1.06)
16 287/827 (34.70) 33/339 (9.73) 9/213 (4.23) 43.55 (39.75 to 47.45)
16/18 331/1098 (30.15) 38/487 (7.80) 14/312 (4.49) 38.49 (34.25 to 41.81)
31/33/45/52/58 152/895 (16.98) 24/480 (5.00) 12/338 (3.55) 23.93 (20.82 to 27.26)
Other 68/1820 (3.74) 24/1103 (2.18) 8/671 (1.19) 6.95 (5.61 to 8.50)
RESULTS
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Tables 20 and 21 indicate the difference in detection of type-speciﬁc CIN2+ and CIN3+, respectively,
among women who had either a newly acquired HPV infection or persistent HPV infection by genotype.
As expected, there is a far higher proportion with disease among women with persistent infection than
newly acquired infection. Types 16/18 and 31/33/45/52/58 conferred a higher risk than other HR types
grouped together.
If screening were based on HPV testing with cytology triage, those women with negative cytology
could be further triaged by HPV genotyping for the purpose of immediate colposcopy referral. The data in
Table 20 show that in round 1, the proportion of CIN2+ and CIN3+ associated with types 16/18 are 56%
and 68%, respectively. Table 21 shows that among screened women ≥ 25 years, this would require an
additional 1.4% (310 out of 21910) of the population to be referred on top of the 4.9% (1074 out of
21910) referred for borderline+ cytology. Referral based on a more inclusive subset of types including
16/18/31/33/45/52/58, for example, could lead to the detection of 82.3% of CIN2+ and 89.2% of CIN3+.
This would, however, necessitate a further 1.8% (347 out of 21910) of the screened population to be
referred for colposcopy. (See Tables 23 and 24 for corresponding tables for all women in ARTISTIC.)
Inﬂuence of different relative light unit/mean control cut-offs
in proportions of women with any lesion of CIN2+
Published data from ARTISTIC6 have indicated that a HC2 cut-off of 2 rather than 1 RLU/Co achieves a
beneﬁcial balance in clinical utility between achieving sensitivity and reducing referral to colposcopy. The
impact of this over three rounds is shown below (Table 22). The projected differential rates of colposcopy
referral and resulting PPVs for HC2-positive women referred with reﬂex cytology showing any
TABLE 20 CIN2+ rate by HPV status at entry and at round
HPV R1
Round 1 (R1) Round 2 (R2) Round 3 (R3)
n CIN2+ %
HPV R2
vs. R1 n CIN2+ %
HPV R3
vs. R1 n CIN2+ %
HC2– 20,697 36 0.17
− 11,770 2 0.02 − 6590 4 0.06
+ (newa) 740 30 4.05 + (newa) 582 27 4.64
16/18 1098 331 30.15
− 211 0 − 193 0
+ (newa) 76 6 7.89 + (newa) 58 4 6.90
+ (persistentb) 108 29 26.85 + (persistentb) 46 9 19.57
31/33/45/
52/58
895 152 16.98
− 237 3 1.27 − 234 0
+ (newa) 66 2 3.03 + (newa) 53 6 11.32
+ (persistentb) 90 15 16.67 + (persistentb) 37 5 13.51
Other or
no HPV
1820 68 3.74
− 746 4 0.54 − 520 1 0.19
+ (newa) 148 10 6.76 + (newa) 104 7 6.73
+ (persistentb) 40 6 15.00 + (persistentb) 12 0
−, negative; +, positive.
a New HR-HPV and no HR-HPV that was present in round 1.
b Any HR-HPV that was present in round 1.
RESULTS
40
NIHR Journals Library www.journalslibrary.nihr.ac.uk
abnormalities when different cut-offs of HC2 are shown in Table 22. The cut-off of ≥ 1 RLU/Co represents
the manufacturer’s recommendation, and the cut-off of ≥ 2.0 represents a clinically more relevant cut-off
based on previously published ARTISTIC data. Essentially, over three rounds there would have been 101
fewer colposcopies (6.2%), with only four (1.5%) fewer CIN3+ and 15 (3.1%) fewer CIN2+ lesions
being detected.
Table 23 shows CIN2+ detection respectively by age, cytology and HPV status (RLU/Co ≥ 1 and
RLU/Co ≥ 2). Among women with abnormal cytology who were HPV positive, the proportion with CIN2+
TABLE 22 Projected rates of colposcopy referral and the resulting PPVs over three rounds of screening based
on borderline or worse (borderline+) cytology in women aged 25 and over testing HC2+ve at cut-offs of ≥ 1
and ≥ 2 RLU/Co
Round
≥ 1.0 RLU/Co ≥ 2.0 RLU/Co
Borderline+/
no. screened
No. lesions/
no. colposcoped (PPV)
Borderline+/
no. screened
No. lesions/
no. colposcoped (PPV)
Cytology (%) CIN3+ (%) CIN2+ (%) Cytology (%) CIN3+ (%) CIN2+ (%)
Round 1 1074/21,910 (4.9) 217/1074 (20.2) 374/1074 (34.8) 1004/21,910 (4.6) 215/1004 (21.4) 363/1004 (36.6)
Round 2 293/13,814 (2.1) 35/293 (11.9) 68/293 (23.2) 277/13,814 (2.0) 35/277 (12.6) 67/277 (24.2)
Round 3 244/8414 (2.9) 27/244 (11.1) 54/244 (22.1) 229/8414 (2.7) 25/229 (10.9) 51/229 (22.3)
Total 1611/44,138 (3.6) 279/1611 (17.3) 496/1611 (30.8) 1510/44,138 (3.4) 275/1510 (18.2) 485/1510 (32.1)
TABLE 21 CIN3+ rate by HPV status at entry and at round
HPV R1
Round 1 (R1) Round 2 (R2) Round 3 (R3)
n CIN3+ %
HPV R2
vs. R1 n CIN3+ %
HPV R3
vs. R1 n CIN3+ %
HC2– 20,697 9 0.04
− 11,770 0 − 6590 0
+ (newa) 740 10 1.35 + (newa) 582 10 1.72
16/18 1098 213 19.40
− 211 0 − 193 0
+ (newa) 76 2 2.63 + (newa) 58 3 5.17
+ (persistentb) 108 20 18.52 + (persistentb) 46 7 15.22
31/33/45/
52/58
895 67 7.49
− 237 1 0.42 − 234 0
+ (newa) 66 0 + (newa) 53 4 7.55
+ (persistentb) 90 10 11.11 + (persistentb) 37 0
Other or
no HPV
1820 25 1.37
− 746 1 0.13 − 520 1 0.19
+ (newa) 148 3 2.03 + (newa) 104 4 3.85
+ (persistentb) 40 2 5.00 + (persistentb) 12 0
−, negative; +, positive.
a New HR-HPV and no HR-HPV that was present in round 1.
b Any HR-HPV that was present in round 1.
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was fairly consistent between rounds in each age range. In round 1, 37% of HPV-positive women aged
between 25 and 34 years with abnormal cytology had CIN2+ detected, indicating that a policy of
restricting colposcopy referral to those women of 35 years or over would not be relevant to our screened
population. The data shown in the tables are for both arms of the trial combined; however, in the revealed
arm the CIN2+ rate in HPV-positive women with normal cytology was 2.0% (11 out of 564), 1.4% (7 out
of 501) and 0.9% (2 out of 217) for age groups 25–34, 35–49 and 50+ years, respectively, in round 1.
Table 24 shows similar data for CIN3+.
What these data do not reﬂect precisely is what would have happened had these two cut-offs been used
prospectively as a triage. A RLU/Co of 1 was used in ARTISTIC round 3 to deﬁne HPV positive for the
purpose of colposcopy triage. In rounds 1 and 2, colposcopy was offered to women with normal cytology
who were persistently HPV positive at 12–24 months. Otherwise, in rounds 1 and 2, HPV status did not
affect referral to colposcopy. In round 3, HPV triage was used with a RLU/Co of 1 to refer women with
low-grade cytological abnormality to colposcopy. A RLU/Co of 2 was used for women in the NHSCSP
Sentinel Sites who were not in the ARTISTIC trial. This threshold of RLU/Co 2 was used based on published
ARTISTIC data showing that it provided a beneﬁcial balance between sensitivity and PPV.
The overall HPV-positive proportions for three rounds using RLU/Co 1 and 2 are shown in Table 25, and
Table 26 shows the corresponding CIN2+ rates by HPV status. A RLU/Co of 2 would result in an absolute
reduction in HPV positive of around 1.5–2.5% per round and a relative reduction in HPV-positive women
of 15–20%. The number of HPV-positive CIN2+ cases if the cut-off were increased from 1 to 2 would be
reduced by only 2.4% (14 out of 587) in round 1 and 5.3% (9 out of 170) in rounds 2 and 3 combined.
The proportion of women with CIN2+ according to HPV RLU/Co is shown in Table 27. It can be seen that
a cut-off of 2 in a given round is associated with a slightly higher PPV in all rounds, reﬂecting a slightly
greater speciﬁcity and a slightly reduced sensitivity with a cut-off of 2. The balance in terms of clinical
utility, however, is considered to be in favour of a cut-off of 2.6 Across the three consecutive screening
rounds, a change of RLU/Co of 2 from 1 would have resulted in 999 out of 5172 (16.6%) fewer
HPV-positive results, with only 23 (2.28%) fewer CIN2+ lesions detected. The PPV for HPV-positive
tests for detected CIN2+ would increase by around 15% in each round (see Table 26).
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TABLE 25 Human papillomavirus prevalence by RLU cut-off (% HPV+ve)
Round HPV+ve (RLU/Co ≥ 1) HPV+ve (RLU/Co ≥ 2)
Round 1 3813/24,510 (15.56) 3200/24,510 (13.06)
Round 2 1268/14,232 (8.91) 1029/14,232 (7.23)
Round 3 891/8428 (10.57) 744/8428 (8.83)
−ve, negative; +ve, positive.
TABLE 26 CIN2+ by HPV result (by RLU cut-off) at round (%)
Round HPV+ve HPV−ve
RLU/Co ≥ 1
Round 1 551/3813 (14.45) 36/20,697 (0.17)
Round 2 98/1268 (7.73) 9/12,964 (0.07)
Round 3 58/891 (6.51) 5/7537 (0.07)
RLU/Co ≥ 2
Round 1 537/3200 (16.78) 50/21,310 (0.23)
Round 2 92/1029 (8.94) 15/13,203 (0.11)
Round 3 55/744 (7.39) 8/7684 (0.10)
−ve, negative; +ve, positive.
TABLE 27 CIN2+ by HPV result (by RLU cut-off) at entry (% with CIN2+)
Round HPV+ve HPV−ve
RLU/Co ≥ 1
Round 1 551/3813 (14.45) 36/20,697 (0.17)
Round 2 86/2070 (4.15) 37/13,720 (0.27)
Round 3 34/1321 (2.57) 32/7552 (0.42)
RLU/Co ≥ 2
Round 1 537/3200 (16.78) 50/21,310 (0.23)
Round 2 82/1679 (4.88) 41/1411 (0.29)
Round 3 33/1114 (2.96) 33/7759 (0.43)
−ve, negative; +ve, positive.
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Potential impact of the national human papillomavirus
vaccination programme on the incidence of disease in
women in the screening age range (≥ 25 years)
Tables 28, 29 and 30 show the grades of cytological abnormality in rounds 1, 2 and 3, respectively, by
HPV types with 16/18 and 31/33/45/52/58 grouped. The rationale for these groupings was that 16/18 are
the HR types used in the Cervarix™ vaccine, which was used in the UK vaccination programme up until
September 2012 (at which time it switched to Gardasil®, which also protects against genital warts) and
reported cross-protection for Cervarix™ against types 31/33/45/52/58.46 According to the published data,
the degree of protection in women who were HPV naive prior to vaccination with Cervarix™ achieved a
98% efﬁcacy against HPV 16/18-related CIN2+, and 68% efﬁcacy against HPV 31/33/45/52/58-related
CIN2+, and 70% against CIN2+ of any HR type.13 Cross-protection against types 31 and 45 was reported
in a recent systematic review47 to be signiﬁcantly less than for Cervarix but, overall, the two vaccines are
likely to provide similar levels of protection. As shown in Table 29, vaccination of young adolescents could
be expected to reduce cytology-graded moderate+ by almost 70%, but borderline/mild by less than 25%.
The proportion of cytological abnormalities of a given grade is relatively similar within groups of types
between rounds 1, 2 and 3; therefore, the degree of protection should be similarly consistent.
TABLE 28 Cytological abnormality and HPV status in round 1 in women aged ≥ 25 years
Cytological grade −ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45/52/58,
n (%)
Other HC2+ve,
n (%) Total, N
Negative 17,730 (91.2) 310 (1.6) 347 (1.8) 1046 (5.4) 19,433
Borderline 1122 (74.7) 104 (6.9) 111 (7.4) 166 (11.0) 1503
Mild 240 (38.5% 102 (16.4) 95 (15.2) 186 (29.9) 623
Moderate 33 (16.7) 84 (42.4) 53 (26.8) 28 (14.1) 198
Severe+ 8 (5.2) 92 (60.1) 37 (24.2) 16 (10.5) 153
Total 19,133 (87.3) 692 (3.2) 643 (2.9) 1442 (6.6) 21,910
−ve, negative; +ve, positive.
TABLE 29 Cytological abnormality and HPV status in round 2 in women aged ≥ 25 years
Cytological grade −ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45/52/58,
n (%)
Other HC2+ve,
n (%) Total, N
Negative 12,381 (93.7) 146 (1.1) 180 (1.4) 510 (3.9) 13,217
Borderline 256 (66.7) 33 (8.6) 31 (8.1) 64 (16.7) 384
Mild 43 (25.7) 40 (24.0) 26 (15.6) 58 (34.7) 167
Moderate 1 (4.0) 9 (36.0) 6 (24.0) 9 (36.0) 25
Severe+ 4 (19.0) 12 (57.1) 4 (19.0) 1 (4.8) 21
Total 12,685 (91.8) 240 (1.7) 247 (1.8) 642 (4.6) 13,814
−ve, negative; +ve, positive.
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ECONOMIC ANALYSIS VALIDATION RESULTS
Validation of detected cervical intraepithelial neoplasia
Interval-specific findings for detected CIN2+
Model outputs for the predicted histology conﬁrmed that cases of CIN over time were compared with
observed histology-conﬁrmed CIN cases from the ARTISTIC trial. The model predicted the numbers of
histology-conﬁrmed CIN cases at 6-monthly intervals, for both the concealed and the revealed arms of the
trial, by 10-year age groups. In this section we produce summarised versions of our results. (For more
details of the model predictions by age group see Appendix 18.)
We began by investigating how well the model predicted histology-conﬁrmed CIN2+. We assumed that
once women had a histology result of CIN2+ they received treatment, and censored the data thereafter.
Figure 17 shows the cumulative rate of CIN2+ for both the model (solid green diamonds) and the
ARTISTIC data (hollow blue squares). These cumulative rates were generated using Kaplan–Meier methods
that take into account censoring after the occurrence of histology-conﬁrmed CIN2+ or loss to follow-up.
The horizontal axis shows the time since the ﬁrst screening round in the trial.
Figure 17 indicates that the model-predicted cumulative rate of CIN2+ at 6-monthly intervals compares
very well with the ARTISTIC data in both trial arms, with most model predicted cases of cumulative CIN2+
remaining well within, or just outside of, the 95% CI for each 6-monthly observation. For women aged
40–49 years, the predicted cumulative detection of CIN2+ by 6 years is slightly higher than the 95% CI for
the revealed arm; however, rates of cumulative detection in this age group for the concealed arm and in
both arms for younger and older age groups (50+ years) showed adequate ﬁt to the observed data.
Cumulative rate of CIN2+
Results for histologically confirmed low-grade disease
The model-predicted incidence of histologically conﬁrmed low-grade cervical disease was compared with
data from the ARTISTIC trial. In the ARTISTIC trial, women without CIN2+, but who still had a histological
abnormality, were said to have a histology result of ‘< CIN2’. Thus, ‘< CIN2’ captured women with
detected CIN1, and women with histological evidence of HPV infection. In the model we assumed that all
women with a true underlying health state of CIN1 will have a histology result of ‘< CIN2’ if they have a
biopsy. As women were not censored from further analysis after a ‘< CIN2’ histology, women can have
TABLE 30 Cytological abnormality and HPV status in round 3 in women aged ≥ 25 years
Cytological grade −ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45/52/58,
n (%)
Other HC2+ve,
n (%) Total, N
Negative 7389 (92.0) 109 (1.4) 109 (1.4) 425 (5.3) 8032
Borderline 113 (56.5) 14 (7.0) 22 (11.0) 51 (25.5) 200
Mild 21 (15.4) 31 (22.8) 31 (22.8) 53 (39.0) 136
Moderate 2 (9.5) 9 (42.9) 7 (33.3) 3 (14.3) 21
Severe+ 2 (8.0) 10 (40.0) 6 (24.0) 7 (28.0) 25
Total 7527 (89.5) 173 (2.1) 175 (2.1) 539 (6.4) 8414
−ve, negative; +ve, positive.
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‘< CIN2’ results if subsequent biopsies are taken throughout the trial (in fact, the ARTISTIC data show
that many women who have detected < CIN2 will have another biopsy within 2 years). By contrast,
as mentioned previously, once a woman has a histology result of CIN2+, any subsequent results
were censored.
Figure 18 shows the cumulative detected < CIN2 cases for both the model (solid green diamonds) and the
ARTISTIC observed data (hollow blue squares). The cases are presented as a percentage of the starting
total number of women in the corresponding trial arm and age group. Overall, the model results
compared well with the ARTISTIC data throughout the trial and the number of ‘< CIN 2’ cases detected by
the model compared well with the number of cases as detected in the trial. In this case, for women aged
40–49 years, the predicted cumulative detection of < CIN2 by 6 years is slightly lower than the 95% CI for
the concealed arm; however, rates of cumulative detection in this age group for the revealed arm and in
both arms for younger and older age groups (50+ years) showed adequate ﬁt to the observed data.
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FIGURE 17 Cumulative rate of histology detected CIN2+ by time since enrolment (months), expressed as a percentage
for each trial arm and each age group. The model results are shown as the solid green diamonds and the data
are shown as the hollow blue squares. 95% CIs are also shown. The value ‘n = ’ in each graph represents the
number of women who entered the trial in that age group and trial arm.
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Cumulative detected CIN2+ cases
Validation of model outcomes by human papillomavirus type
Cervical intraepithelial neoplasia cases attributed to infection with human
papillomavirus 16, 18 and other high-risk types
In the previous sections, model results of CIN cases were reported by aggregating over all HPV types.
In this analysis each case of detected CIN was allocated with an HPV type according to HPV status at
enrolment, in order to compare HPV type-speciﬁc CIN cases with those from the ARTISTIC trial. We
consider three different HPV type-groups: 16, 18, and all other oncogenic HPV types. For some of the
ﬁndings, results were aggregated over both trial arms for simplicity (after taking into account in the
modelling the differing screening protocols in each trial arm).
Cumulative outcomes by human papillomavirus type at enrolment (baseline)
For this analysis it was assumed that the underlying HPV type of a CIN diagnosis was the HPV type
detected at baseline. For the small number of HPV-negative women at enrolment with a non-negative
histology result within 12 months of enrolment, the assumption was made, for the purposes of this
exercise, that the baseline HPV status was positive but with a false-negative HPV test.
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FIGURE 18 Cumulative ‘< CIN2’ cases by time since enrolment (months) expressed as a percentage of the total
number of women who entered the trial in the corresponding trial arm and age group. The model results are shown
as the solid green diamonds and the data are shown as the hollow blue squares. The value ‘n = ‘ in each graph
represents the number of women who entered the trial in that age group and trial arm.
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Summary results for all ages and across each trial arm are presented in Figure 19, which shows the
cumulative incidence of CIN2+ by assumed baseline HPV type over 5 years. This representation shows that
the model captures the cumulative incidence of CIN2+ by HPV type at baseline over the ﬁrst 5 years of the
ARTISTIC trial.
Figure 20 shows incident CIN2+ in women who present as negative at baseline or HPV positive for any
type. More detailed model outputs on cumulative incidence of CIN2+ by age group is shown in Figure 21,
which demonstrates that the model is capturing the incidence of CIN2+ by HPV type for different age
groups. The model predicted rate of CIN2+ in HPV negative women is within the 95% CI of the observed
data at 5 years.
Summary of the findings of the ARTISTIC validation procedure
The purpose of simulating the ARTISTIC trial cohort was to determine whether the natural history model
or the test probability matrices required recalibration. We found that the model results were in close
agreement with ARTISTIC trial results. We concluded that the natural history model was accurately
capturing the true underlying rate of disease progression and regression, in time steps of 6-monthly
intervals and when considering the underlying HPV type. In conjunction with prior validation exercises for
previously reported evaluations, this ﬁnding supported the use of the current model platform for use in a
national assessment of the role of primary HPV testing in England.
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FIGURE 20 Overall cumulative incidence of CIN2+ by HPV positivity at baseline.
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FIGURE 19 Cumulative incidence of CIN2+ at 6-monthly intervals by HPV type status at baseline. OHR, other high risk.
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FIGURE 21 Cumulative incidence of developing CIN2+ for each age group at 6-monthly intervals by HPV type status
at baseline. OHR, other high risk. (continued)
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Economic evaluation of primary human papillomavirus
screening in England
Calibration and validation of the England-wide model under current
screening practice in an unvaccinated cohort
In this section we report on the outcomes of an England-wide evaluation of primary HPV screening. The
model used for this evaluation incorporated the natural history model prevalidated in other countries and
then validated against the ARTISTIC data. We also modelled sexual behaviour assumptions, which were
calibrated to the NATSAL II report25 using a dynamic simulation of sexual behaviour and HPV transmission.
We predicted HR HPV prevalence in cytologically normal women by age in England, comparing the results
to the prevalence reported in the ARTISTIC trial (in this instance using the ARTISTIC prevalence data as a
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FIGURE 21 Cumulative incidence of developing CIN2+ for each age group at 6-monthly intervals by HPV type status
at baseline. OHR, other high risk.
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proxy for all-England prevalence).3 We also validated the model against England data for age-speciﬁc
cervical cancer incidence, cervical cancer mortality, and a number of other outcomes.
The England-wide model predicted age-speciﬁc and type-speciﬁc HPV prevalence rates across the
population (including those women subsequently found to have conﬁrmed CIN) similar to those observed
in the baseline round of the ARTISTIC trial3 (Figure 22).
Cervical cancer incidence
The model-predicted cervical cancer incidence compares well with recent national observed cervical
cancer, as shown in Figure 23. The data used for comparison are 2010 data from the Ofﬁce for
National Statistics.49
0
20
 – 2
4
25
 – 2
9
30
 – 3
4
35
 – 3
9
40
 – 4
4
45
 – 4
9
50
 – 5
4
55
 – 5
9
60
 – 6
4
65
 – 6
9
70
 – 7
4
75
 – 7
9
80
 – 8
4
5
10
15
20
25
C
an
ce
r 
in
ci
d
en
ce
 p
er
 1
00
,0
00
 w
o
m
en
Age (years)
Age-specific cervical cancer incidence
Current practice predictions
cancer incidence
(unvaccinated cohort)
Calibration target: England
2010
FIGURE 23 Cancer incidence rates per 100,000 women as predicted by the model are shown as the black dashed
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The predicted age- and type-speciﬁc incidence of invasive cervical cancer shown in Table 31 indicates that
52.5% and 13% of cervical cancers are predicted to be attributable to HPV to types 16 and 18,
respectively. This compares well with observed international data.50
The proportion of cancers detected at each of the four FIGO stages is also shown in Figure 24, and this
compares well with observed data from the West Midlands.51
Cervical cancer mortality
Age-speciﬁc rates of cancer mortality, as predicted by the model, are shown in Figure 25. The model
age-speciﬁc predictions compare relatively well with 2008 mortality data (predicted results within the
95% CI of observed data for women aged > 45 years; rates are slightly higher than observed values for
younger women).
70.0
60.0
50.0
40.0 Model prediction
Target: West Midlands30.0
20.0
10.0
0.0
FIGO stage 1 FIGO stage 2 FIGO stage 3
Cancer stage at time of diagnosis
Distribution of cancer staging
Pr
o
p
o
rt
io
n
 o
f 
ca
n
ce
r 
d
ia
g
n
o
se
d
 (
%
)
FIGO stage 4
FIGURE 24 The stage distribution of invasive cervical cancer as predicted by the model is shown as the black bars.
We assume an age structure in England as observed in the 2011 census.49 White bars show observed cancer staging
from the West Midlands.
TABLE 31 Predicted type-speciﬁc incidence of invasive cervical cancer as predicted by the model
HPV type
Proportion of cancers detected attributable to HPV type (%)
Model predicted Observed
HPV 16 52.5 55.00
HPV 18 12.9 13.00
HPV OHR 34.5 32.00
OHR, other high risk.
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Predictions of cost, effectiveness and resource utilisation outcomes for
current practice
A summary of resource utilisation, cancer incidence and mortality and costs as predicted by the model for
current practice is given in Table 32. Note that the life-years presented in the table are a somewhat
counterintuitive measure to which discounting has been applied and which reﬂects the discounted
additional number of years a woman is predicted to live given that she has already survived to 10 years of
age (the model simulation commences at 10 years of age). Compared with observed data, the model
predicts very similar cervical cancer case numbers and cervical cancer deaths overall (although the
age-standardised mortality rate is slightly higher than observed).
The model was also used to calculate the predicted annual number of screening events in England under
current practice and the results were compared with values reported in the 2010–11 report of the
NHSCSP. Compared with these data, the model predicts very similar numbers of cytology tests overall
(within 2%). Other predicted model outcomes, such as the number of colposcopies, biopsies and
treatments for CIN, were calculated although it was not always possible to directly compare these with
the reported observed data which were often available as a per-woman versus per-test number (as noted
in Table 32).
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FIGURE 25 Age-specific cancer mortality rates per 100,000 women as predicted by the model are shown as the black
dashed curve. We assume an age structure in England as observed in the 2011 census.49 Observed mortality rates
in the UK in 2008 are shown as the solid green curve, with 95% CIs.16
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TABLE 32 Summary of model outputs for current practice
Current practice (unvaccinated cohorts)
Predicted
outcomes Target outcomes
Per cent difference
between predicted
and target outcomes
(negative indicates
underestimation)
Predicted cost and effectiveness
Total discounted life-time cost per woman £159 – –
Total discounted LYs per woman 26.2307 – –
Total discounted QALYs per woman 26.2098 – –
Annual screening-associated cost in Englanda £155,127,987 – –
Predicted health outcomes in England
Cervical cancer cases p.a.a 2521 2511 0.4%
ASR cancer incidence per 100,000 womenb 8.88 8.9 (95% CI 8.7 to 9.1) −0.2%
Cervical cancer deaths p.a.a 761 762 −0.2%
ASR cancer mortality per 100,000 womenb 2.45 2.2 (95% CI 2.1 to 2.3) 11.4%
Cumulative lifetime risk of cervical cancer 0.74% – –
Predicted resource utilisation (annually in England)a
No. of cytology tests (all ages) 3,703,772 3,662,33651 1%
No. of cytology abnormalities (all ages) 272,552 – –
No. of women with an abnormal cytology test – 218,000 –
No. of HG cytology testsc 53,923 – –
No. of women aged 25–64 with a HG cytology – 36,30051 –
No. of HPV tests 245,330 – –
No. of women receiving a biopsy 87,821 – –
No. of diagnostic biopsies – b85,14351 –
No. of ﬁrst colposcopies after referral 128,254 –
No. of women attending colposcopy
(ﬁrst attendance)
– 137,69351 –
No. of women with histologically
conﬁrmed CIN2/3
41,309 b45,00051 −8%
ASR, age-standardised rate; HG, high-grade; LY, life-year; p.a., per annum.
a Note that this cost does not include overheads and cannot be directly compared to some estimates as it considers total
cost after implementation of new HPV triage and test-of-cure management recommendations.
b Calculated as three times the reported numbers in a 4-month period. For a broad comparison with modelled predictions
of histologically conﬁrmed CIN2/3 here we used data on reported number of excisional biopsies. However, note that the
model also captures treatment for other indications according to recommendations (e.g. in women with a history of
prior treatment who then have histologically conﬁrmed CIN1).
c Includes those for women in follow-up management after treatment for CIN.
Notes: Predicted numbers assume an age distribution of the population as was observed in England in 2011.48 Rates
calculated assuming the European Standard Population.52 Discount rate used was 3.5% and QALY weights set one used for
this table.
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Model predictions for current screening practice in the context
of vaccination
Current practice in cervical screening in England was simulated for vaccinated cohorts (i.e. for cohorts
offered vaccination after the national vaccination programme commenced, although such cohorts include
both vaccinated and unvaccinated individuals). A range of assumptions were considered for vaccine coverage
and catch-up coverage rates in sensitivity analysis. For the baseline evaluation we assumed 84% coverage in
12- to 13-year-old girls and catch-up coverage rates as recently reported. Lifetime outcomes for HPV
prevalence, cancer incidence and mortality are presented. It should be noted that these are lifetime
predictions for the vaccinated cohort but these predictions can also be interpreted as cross-sectional
outcomes in the future once all age cohorts have been offered vaccination as pre-adolescents. The assumed
age structure in England for the calculation of case numbers was that observed in 2011.48
Human papillomavirus prevalence
The predicted HPV prevalence for all oncogenic types in a vaccinated cohort (vaccinated as 12- to
13-year-olds) is shown in Figure 26. This indicates that vaccination against 16/18 with current vaccine
coverage rates will reduce the overall oncogenic HPV population prevalence in England by about 25%
(assuming current generation vaccines do not confer signiﬁcant long-lasting cross-protection against
non-vaccine-included types). This is in accordance with expectations, as HPV 16/18 infections are expected
to comprise∼ 30–40% of all oncogenic type infections in the population, and vaccination coverage in
England is approximately 84%.
Cervical cancer incidence
The model-predicted cervical cancer incidence in vaccinated cohorts is depicted in Figure 27. Vaccination
against HPV 16/18 at the current coverage rate is predicted to reduce the incidence of cervical cancer by
close to 56% in women across all ages. This is in accordance with expectations as HPV16/18 infections
are implicated in ∼ 65–70% of invasive cervical cancers and vaccination coverage is assumed to be 84%
(and there is an additional effect of herd immunity).
The predicted age- and type-speciﬁc incidence of invasive cervical cancer after vaccination is shown in
Table 33. This table shows that after vaccination, HPV 16 and 18 associated cancers decrease signiﬁcantly
in relation to the other oncogenic types. Post vaccination, the relative proportions of HPV 16 and HPV 18
in cancer are predicted to be 12% and 3%, respectively.
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FIGURE 26 Predicted overall HPV prevalence for all oncogenic types in England, assuming 84% vaccination coverage
(green dashed curve) and HPV prevalence predicted by the model in an unvaccinated setting (black dashed curve).
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Cervical cancer mortality
Mortality rates from cervical cancer in the vaccinated cohort are shown in Figure 28. The mortality rate is
predicted to decrease by a similar ratio to that for cancer incidence in the vaccinated cohort.
Predicted resource utilisation, cancer incidence and mortality, and costs associated with current screening
practice in a vaccinated setting are summarised in Table 34.
Table 34 summarises the model-predicted outcomes in the context of current screening practice, with
and without the effect of HPV vaccination. The total annual cost of cervical screening, management and
diagnosis and cancer treatment under current practice is estimated at £155M per annum; and this would
reduce to £129M per annum after vaccination takes effect. This reﬂects the fact that without a change
in screening recommendation, only a modest reduction in the number of cytology and HPV tests are
predicted, although vaccination will have a considerable inﬂuence on the predicted number of
colposcopies, biopsies and treatments for CIN, due to the falling rates of cervical abnormalities in
the population.
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FIGURE 27 Cancer incidence per 100,000 women in a vaccinated cohort in England is shown as the green dashed
curve. Model predictions in an unvaccinated setting are shown as the black dashed curve.
TABLE 33 Predicted type-speciﬁc incidence of invasive cervical cancer in vaccinated cohorts
HPV type
Proportion of cancers detected attributable to HPV type (%)
Vaccinated (84% coverage) Unvaccinated
HPV 16 11.7 52.6
HPV 18 2.7 12.9
HPV OHR 85.6 34.5
OHR, other high risk.
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FIGURE 28 Cervical cancer mortality rates as predicted by the model in cohorts offered vaccination are shown as the
green dashed curve. Model predictions in an unvaccinated cohort are shown as the black curve.
TABLE 34 Summary of predictions for current screening practice with and without vaccination
Current practice outcomes Unvaccinated cohorts Vaccinated cohorts
Predicted cost and effectiveness
Total discounteda lifetime cost per woman £159 £129
Total discounteda LYs per woman 26.2307 26.2366
Total discounteda QALYsb per woman 26.2098 26.2187
Annual screening-associated cost in Englandc £155,127,987 £128,741,901
Predicted health outcomes in England
Cervical cancer cases p.a.c 2521 1064
ASR cancer incidence per 100,000 womend 8.88 3.65
Cervical cancer deaths p.a.c 761 338
ASR cancer mortality per 100,000 womend 2.45 1.05
Cumulative lifetime risk of cervical cancer 0.74% 0.32%
Predicted resource utilisation (annually in England)c
No. of cytology tests (all ages) 3,703,772 3,663,477
No. of HPV tests 245,330 210,687
No. of women receiving a biopsy 87,821 60,897
No. of women with histologically conﬁrmed CIN2/3 41,309 24,365
No. of colposcopies (ﬁrst attendance) 128,254 89,848
ASR, age-standardised rate; LY, life-year; p.a., per annum.
a Assuming a discount rate of 3.5%.
b Using QALY weight set one.
c Assuming an age distribution as was observed in England in 2011.48
d Assuming the European Standard Population.52
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Cost-effectiveness and resource utilisation for human
papillomavirus screening strategies
Each of the four main primary HPV screening strategies were simulated and model outputs were analysed,
for both unvaccinated and vaccinated cohorts. We considered a range of variations on the four basic
primary HPV strategies and several variations on the basic strategies, as summarised in Table 35.
Figure 29 shows the predicted age-speciﬁc cervical cancer incidence rate for each of the four basic
strategies in unvaccinated cohorts. The predicted age-speciﬁc cervical cancer mortality rates are shown in
Figure 30. The basic strategies all involve 6-yearly HPV screening with 24-month follow up of HPV-positive,
triage-negative women.
In general terms, a slight increase in cervical cancer incidence is predicted for women less than 50 years
when primary HPV screening basic strategy 1 is compared with current practice, but not for the other
strategies, and lower incidence rates are predicted for older women (> 60 years) for all primary HPV
strategies. The predicted age-speciﬁc cervical cancer mortality is lower than that for current practice for all
primary HPV basic strategies at most ages, with the exception of strategy 1, which is predicted to have
close-to-equivalent age-speciﬁc mortality in women less than 50 years of age, compared with
current practice.
TABLE 35 Strategy variations for each of the four basic primary HPV screening strategies
Variant 1 Variant 2
Variant 3
(exploratory)
Variant 4
(exploratory) Variant 5
As per the basic
strategy, but assuming
10-yearly screening in
women aged over
50 years (and
6-yearly screening in
younger women)
As per the basic
strategy, but
assuming two sets of
12-monthly follow-up
for intermediate risk
women as opposed
to two sets of
24-month follow-ups
for these women
As per the basic
strategy, but assuming
current practice
management for
women under
30 years (only run for
strategies 1 and 2)
As per the basic
strategy, but
assuming
current practice
management for
women under
35 years (only run for
strategies 1 and 2)
As per the
basic strategy,
but assuming
5-yearly
screening for
women of
all ages
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FIGURE 29 Age-specific cancer incidence as predicted by the model for each of the four basic strategies in
unvaccinated cohorts. Model outputs for current practice management are also shown for comparison.
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Table 36 provides a summary of cost, health and resource utilisation outputs for the four basic strategies in
an unvaccinated population (all basic strategies involve 6-yearly screening with 24-month follow-up of
HPV-positive, triage-negative women).
Compared with current practice, the four basic strategies result in annual cost reductions of between 7%
and 18% (£10M–28M), with strategy 1 associated with the highest cost savings and strategy 4 (co-testing)
associated with the least savings.
With respect to effectiveness, the strategies varied in whether they were more or less effective than current
screening practice. From the perspective of life-years, strategy 1 was associated with a slightly lower
prediction for average life-years in the population compared with current practice, whereas the other
strategies were associated with savings in life-years. (Note that strategy 1 has a lower lifetime risk of
cervical cancer death, even though it is predicted to have fewer life-years saved compared with current
practice. This is due to strategy 1 appearing to be more effective in older, compared with younger, women
relative to current screening practice.) As expected, the strategies increased in effectiveness the more
aggressively that HPV positive women were managed, with strategy 3 (partial genotyping at the primary
screening step with HPV 16/18 referred immediately to colposcopy) being the most effective, followed by
strategy 2 (genotyping in follow-up) and then strategy 1 (no genotyping), with strategy 4 (co-testing)
having intermediate effectiveness between strategies 2 and 3.
In line with the above ﬁndings, strategy 1 was also predicted to be associated with the fewest
colposcopies and biopsies, substantially fewer than current practice, whereas strategy 3 was associated
with the highest number of colposcopies and biopsies.
Model predictions for the screening strategies in an
unvaccinated setting
We considered a range of variations of the four basic primary HPV strategies. Several variations on the
basic strategies were considered.
Cost, effectiveness, life-years predictions and quality-adjusted life-years
predictions in unvaccinated cohorts
Model predictions for the predicted effectiveness of each of the strategies and their variants are presented
in Table 37 and cost and cost-effectiveness outcomes are summarised in Table 38.
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FIGURE 30 Age-specific cancer mortality as predicted by the model for each of the four basic strategies in
unvaccinated cohorts. Model outputs for current practice management are also shown for comparison.
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TABLE 36 Cost, health and resource utilisation outputs for the basic strategies in an unvaccinated population
Model output
No vaccination
Current
practice Strategy 1 Strategy 2 Strategy 3 Strategy 4
Predicted cost and effectiveness
Total discounteda lifetime cost
per woman
£159 £132 £135 £144 £149
Total discounteda LYs per woman 26.2307 26.2306 26.2310 26.2316 26.2313
Total discounteda QALYs per woman 26.2098 26.2105 26.2111 26.2118 26.2095
Additional LYs saved per 100,000
women compared with CP
(negative indicates fewer LYs)
– −14.44 26.42 82.85 54.09
Additional QALYs saved per 100,000
women compared with CP
(negative indicates fewer QALYs)
– 73.92 126.84 201.21 −27.62
Annual screening-associated cost
in Englandb
£155,127,987 £127,573,498 £129,905,553 £136,206,815 £144,958,217
Annual cost difference compared
with CP
– −£27,554,488 −£25,222,434 −£18,921,171 −£10,169,770
Per cent cost difference compared
with CP
– −18% −16% −12% −7%
Predicted health outcomes in England
Cervical cancer cases p.a.b 2521 2590 2495 2366 2418
ASR cancer incidence
per 100,000 womenc
8.88 9.22 8.88 8.41 8.60
Cumulative lifetime risk of
cervical cancer
0.74% 0.76% 0.73% 0.69% 0.71%
Per cent increase in lifetime risk
(compared with CP)
– 1.9% −1.7% −6.8% −4.7%
Cervical cancer deaths p.a.b 761 741 708 663 685
ASR cancer mortality
per 100,000 womenc
2.45 2.43 2.32 2.17 2.24
Cumulative lifetime risk of cervical
cancer death
0.24% 0.23% 0.22% 0.21% 0.21%
Per cent increase in lifetime risk
of death (compared with CP)
– −3.6% −7.7% −13.4% −10.6%
Predicted resource utilisation (annually in England)b
No. of cytology tests (all ages) 3,703,772 636,790 636,161 564,796 2,574,064
No. of HPV tests 245,330 2,255,505 2,251,914 2,244,887 2,269,169
No. of women receiving a biopsy 87,821 75,187 84,156 106,028 87,161
No. of colposcopies
(ﬁrst attendance after referral)
128,254 110,393 123,140 154,754 127,790
No. of women with histologically
conﬁrmed CIN2/3
41,309 39,464 39,850 40,585 40,525
ASR, age-standardised rate; CP, current practice; LY, life-year; p.a., per annum.
a Assuming a discount rate of 3.5%. For QALY outputs, QALY weight set one was used.
b Assuming an age distribution as was observed in England in 2011.48
c Assuming the European Standard Population.52
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These results predict that most of the strategies and the variants considered will be less costly than
current practice. Table 37 also shows the difference in effectiveness (in terms of life-years saved) between
the variant strategies and the corresponding basic strategy without the variant. For each basic strategy,
decreasing the follow-up interval for intermediate risk women from 24 to 12 months was the most
effective variant, resulting in 73–113 more life-years per 100,000 women than with the corresponding
basic strategy. The next most effective strategy was decreasing the routine screening interval from 6- to
5-yearly, which resulted in 40–45 more life-years per 100,000 women than with the corresponding
basic strategy.
These results for cost and life-years saved are also summarised graphically in a cost-effectiveness plane,
shown in Figure 31.
Compared with current practice, and considering the primary effectiveness outcome of life-years saved,
almost all primary HPV screening strategies are in either the ‘south-west’ quadrant of the cost-effectiveness
plane, (i.e. cost saving but less effective) or the ‘south-east’ quadrant (i.e. cost saving and also more
effective). Almost no strategies were predicted to be more costly than current practice, with the notable
exceptions of certain variants of co-testing such as 5-yearly screening and 12-month follow-up of
intermediate risk women (strategy 4) and strategy 3 (partial genotyping) combined with 12-month
follow-up of ‘other oncogenic’ positive women.
It should be noted that the most typical situation for cost-effectiveness analysis is that new strategies are
more costly and more effective compared with current practice (i.e. in the ‘north-east’ quadrant of the
cost-effectiveness plane). For the current evaluation, in which this generally does not apply, incremental
cost-effectiveness ratios are not appropriate or informative53 and, therefore, results for costs, effects and
resource utilisation are presented in a disaggregated form.
As discussed in Chapter 2 [see Methods, Cost and utilities (quality-adjusted life-year weights)], we
considered two sets of QALY weights for exploratory analysis, and the ﬁndings are presented in the
cost-effectiveness planes in Figures 32 (QALY weight set 1) and 33 (QALY weight set 2).
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The ranking of strategies when QALYs were considered as the effectiveness outcome differed considerably
from the life-years saved outcome (see Figure 31) for both QALY weight sets 1 and 2. QALY weights
set one was used to calculate the outcomes depicted in Figure 32, and because this applies a disutility
to the experience of being screened, the primary HPV screening strategies involving more screening
(i.e. decreased screening interval) or more follow-up resulted in lower effectiveness. When the alternative
set of QALY weights two (shown in Figure 33) were used, the position of strategies relative to each other
on the cost-effectiveness plane was different again. QALY weight set two does not apply a disutility to
being screened; however, this QALY weight set applies a higher disutility to having positive HPV test, and
so all of the primary HPV screening strategies appear less effective than current practice. The diversity of
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the ﬁndings when different QALY weights are used emphasises the uncertainty involved in the selection
and application of these weightings. Therefore, this report focuses on the life-years saved outcome as the
main outcome. This result also highlights a need for further investigation into utilities relevant to primary
HPV screening.
When considering the primary outcome of LY saved (see Figure 31), the basic strategies 2 and 3 both
involved cost savings in the context of increased life-years saved. In both cases, increasing the frequency
of screening to 5-yearly and/or decreasing the follow-up interval in HPV-positive, triage-negative women,
improved the effectiveness (and increased costs) of the strategies. Either of these actions applied to
strategy 1 also made this strategy both cost and life-year saving. The increased costs were primarily
driven by increasing numbers of screening tests (for 5-yearly vs. less frequent screening strategies)
or by increasing numbers of diagnostic referrals (for 12-month follow-up of HPV-positive,
triage-negative women).
Most of the primary HPV strategies examined were cost saving and many of the strategies also resulted in
an increase in predicted life-years saved in the population. The most effective strategy involving HPV as the
sole primary screening test incorporated genotyping for HPV 16/18 and direct referral of women positive
for these types to colposcopy, but although this is predicted to be cost saving compared with current
screening practice, it would substantially increase the number of colposcopy referrals.
In general, strategies for which HPV is used as the sole primary screening test were found to be both cost
and life-years saving, if attention was paid to the optimal combination of screening interval (5- or 6-yearly)
and follow-up interval (12 or 24 months) for HPV-positive, triage-negative (‘intermediate risk’) women.
Decreasing the follow-up interval for intermediate risk women from 24 to 12 months increased the
overall effectiveness of primary HPV screening. If 24-month follow-up is retained, the (relative) loss of
effectiveness can be partly compensated for by decreasing the screening interval from 6-yearly to
5-yearly, although this was generally a less effective approach than optimising the follow-up of
intermediate risk women.
The exploratory strategies for which cytology screening was retained until either age 30 or 35 years, and
for which a switch to primary HPV screening was implemented in older women, were predicted to be of
somewhat higher costs than those associated with full implementation of primary HPV screening from
age 25 years. Findings for this variant of strategy 1 are somewhat difﬁcult to interpret, because the basic
version of this strategy was slightly less effective than current practice. However, for strategy 2, the mixed
strategy of cytology in younger women switching to HPV screening in older women was found to be of
intermediate effectiveness to the related ‘pure’ strategies (i.e. less effective than full implementation
of primary HPV screening but more effective than current practice).
Health outcomes, cervical cancer and mortality rates in an
unvaccinated setting
Model predictions for health outcomes in an unvaccinated setting (i.e. prior to the impact of vaccination)
are summarised in Table 39, and the related data for predicted age-standardised incidence and mortality
rates for cervical cancer in England under current practice and for each of the potential primary HPV
screening strategies are shown graphically in Figure 34. Each point on the graph represents the predicted
incidence and mortality rate associated with a particular strategy (as shown in the ﬁgure). In general terms,
most of the primary HPV screening strategies resulted in a predicted equivalence (or close-to-equivalence)
or improvement in the predicted rates of cervical cancer incidence and mortality, compared with current
practice, with the notable exception of strategies involving 10-yearly screening in women over 50 years
of age.
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Resource utilisation in an unvaccinated setting
Table 40 shows predicted annual outcomes of resource utilisation in England (assuming an unvaccinated
setting, i.e. prior to the impact of vaccination). The annual number of HPV tests and cytology tests are
shown graphically in Figure 35. This ﬁgure shows that the number of screening tests in the majority
of strategies is predicted to be lower than current practice, although in the co-testing strategies
(strategy 4 and variants), the number of overall number of HPV and cytology tests is, not unexpectedly,
predicted to increase.
The annual number of colposcopies performed in England is shown in Figure 36. The strategies varied
in respect to whether a greater or lower number of colposcopies were predicted in relation to current
practice. In general terms, more colposcopies were predicted for strategy 3, which involved genotyping
and thus referred HPV 16/18 positive women to colposcopy immediately. In general terms, the number of
biopsies was predicted to be proportional to the number of colposcopies performed – the model generally
predicts that about 48% of women who attend a colposcopy will have a biopsy taken.
Summary of the effectiveness and costs of the strategies in an
unvaccinated cohort
Overall, when considering unvaccinated women, strategies 2 and 3 (and most of their variants) were cost
and life-years saving, but strategy 1 could also be tailored to be cost and life-years saving by decreasing
the follow-up time for intermediate risk women to 12 months.
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FIGURE 34 Age-standardised rate (ASR) (assuming the European Standard Population52) predictions for cancer
incidence and mortality are shown for each strategy and the variants as the black circles and green squares,
respectively. Current practice (CP) predictions for cancer incidence and mortality are shown as the black and green
lines, respectively, for ease of comparison with the other strategies.
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FIGURE 35 Annual number of cytology and HPV tests performed in England as predicted by the model for each of the
strategies and the variants in an unvaccinated setting. CP, current practice; S, strategy.
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FIGURE 36 Annual number of colpsocopies performed in England as predicted by the model for each of the
strategies and the variants. CP, current practice; S, strategy.
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Model predictions for the screening strategies in a
vaccinated setting
A general summary of resource utilisation, cancer incidence and mortality, and costs as predicted by the
model for each of the strategies and the variants in a vaccinated setting is given in this section.
A summary of cost, health and resource utilisation outputs for the four main strategies when considering
the effect of vaccination is shown in Table 41.
The cost savings associated with primary HPV screening in a vaccinated cohort range from 9% to
22%. The cost savings are driven both by reduction in the overall number of screening tests and the
number of diagnostic referrals. The most effective strategies in a vaccinated cohort are predicted to be
strategy 3 (genotyping) and strategy 4 (co-testing).
Model predictions for effectiveness are summarised in Table 42 and model predictions for cost
and cost-effectiveness are summarised in Table 43. These results are summarised graphically in a
cost-effectiveness plane (i.e. a diagram summarising the cost and effectiveness for each strategy)
depicting the relative costs and effects associated with each of the strategies. Figures 37 and 38 provide
an alternative representation where variant strategies are grouped graphically by type of variation.
These graphics emphasise the importance of the follow-up of intermediate risk women, because strategies
involving 12-month follow-up are consistently the most effective (compared with 24-month follow-up with
the same strategy) in a vaccinated cohort.
Overall, the ﬁndings for costs and effects in a vaccinated cohort follow a similar pattern as for an
unvaccinated cohort. Of the basic strategies, the order of strategies in terms of increasing effectiveness is
strategy 1, followed by strategy 2, then strategy 3 and, lastly, strategy 4. For all strategies, the most
important modiﬁcation to increase effectiveness was to decrease follow-up time in intermediate risk
women to 12 months. If 24 months was retained, it could be partly compensated via decreasing the
recommended screening interval to 5-yearly screening. One or both of these modiﬁcations was required to
bring strategies 1, 2 and 3 into the ‘south-east quadrant’ (i.e. to become both cost and life-year saving),
when the effect of vaccination was considered.
Again, supplementary analysis using QALYs as an outcome for effectiveness considerably changed the
relative ranking of strategies (Figure 39 for QALY weight set 1 and Figure 40 for QALY weight set 2).
In particular, use of QALY weight set 2 resulted in many strategies becoming less effective than current
practice, but this was not true for QALY weight set 1, where a different pattern was observed and almost
all primary HPV strategies were more effective than current practice. Again, owing to these uncertainties in
the application of appropriate weights, this was considered a secondary outcome and more research on
the appropriate QALY weights for HPV screening strategies in a vaccinated population is required.
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FIGURE 37 Cost-effectiveness plane in a vaccinated setting (life-years saved outcome). CP, current practice;
FU, follow-up; S, strategy.
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Health outcomes, cervical cancer and mortality rates in
a vaccinated setting
Model predictions for health outcomes in a vaccinated setting are summarised in Table 44 and the related
data for predicted age-standardised incidence and mortality rates for cervical cancer in England under
current practice, and for each for the potential primary HPV screening strategies, are shown graphically in
Figure 41. In Figure 34, the predictions for unvaccinated women are also shown for reference. Each point
on the graph represents the predicted incidence and mortality rate associated with a particular strategy.
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FIGURE 39 Cost-effectiveness plane for QALYs in a vaccinated setting, using QALY weight set 1. CP, current practice;
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As expected, substantial decreases in cancer incidence and mortality are predicted in the context
of vaccination, but in general terms the relative health outcomes of new screening strategies in relation to
current screening practice were broadly preserved. As for unvaccinated women, most of the primary
HPV screening strategies resulted in a predicted equivalence (or close-to-equivalence) or improvement in
the predicted rates of cervical cancer incidence and mortality in a vaccinated setting compared with current
practice, with the notable exception of strategies involving 10-yearly screening in women over 50 years
of age.
TABLE 44 Health outcomes for each of the strategies and the variants in a vaccinated setting
Strategy
Predicted health outcomes in England
Cervical
cancer
cases
p.a.a
Cumulative lifetime
risk of cervical cancer
(% increase compared
with CP)
ASR cancer
incidence
per 100,000
womenb
Cervical
cancer
deaths
p.a.a
ASR cancer
mortality
per 100,000
womenb
Current practice 1064 0.32 (–) 3.65 338 1.05
Strategy 1 1104 0.33 (2.7%) 3.84 333 1.05
Strategy 1, 10-yearly screening in 50+ years 1210 0.37 (–) 4.13 393 1.21
Strategy 1, follow-up in 12 months 1012 0.3 (−5.4) 3.50 303 0.95
Strategy 1, CP screening in < 30 years 1092 0.33 (–) 3.78 335 1.05
Strategy 1, CP screening in < 35 years 1077 0.32 (0.6) 3.72 331 1.04
Strategy 1, 5-yearly screening in all ages 1041 0.31 (–) 3.63 307 0.97
Strategy 2 1096 0.33 (1.9) 3.81 330 1.04
Strategy 2, 10-yearly screening in 50+ years 1201 0.36 (–) 4.10 390 1.20
Strategy 2, follow-up in 12 months 1006 0.3 (−5.8) 3.48 301 0.94
Strategy 2, CP screening in < 30 years 1087 0.32 (–) 3.76 333 1.05
Strategy 2, CP screening in < 35 years 1074 0.32 (0.3) 3.71 330 1.04
Strategy 2, 5-yearly screening in all ages 1032 0.31 (–) 3.60 304 0.96
Strategy 3 1083 0.32 (0.8) 3.76 326 1.03
Strategy 3, 10-yearly screening in 50+ years 1189 0.36 (–) 4.06 386 1.18
Strategy 3, follow-up in 12 months 998 0.3 (−6.6) 3.45 299 0.93
Strategy 3, 5-yearly screening in all ages 1020 0.3 (–) 3.55 300 0.95
Strategy 4 1066 0.32 (−0.8) 3.70 320 1.01
Strategy 4, 10-yearly screening in 50+ years 1170 0.35 (–) 3.99 379 1.16
Strategy 4, follow-up in 12 months 974 0.29 (−8.8) 3.36 291 0.91
Strategy 4, 5-yearly screening in all ages 1007 0.3 (–) 3.51 296 0.94
ASR, age-standardised rate; CP, current practice; p.a., per annum.
a Assuming an age distribution as was observed in England in 2011.48
b Assuming the European Standard Population.52
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Resource utilisation in a vaccinated setting
Table 45 shows the predicted annual resource utilisation in England in a vaccinated setting. The annual
number of HPV tests and cytology tests are shown graphically in Figure 42, with the results for
unvaccinated women shown for comparison. The predicted number of screening tests is predicted to be
very similar in vaccinated and unvaccinated women (unsurprisingly, as this is driven primarily by screening
recommendations and behaviour, not the underlying disease in the population). Again, this ﬁgure shows
that the number of screening tests in the majority of strategies is predicted to be lower than current
practice, although in the co-testing strategies (strategy 4 and variants), the overall number of HPV and
cytology tests are, not unexpectedly, predicted to increase.
The annual number of (ﬁrst) colposcopies performed in England in a vaccinated setting is shown in
Figure 43, with the ﬁndings for an unvaccinated setting shown for comparison. As expected, the number
of coloscopies performed was substantially lower in a vaccinated cohort by a factor of about one-third
(for strategies 1, 2 and 4) or by about 50% (for strategy 3). Strategy 3 involves direct referral to
colposcopy for women positive for HPV types 16/18, and therefore the model predicts a greater drop in
the number of colposcopies performed for this strategy in the context of lower prevalence of HPV 16/18
infection and its associated disease. In this sense it can be said that strategy 3 is predicted to become more
‘efﬁcient’ in the context of vaccination, although, as noted earlier, it is cost saving and life-years saving
compared with current practice under most conditions. Overall, because of this effect, the primary HPV
screening strategies became more similar to each other in terms of the overall number of colposcopies,
compared with the ﬁndings in an unvaccinated setting. In general terms, more colposcopies were
predicted for strategies involving 12-month follow-up of intermediate-risk women, as was the case for the
unvaccinated setting.
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Again, the number of biopsies was predicted to be proportional to the number of colposcopies
performed – the model generally predicts that about 68% of women who attend a colposcopy will have a
biopsy taken.
Summary of ﬁndings from sensitivity analysis
The ﬁndings from the sensitivity analysis are provided in Appendix 17. This gives detailed results for
one-way sensitivity analysis of the impact of various parameter assumptions on the incremental costs and
effectiveness life-years saved of several of the key primary HPV screening strategies in relation to current
practice. It also provides the ﬁndings from a PSA which varied all costs in the model, and a PSA on sexual
behaviour assumptions.
TABLE 45 Resource utilisation as predicted by the model for each of the strategies and their variants in a
vaccinated setting
Strategy
Predicted resource utilisation (annually in England)a
No. of
cytology
tests
(all ages)
No. of
HPV tests
No. of
colposcopies
(ﬁrst attendance)
No. of
women
receiving
a biopsy
No. of
women with
histologically
conﬁrmed
CIN2/3
Current practice 3,663,477 210,687 89,848 60,897 24,365
Strategy 1 493,864 2,272,954 72,943 49,123 22,909
Strategy 1, 10-yearly screening in 50+ years 465,212 2,017,290 70,434 48,106 22,574
Strategy 1, follow-up in 12 months 561,572 2,344,750 94,828 63,831 24,999
Strategy 1, CP screening in < 30 years 958,178 1,950,267 88,034 60,040 24,170
Strategy 1, CP screening in < 35 years 1,361,372 1,720,782 89,517 60,867 24,249
Strategy 1, 5-yearly screening in all ages 549,394 2,651,382 78,199 52,450 23,594
Strategy 2 493,749 2,272,615 74,112 49,975 22,951
Strategy 2, 10-yearly screening in 50+ years 465,094 2,016,977 71,590 48,952 22,616
Strategy 2, follow-up in 12 months 561,335 2,344,299 96,785 65,259 25,019
Strategy 2, CP screening in < 30 years 958,362 1,950,325 88,967 60,694 24,175
Strategy 2, CP screening in < 35 years 1,361,465 1,720,785 89,957 61,159 24,251
Strategy 2, 5-yearly screening in all ages 549,275 2,651,009 79,436 53,349 23,636
Strategy 3 486,707 2,271,942 77,048 52,072 23,036
Strategy 3, 10-yearly screening in 50+ years 458,145 2,016,361 74,477 51,030 22,702
Strategy 3, follow-up in 12 months 553,961 2,343,580 99,676 67,326 25,070
Strategy 3, 5-yearly screening in all ages 541,841 2,650,268 82,625 55,614 23,721
Strategy 4 2,505,463 2,290,185 77,660 52,200 23,383
Strategy 4, 10-yearly screening in 50+ years 2,210,414 2,033,345 74,901 51,084 23,056
Strategy 4, follow-up in 12 months 2,606,734 2,368,447 101,134 68,039 25,507
Strategy 4, 5-yearly screening in all ages 2,913,242 2,668,517 83,278 55,734 24,028
CP, current practice.
a Assuming an age distribution as was observed in England in 2011.48
DOI: 10.3310/hta18230 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 23
85
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
0123
Number of tests (000,00)
456
A
n
n
u
al
 n
u
m
b
er
 o
f 
cy
to
lo
g
ie
s
(i
n
 u
n
va
cc
in
at
ed
 w
o
m
en
)
A
n
n
u
al
 n
u
m
b
er
 o
f 
cy
to
lo
g
ie
s
(i
n
 v
ac
ci
n
at
ed
 w
o
m
en
)
A
n
n
u
al
 n
u
m
b
er
 o
f 
cy
to
lo
g
y 
an
d
H
PV
 t
es
ts
 (
in
 u
n
va
cc
in
at
ed
 w
o
m
en
)
A
n
n
u
al
 n
u
m
b
er
 o
f 
cy
to
lo
g
y 
an
d
H
PV
 t
es
ts
 (
in
 v
ac
ci
n
at
ed
 w
o
m
en
)
A
n
n
u
al
 n
u
m
b
er
 o
f 
H
PV
 t
es
ts
(i
n
 u
n
va
cc
in
at
ed
 w
o
m
en
)
A
n
n
u
al
 n
u
m
b
er
 o
f 
H
PV
 t
es
ts
(i
n
 v
ac
ci
n
at
ed
 w
o
m
en
)
Cur
ren
t pr
acti
ce (
CP)
S1
S1, 
10-y
ear
ly sc
ree
nin
g in
 50+
 yea
rs
S1, 
foll
ow-
up 
in 1
2 m
ont
hs
S1, 
CP s
cree
nin
g in
 < 3
0 ye
ars
S1, 
CP s
cree
nin
g in
 < 3
5 ye
ars
S1, 
5-ye
arly
 scr
een
ing
 in a
ll ag
es
S2
S2, 
10–
yea
rly s
cree
nin
g in
 50+
 yea
rs
S2, 
foll
ow-
up 
in 1
2 m
ont
hs
S2, 
CP s
cree
nin
g in
 < 3
0 ye
ars
S2, 
CP s
cree
nin
g in
 < 3
5 ye
ars
S2, 
5-ye
arly
 scr
een
ing
 in a
ll ag
es
S3
S3, 
10–
yea
rly s
cree
nin
g in
 50+
 yea
rs
S3, 
foll
ow-
up 
in 1
2 m
ont
hs
S3, 
5-ye
arly
 scr
een
ing
 in a
ll ag
es
S4
S4, 
10–
yea
rly s
cree
nin
g in
 50+
 yea
rs
S4, 
foll
ow-
up 
in 1
2 m
ont
hs
S4, 
5-ye
arly
 scr
een
ing
 in a
ll ag
es
FI
G
U
R
E
42
Th
e
n
u
m
b
er
o
f
cy
to
lo
g
y
an
d
H
PV
te
st
s
p
er
fo
rm
ed
in
En
g
la
n
d
as
p
re
d
ic
te
d
b
y
th
e
m
o
d
el
in
an
u
n
va
cc
in
at
ed
an
d
a
va
cc
in
at
ed
se
tt
in
g
.
Pr
ed
ic
ti
o
n
s
fo
r
ea
ch
o
f
th
e
st
ra
te
g
ie
s
an
d
th
e
va
ri
an
ts
ar
e
sh
o
w
n
.
RESULTS
86
NIHR Journals Library www.journalslibrary.nihr.ac.uk
In brief, the ﬁndings of the one-way sensitivity analysis consistently identiﬁed the relative test
characteristics for HPV testing and cytology (summarised as the assumed relative sensitivity and speciﬁcity),
and the level of compliance to 12-month or 24-month follow-up for intermediate risk women and
compliance with colposcopy, as the most important factors in the comparison of the relative costs and
effects of primary screening HPV in relation to current practice. With respect to compliance with follow-up,
this ﬁnding further emphasises the importance of achieving adequate and timely follow-up in the group of
women who are HPV positive at screening but who are then found to be reﬂex cytology negative. Again,
the ﬁndings of the evaluation suggest that a considerable proportion of the progressive disease in primary
HPV strategies originates from this group (as opposed to from the HPV-negative women). These ﬁndings
are in line with those in the baseline analysis, which found that decreasing the follow-up interval to
12 months (from 24 months) in intermediate risk women has a major positive effect on the overall
effectiveness of primary HPV screening.
The ﬁndings of the partial PSA for costs were that under all combinations of costs tested, all primary HPV
screening strategies considered in the PSA, with the exception of strategy 4 (co-testing), were predicted to
be cost saving compared with current practice in vaccinated cohorts; in unvaccinated cohorts with
12 months’ follow-up of HPV-positive, triage-negative women, a very small proportion of scenarios for
strategy 2 (0.5%), 29% of scenarios for strategy 3, and 69% of scenarios for strategy 4 were predicted to
be more costly than current practice. Overall, this ﬁnding provides reassurance that primary HPV screening
is likely to be cost saving for a range of possible future screening, diagnostic evaluation and treatment
costs for a number of potential strategies in both unvaccinated and vaccinated cohorts.
A PSA was conducted to examine the impact of the detailed sexual behaviour assumptions used by the
model. The results indicate that feasible variations in sexual behaviour assumptions do not substantially
alter the predicted lifetime cost saved and life-years saved associated with the primary HPV screening
strategies, or the relative costs and effects of the main strategies in relation to each other.
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FIGURE 43 The number of colposcopies performed in England as predicted by the model for each of the strategies
and their variants, in an unvaccinated and vaccinated setting.
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Chapter 4 Discussion
The key ﬁndings of this extended follow-up of the ARTISTIC trial are summarised as follows: negativeHPV testing provides a longer period of protection from CIN2+ than cytology; HPV genotyping can
identify subsets of women at greater risk; the HPV vaccination programme is likely to prevent over half
of high-grade CIN given current rates of coverage; the cost-effectiveness evaluation has predicted that
strategies involving HPV primary screening will save life-years and costs for both unvaccinated and
vaccinated cohorts compared with current practice, particularly if screening intervals are 5 years with early
recall of HPV-positive/cytology-negative women taking place after 12 months.
The results reported in this extension to the previously published HTA report on ARTISTIC1 are based on up
to 8 years of follow-up with HPV testing and cytology (median round 3 follow-up of 72.7 months). The
particular value of this extension is the duration of follow-up, rather than the comparison of the original
randomised arms of the trial. ARTISTIC now constitutes one of the largest prospective follow-up studies
reported over 6 years, and conducted with protocol compliance for recall of HPV-positive women over
two rounds of screening and HPV testing over three rounds, and is the largest to have been conducted in
the UK. One of the principal strengths of the ARTISTIC study is its relevance to the NHSCSP, particularly in
England. ThinPrep® LBC was the standard throughout, and the HC2 HPV test has been used for several
years in a process of limited implementation of HPV testing for triage of low-grade cytological
abnormalities. Because the ARTISTIC trial and the cost-effectiveness study have been conducted
within the framework of the NHSCSP, the ﬁndings of this study are likely to be generalisable within the
English programme.
Three key strands of the ARTISTIC study 6-year follow-up will provide valuable insight into future
considerations of the cervical screening programme: (i) the comparative outcomes following baseline
cytology and baseline HPV testing; (ii) estimating the outcome of HPV genotyping in initial screening,
followed by reﬂex cytology for HPV-positive samples; and (iii) estimating the impact of pre-teenage
prophylactic vaccination by Cervarix™ on cervical abnormalities. In addition, this follow-up study now
includes an economic analysis, which models the long-term cost-effectiveness of HPV primary screening
compared with primary cervical cytology.
Cytology, human papillomavirus and cervical intraepithelial
neoplasia detection between rounds 1, 2 and 3 of screening
The study cohort decreased in size by about 40% between rounds 1 and 2, and between rounds 2 and 3,
which is consistent with the approximate rate of serial coverage of 60% achieved between consecutive
2-year rounds in Greater Manchester. Accrual to the third round was initially hampered by the ethics
committee’s requirement to reconsent participants for this extended follow-up with continued HPV testing
but, following a number of conditions around anonymity being met, which avoided the need for consent,
accrual increased. Because of the reduced accrual and older ages in round 3, as deﬁned by at least
54 months of follow-up, the numbers of lesions detected was just over 50% of that in round 2.
Human papillomavirus prevalence did not change much within age quinquennia, declining by 2–3% at all
ages above 25 years from round 2, and increasing by a similar amount from round 2 to round 3 above
age 40 years, although not in younger women. The reasons for these changes are not clear. It could be
that, above age 40, HPV is less likely to clear, and that following the effect of treatment and natural
clearance over the preceding 6 years there was an element of reinfection or possibly latent virus becoming
detectable. As previously reported,1,2 there was a marked reduction in abnormal cytology among both
HPV-positive and HPV-negative women from round 1 to round 2, particularly for moderate or worse
cytology. This was probably due in part to a higher rate of mild abnormalities following the introduction of
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LBC with a higher colposcopy rate than that seen in routine screening. The impact of LBC on the
prevalence round was unique to ARTISTIC, as other international trials used conventional cytology.
The relationship between HPV positivity and abnormal cytology remained fairly consistent between
rounds 2 and 3, suggesting that HPV-positive status conferred similar risks of abnormal cytology, and
conﬁrming the strong relationship between high-grade cytology and the presence of HPV infection.
Women who were cytology negative but HPV positive at entry remained at higher risk in rounds 2 and
3 than the screened cohort overall, which means that in routine screening, where HPV testing was
employed as the primary test, there would need to be care taken either to keep such women under
surveillance or to further triage them, for example with HPV typing, in order to refer those most at risk to
colposcopy. This is reinforced in the cost-effectiveness study. The fact that 28% of women screened in
round 3 had not attended for screening in round 2 allows some insight into the effect of missing a round.
The proportion of women with CIN2+ detected in round 3 was 0.50% (3 out of 6337) for those screened
in all three rounds, whereas, of those who were not screened in round 2, 1.34% (34 out of 2536) had
CIN2+ detected. The risk is, of course, very heavily dependent on HPV status. Among those screened in all
three rounds, the detection of CIN2+ in round 3 was 1.6% and 0.3% for women who were HPV positive
and HPV negative at entry, respectively. Among those who were not screened in round 2, the detection of
CIN2+ in round 3 was 5.2% and 0.7% for women who were HPV positive or HPV negative at entry,
respectively. The management of HPV-positive/cytology-negative women could be enhanced by further
triage using a biomarker of increased risk. So far, no biomarkers offer clear-cut clinical utility, although
markers based on p16 and minichromosome maintenance proteins are under investigation.
Inﬂuence of human papillomavirus and cytology screening
results on cumulative incidence of cervical intraepithelial
neoplasia over three rounds
The cumulative incidence of CIN2+ and CIN3+ over three screening rounds (see Table 12) was strongly
dependent on baseline screening results, with a greater than 50-fold difference between women who
were cytology negative/HPV negative at baseline and those who were cytology positive/HPV positive.
If cytology and HPV testing are considered alone (see Table 14), abnormal cytology and testing HPV
positive gave similar cumulative CIN2+ and CIN3+ rates over three rounds. Testing HPV negative at
baseline was associated with a signiﬁcantly lower cumulative CIN2+ incidence than negative baseline
cytology. It is necessary to consider whether or not ascertainment bias contributed to this result. It is true
that, in round 1, women who tested cytology negative/HPV positive were recalled after 1 year and, if still
HPV positive, were offered colposcopy, and as a result some CIN2+ was detected. While these lesions may
well have been detected as a result of cytology in the next screening round, the revealed arm in which
HPV status did not inﬂuence referral showed that baseline negative cytology was associated with a higher
incidence of CIN2+ in rounds 2 and 3 than negative HPV (0.58% and 0.61%, respectively, vs. 0.23% and
0.26%). This suggests that primary HPV testing would allow longer screening intervals than cytology,
which could be highly cost-effective and preferable to women. The reason for the longer duration of
protection is that HPV signiﬁes not only a risk of underlying disease but also a risk of developing a lesion.
HPV-negative status signiﬁes not only a very low risk of having an underlying lesion, but also a reduced
risk of developing one over the next 6 years. In fact, the cost-effectiveness analysis, which takes account
of real-life rescreening rates, predicts that a 5-year interval would be a better strategy than 6 years.
Indeed, many women recalled after 5 years may take up to 12 months to attend.
The cytology-negative/HPV-positive women represent an important group if screening were based on
HPV. The recognition that they remain at risk suggests the need to base management on repeat tests at
short-term follow-up. This risks default, but there would be the beneﬁt of allowing HPV infection to clear
and regression of minor abnormalities. As shown in the cost-effectiveness analysis, follow-up at 12 months
would be more cost-effective than after 24 months. Detection of certain HR types, particularly type 16
which is associated with a higher risk of cumulative disease, can be considered in relation to colposcopy
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referral. Algorithms which employed novel biomarkers could also be proven in the future to be capable of
selecting high-grade CIN without resulting in excessive referral and risk of over treatment.
Human papillomavirus genotyping at baseline conﬁrms that types 16/18 and 31/33/45/52/58 were much
more likely to result in detection of CIN2+ and CIN3+ in rounds 1, 2 and 3, either individually or
cumulatively; HPV types 16/18/31/33/45/52/58 were detected in over 80% of CIN2+ in round 1 but fewer
than half of HC2-positive women, thus conferring greater speciﬁcity.
Persistence of human papillomavirus and the incidence
of CIN2+
The HPV status of individual women over three rounds allowed estimates of the impact of persistent or
ﬂuctuating HPV status. Remaining HPV positive by HC2 between rounds 1 and 2 was associated with a
higher risk of CIN2+ than acquiring HPV having screened negative in round 1. True persistence needs to
be conﬁrmed by typing and this revealed that among those who remained HPV positive, those who
remained positive with the same type (true persistence) had a threefold greater likelihood of having CIN2+
in round 2 than those whose round 2 HPV type(s) were not detected in round 1 (see Table 17). A similar
effect was seen in round 3, and the same pattern was seen with CIN3+ between rounds 1 and 2/3
(see Table 18).
The use of human papillomavirus testing followed by
cytology to determine colposcopy referral
The data arising from the relationship between age, HPV status, cytology and histology (see Table 23)
allow a view of how screening with HPV testing followed by cytology would translate into colposcopy
referral and detection of CIN. Had a policy of referral of HPV positive/abnormal cytology been adopted, the
round 1 ARTISTIC data suggest an initial referral rate of 5% with a PPV of around 35% for CIN2+. Among
women who would have been screened in previous rounds, this would fall to a 2–3% referral rate with a
PPV of around 23% for CIN2+.
The major unresolved issue from HPV screening triaged with cytology is the management of women who
test HPV positive/cytology negative. Immediate colposcopy for all would result in excessive referral, yet
early follow-up with repeat testing to conﬁrm persistent infection would risk signiﬁcant default. In rounds 1
and 2 of ARTISTIC there was a policy of offering repeat HPV testing at 12 months. Out of 1675
HPV-positive/cytology-negative women at baseline in the revealed arm, only 929 (55%) reported for
repeat testing, of whom 393 out of 929 (42%) were still HPV positive. It is likely, therefore, that a policy
relying on evidence of persistent HPV to direct referral to colposcopy would result in a proportion of
non-attendance. It is likely that nationally, the adherence to early recall for cytology negative/HPV positive
would be higher than the Manchester population in a clinical trial. In the original HPV triage studies
in England, around 90% of women who were HPV positive with low-grade cytology attended for
colposcopy.34 Although this is not an identical situation, and a new class of ‘abnormality’ in the screening
programme, it is reasonable to assume that early recall in real life will achieve high response rates. This
will, however, need to be carefully monitored.
The cost-effectiveness analysis predicted that genotyping triage referrals to colposcopy is likely
to be beneﬁcial, and if not employed at baseline then at 12 months’ follow-up. If colposcopy
were recommended only for women with negative cytology who were very HR-type positive
(16/18/31/33/45/52/58), the referral rate would increase to 8% and the PPV would fall to 22%, which
could be regarded as acceptable from a clinical perspective. The increased incidence of CIN2+ in
women with low-grade cytology/HPV16/18 positive has been well documented in the prospective
Portland cohort.54
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Implications for screening intervals
These extended follow-up data strengthen indications from the initial ARTISTIC report1 showing that
primary HPV testing would detect similar amounts of CIN2+, and now indicate it could do so with
extended screening intervals of 5–6 years. There would be a need to consider how to manage
HPV-positive women with negative cytology but typing could have a role in selecting women for colposcopy
as opposed to surveillance by repeat cytology or HPV testing. What is not known is how accurate negative
cytology would be among a population of HPV-positive women. It is possible that the negative predictive
value of negative cytology would be lower than it is for the whole screened population. The typing data
have conﬁrmed the massive impact that HPV vaccination can be expected to have on high-grade cervical
abnormalities. A move to HPV primary screening with cytology reserved for HPV-positive women would
involve considerable shrinkage of the overall amount of cytology, but it would allow cytology, which is of a
very high quality in the UK, to continue to play a valuable role in determining referral to colposcopy.
The effect of human papillomavirus vaccination with Cervarix™
on screening abnormalities
The ARTISTIC data conﬁrm how dominant HPV types 16 and 18 are in terms of CIN2+, accounting for well
over half of all lesions. Cervarix™ has been reported to prevent 98% of HPV 16/18 associated CIN2+ in
women who were HPV DNA negative and HPV sero-negative when they were vaccinated. Additionally,
Cervarix™ has been reported to cross-protect in the sense that, among the same vaccinated population,
there was vaccine efﬁcacy of almost 70% among a composite of CIN2+ associated with 31/33/45/52/58.13
Although a recent systematic review47 indicated signiﬁcantly less cross-protection against types 31 and 45,
the overall protective effect of Gardasil will probably not be signiﬁcantly different. When combined, these
efﬁcacies would account for around 65% of CIN2+, according to round 1 ARTISTIC data. With the current
vaccine coverage of 80% in 12- to 13-year-old girls, the reduction in the population overall could be
50–55%. These are approximations because of multiple infections but it conﬁrms the predictions from
other sources. The effect will begin to become apparent when these vaccinees start screening, as the rates
of HPV 16/18 are highest in young women and the rates of HPV positive/abnormal cytology are very high
in the 25–29 age group, although the impact on cancer will not be seen for about 20 years. In fact, the
earliest signal of the impact of the vaccine will be seen in Scotland and Wales where screening begins at
age 20 years, and where late teenagers who were vaccinated in the catch-up campaign began to be
screened in 2012. The immediate impact of this will be determined by the rate of vaccine uptake, the
attendance for cervical screening by these young women, and the rate of established HPV infection at
the time of vaccination.
Effect of Hybrid Capture 2 cut-off
The analysis has shown that using a cut-off of 2 RLU/Co, instead of the manufacturers’ recommended RLU
of 1, would provide a useful increase in speciﬁcity with an acceptable reduction in sensitivity. A recent
study55 comparing new commercially available HPV tests with HC2 at 2 RLU/Co demonstrated that HC2
was generally as speciﬁc in the triage setting but within acceptable sensitivity. This means that with HPV
primary screening there may be fewer screen positive results, and this is being evaluated as part of the
NHSCSP primary screening pilot which has just begun.
Cost-effectiveness evaluation
The results of this evaluation have identiﬁed a number of strategies for primary HPV screening which are
predicted to be both life-years and cost saving compared with current screening practice with cervical
cytology in England for vaccinated and unvaccinated cohorts. The data supporting longer interval
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HPV-based screening are based, in large part, on consistent information from a number of observational
studies and randomised controlled trials which demonstrate that HPV-negative women are at lower
subsequent risk of developing the most serious grade of CIN or invasive cancer (CIN3+), compared with
HPV-positive women. The international data demonstrate that HPV-negative women are at low risk of
developing serious precancerous disease (CIN3+) for 6 years or longer; and these data have (appropriately)
underpinned the concept that HPV primary screening can safely be conducted at screening intervals
of 5–6 years.
We have, however, in this analysis identiﬁed an element important to the practical realisation of primary
HPV screening, which needs to be considered to ensure that implementation of primary HPV screening
does not result in a loss of screening effectiveness compared with current screening practice. The ﬁndings
of the current analysis emphasise that in order for primary HPV screening to maintain its effectiveness
overall, considerable attention needs to be paid to the optimal management of HPV-positive/
cytology-negative women (i.e. an intermediate risk group not immediately referred to colposcopy). This
result applies to both vaccinated and unvaccinated cohorts. Because triage testing with cytology has
imperfect sensitivity, some women in this group will be at risk of disease progression. If there is delay in
follow-up in this group, a higher proportion will develop progressive disease. Furthermore, compliance
with follow-up in this group is extremely important. In the base-case analysis, we assumed that 80% of
women were followed by the recommended interval. If fewer women were compliant with follow-up,
greater rates of disease progression are predicted for both unvaccinated and vaccinated cohorts, as shown
in our sensitivity analysis.
From a resource utilisation perspective, although many of the evaluated strategies are predicted to be
life-years and cost saving overall, some of the strategies, notably strategy 3 (genotyping and its variants),
did result in a higher predicted number of colposcopies, and their downstream sequelae, including a
greater number of diagnostic biopsies, in unvaccinated women. This increase in the number of diagnostic
evaluations should be considered in terms of a trade-off against the reduced overall costs and greater
overall effectiveness (in terms of life-years saved) predicted for these strategies. However, it should be
noted that strategy 3 became more ‘efﬁcient’ in a vaccinated setting, where the number of colposcopies,
in context of lower prevalence of HPV 16/18 in the population, was comparable with the other primary
HPV screening strategies.
We note that the results from this evaluation cannot be directly applied to settings other than England.
Other countries may have different screening regimes currently in place, and therefore the results of
primary HPV screening strategies would need to be evaluated against a different comparator. In addition,
sexual behaviour, vaccination uptake, compliance with routine screening and follow-up management, and
costs of screening tests and treatment can vary greatly from setting to setting and, therefore, the results
presented in the report should be restricted to England. That said, the promising conclusion that the
modelled analysis suggests, that primary HPV screening strategies can be more effective and less costly
than current screening practice, should encourage other countries to perform similar evaluations to
investigate the potential beneﬁts of changing from primary cytology to primary HPV screening
management strategies.
Strengths of the current analysis
The analysis presented in this report used a model with extensive type-speciﬁc natural history calibration to
ARTISTIC data and shows close duplication of the actual ﬁndings in the ARTISTIC trial. The England-wide
model, which was used for the overall evaluation of the costs and effects of primary HPV screening in
England, incorporated a careful and detailed simulation of sexual behaviour in England, the natural history
of type-speciﬁc HPV natural history (progression and regression), and a detailed simulation of cervical
screening, follow-up and management. This incorporated information on compliance with screening
recommendations and also explicit modelling of post-treatment recurrence and test-of-cure management
for England. We performed extensive calibration of the England-wide model, including ﬁtting of the sexual
behaviour assumptions to national survey data for sexual behaviour (NATSAL II), validation to ensure that
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the model accurately predicted type-speciﬁc HPV infection rates (pre-vaccination) and accurate predictions,
under conditions of current screening practice, of age-speciﬁc cancer incidence and mortality rates, as well
as stage-speciﬁc survival. In addition, we validated model predictions for the predicted number of cervical
screening tests and other outcomes against current data.
Unlike many previous models of cervical screening, we have also taken into account detailed information
on age-speciﬁc compliance with cervical screening, incorporating not only overall participation rates, but
also the timing of reattendance after a negative screening test.
Other cost-effectiveness evaluations of primary HPV screening has been performed in the Netherlands,56
Germany,57 Norway58 and Canada,59 and each of these analyses concluded in favour of switching to
longer-interval HPV-based screening over cytology-based screening. However, our modelled analysis
involved a signiﬁcantly more detailed validation of the modelled natural history assumptions and
signiﬁcantly more detail in terms of the speciﬁcation of how cervical screening is modelled, as well as a
detailed simulation of the effect of vaccination. In addition, we performed extensive analysis of a large
number of potential strategies, allowing overall patterns and generalisable model conclusions to
be analysed.
Limitations of the current analysis
The main limitations of the current analysis relate to the fact that a number of assumptions about future
population behaviour were made, by necessity, and to some extent the conclusions of the current analysis
are dependent on whether the assumptions made reﬂect future screening and vaccination practice.
For example, a key assumption in this modelled analysis was that compliance with follow-up for
HPV-positive, triage-negative women will involve approximately 80% of women attending within the
recommended follow-up time. However, in sensitivity analysis we demonstrated that the overall outcomes
of the analysis are highly dependent on such assumptions, and if actual compliance is less (or more) than
80%, this will have a substantial impact on the ﬁndings for the relative costs and effects of primary HPV
screening. We also assumed independence of screening and vaccination compliance rates in the
population. In the context of high coverage rates for vaccination, as observed in England, heterogeneities
between vaccination and screening uptake may not be a major driver of outcomes. There exists high
coverage of the vaccine in the school-based system, and there is not strong evidence to suggest that
vaccination uptake in individual 12- to 13-year-olds will be correlated with their screening compliance as
adults in England. Therefore, we believe this assumption is reasonable at the current time.
Secondly, there are major uncertainties in relation to the costs of primary HPV screening in the future.
Although we used the ﬁndings of a dedicated costing exercise in relation to current test prices, there has
been a general move towards automation of HPV testing (which may drive down test-associated costs) and
there is an active competitive environment, with several new HPV test technologies entering the market in
recent years. If HPV test costs eventually drop to lower values than those considered here, this will further
increase the favourable cost-effectiveness proﬁle of primary HPV testing relative to cytology. In this sense
the current evaluation should be considered conservative in relation to the relative costs of primary HPV
testing compared to current screening practice. However, we did consider a range of potential future costs
in a PSA for costs, and found that HPV screening (if HPV is used as the sole primary test) is predicted to be
cost saving under many combinations of projected costs.
Thirdly, the baseline analysis assumed that current levels of HPV vaccination coverage rates will be
sustained, and that the vaccine-induced duration of protection will be lifelong. Both of these are likely to
be reasonable assumptions given the school-based programme and an absence of evidence that vaccine
efﬁcacy substantively decreases over time. We presented our ﬁndings for the costs and effects of new
potential screening strategies in both unvaccinated and vaccinated cohorts, and it should be noted that
both are important in interpretation of the overall results. The results for unvaccinated and vaccinated
cohorts (with high coverage rates) should be considered to encompass a range of possibilities with respect
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to the inﬂuence of vaccination coverage on the ﬁnding for primary HPV screening. Strategies that were
found to have a favourable balance of costs and effects in both situations are likely to also have a
favourable balance with respect to intermediate vaccination coverage situations. We also considered
vaccination coverage in sensitivity analysis, and found that this factor was not a major inﬂuence on the
ﬁndings for the relative costs and effects of primary HPV screening strategies in relation to current practice.
Fourthly, we made several assumptions about vaccine efﬁcacy. The potential for type-replacement of
non-vaccine HPV types has been raised as a concern, although substantive evidence for this phenomenon
has not emerged.60 It is thought to be unlikely as there is little evidence for interaction between HPV types.
If substantive evidence type replacement were to be identiﬁed then our ﬁndings for a vaccinated setting
would require re-evaluation. Also, because we used a hierarchical approach to lesion type-assignment
when ﬁtting the model to data (HPV 16, then HPV 18, then other oncogenic infections), the rate of other
oncogenic type infections may be underestimated, and thus there is potential for HPV 16/18 vaccination
to ‘unmask’ underlying co-infections with other oncogenic types. In terms of the effect on the analyses
presented here, it is possible that we have somewhat overestimated the efﬁcacy and efﬁciency (in terms of
colposcopy referrals) of partial genotyping strategies in a vaccinated population.
In terms of the partial genotyping strategies considered, we assumed that HPV 16/18 women would be
managed in the same way, and did not consider differential management strategies for HPV 16- and
HPV 18-positive women. Further work would be needed to assess the potential for strategies involving
differential consideration of women according to their infection status with respect to these types or with
respect to type 45. In addition, although we did perform initial exploratory analysis of cytology-to-HPV
‘switching’ strategies (where the choice of primary screening test is dependent on a women’s age at the
time of screening), the results of such analyses must be considered preliminary as they critically depend on
a range of assumptions made about the management of women in follow-up and about the management
of underscreened women around the time of the primary test ‘switch’.
In general terms, we have attempted to deal with the uncertainties inherent in modelled analysis via a
range of methods. Firstly, we used a modelling platform that was extensively pre-validated against data
from several other countries, and was then speciﬁcally revalidated against both ARTISTIC data (via a
speciﬁc simulation of the ARTISTIC cohort) and, for the England-wide model, several observational data
sets. Secondly, we have performed extensive sensitivity analysis using a range of techniques including
exploring the impact of using different utility weight sets, performing one-way sensitivity analysis of the
main results of the analysis, and performing PSA for costs.
The consistency of our ﬁndings overall is an important outcome. We found, for a range of strategies, that
primary HPV screening is likely to be more effective and less costly than current practice for cervical
cytology, provided that attention is paid to the optimal management of HPV-positive, cytology-negative
intermediate risk women. Ultimately, the ﬁnal choice of the particular strategy to be used will consider a
trade-off between effectiveness, costs, colposcopy referrals, acceptability to women, and practicalities.
The ARTISTIC protocol originally deﬁned deﬁnitions of the duration of time for the second and third
screening rounds. This was necessary because women attend following recall for screening over a
continuum of time following the invitation. As it turned out, this continuum was of longer duration than
anticipated, and it was felt that to avoid lesions being attributed to the wrong screening round, the
deﬁnitions should be widened. This would of course not affect the combined results for rounds 2 and 3,
which is of greatest relevance to this report, and its transfer of some lesions that would have been
attributed to round 3, to round 2, is not considered to be of great signiﬁcance.
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Chapter 5 Policy implications
We have identiﬁed in this analysis a number of feasible, highly effective and cost-saving strategies forprimary HPV screening. The policy decision on which of these strategies to consider for piloting and
implementation in England is likely to take into account a range of factors beyond the scope of the current
modelled analysis. These might include, for example, factors such as the acceptability to women of the
various screening intervals and follow-up and management strategies. Nevertheless, in general terms
the current analysis has found that a range of potential primary HPV strategies compared favourably with
current screening practice in England.
In terms of the criteria laid down by the National Screening Committee for appraising the effectiveness of
a screening programme, the replacement of cytology by HPV as the primary test appears appropriate in
the following terms:
1. The test is simple, reliable and less subjective than cytology.
2. Its high negative predictive value and sensitivity compared with cytology will allow extended
screening intervals.
3. The modelling suggests that it will be cost effective and cost saving, thus achieving a beneﬁcial balance
of expenditure versus health gain.
A less well-understood area relates to the response of women to being told they are HPV positive/cytology
negative in terms of understanding the need for follow-up and at the same time avoiding anxiety
and uncertainty.
Compliance with surveillance and optimal management of HPV-positive/cytology-negative women after
primary HPV screening is of key importance.
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Chapter 6 Conclusions
In conclusion, an extended 6-year follow up of the ARTISTIC trial together with an associatedcost-effectiveness analysis both support HPV primary screening triaged by cytology in place of cytology
triaged by HPV testing. This would apply to both unvaccinated and vaccinated women. Most of the
primary HPV strategies examined were not only cost saving but also resulted in an increase in predictive
life-years saved in the population. The most feasible and cost-effective strategy in terms of delivery could
involve a single policy across the screening age range with 5- or 6-yearly screening intervals and 12-month
recall for HPV positive women with negative cytology. High compliance with early recall is predicted to be
critical and careful attention should be paid to this aspect. A HC2 cut-off of 2RLU/Co instead of the
manufacturers’ recommended cut-off of 1 would be clinically beneﬁcial in terms of an optimal balance
between sensitivity and speciﬁcity. This study and economic evaluation lend support to convert from
cytology to HPV-based screening, piloting of which commenced in the English programme in the second
quarter of 2013.
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Chapter 7 Research recommendations
1. There needs to be research into the attitudes of women who have been found to be HPV positive/
cytology negative, in terms of how to achieve a high level of adherence to follow-up.
2. Other potentially complementary biomarkers should be evaluated in conjunction with HPV testing.
Real-time co-testing with such biomarkers could be used to increase the speciﬁcity of HPV
testing without signiﬁcant loss of sensitivity. These include p16 and minichromosome maintenance
protein which have been incorporated in CINtec™ (Roche Molecular Diagnostics, Pleasanton, CA, USA)
and SurePathPlus™ (Becton, Dickenson and Company, Franklin Lakes, NJ, USA), respectively.
3. The ranking of strategies when QALYs were considered as the effectiveness outcome differed
considerably from the life-years saved outcome for both QALY weight sets one and two when
investigating outcomes for both unvaccinated cohorts and vaccinated cohorts. The diversity of the
ﬁndings when different QALY weights are used highlights a need for further investigation into utilities
relevant to primary HPV screening, in both unvaccinated and vaccinated populations.
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Appendix 1 Type-specific cumulative incidence
supplementary tables
The hierarchy of type-speciﬁc cumulative incidence is shown in Tables 46 and 47 (see table footnotes).Type 16 is the most dominant type, with types 31 and 33 some way ahead of the other HR types.
TABLE 46 Cumulative CIN2+ rate by HPV type at entry
HPV at round 1a
Round 1,
CIN2+/n (%)
Round 2,
CIN2+/n (%)
Round 3,
CIN2+/n (%)
Cumulative CIN2+ rate,14
% (95% CI)
– 36/20,697 (0.17) 37/13,720 (0.27) 32/7552 (0.42) 0.87 (0.70 to 1.06)
16 287/827 (34.70) 33/339 (9.73) 9/213 (4.23) 43.55 (39.75 to 47.45)
33 40/166 (24.10) 6/78 (7.69) 1/54 (1.85) 31.23 (23.55% to 39.59)
31 70/299 (23.41) 9/145 (6.21) 6/109 (5.50) 32.12 (26.12 to 38.44)
18 32/228 (14.04) 4/128 (3.13) 5/86 (5.81) 21.56 (15.53 to 28.74)
45 19/137 (13.87) 5/86 (5.81) 2/54 (3.70) 21.88 (14.51 to 30.70)
58 17/107 (15.89) 1/54 (1.85) 1/35 (2.86) 19.80 (11.96 to 29.75)
52 18/229 (7.86) 4/137 (2.92) 2/99 (2.02) 12.36 (7.91 to 18.11)
Other 68/1820 (3.74) 24/1103 (2.18) 8/671 (1.19) 6.95 (5.61 to 8.50)
a Women with multiple HPV infections at entry have been assigned to the HPV type highest in the hierarchy as listed in
the table. This hierarchy reﬂects the order of crude CIN3+ rates in round 1 among women who had only one of these
seven HPV infections at entry.
TABLE 47 Cumulative CIN3+ rate by HPV type at entry
HPV at round 1a
Round 1,
n/CIN3+ (%)
Round 2,
CIN3+/n (%)
Round 3,
CIN3+/n (%)
Cumulative CIN3+ rate,14
% (95% CI)
– 9/20,697 (0.04) 12/13,720 (0.09) 11/7552 (0.15) 0.28 (0.18 to 0.40)
16 191/827 (23.10) 20/339 (5.90) 8/213 (3.76) 30.35 (26.70 to 34.24)
33 21/166 (12.65) 3/78 (3.85) 1/54 (1.85) 17.57 (11.37 to 25.43)
31 32/299 (10.70) 5/145 (3.45) 2/109 (1.83) 15.36 (10.90 to 20.83)
18 16/228 (7.02) 2/128 (1.56) 3/86 (3.49) 11.66 (6.93 to 17.99)
45 6/137 (4.38) 2/86 (2.33) 0/54 6.60 (2.90 to 12.61)
58 6/107 (5.61) 1/54 (1.85) 0/35 7.36 (2.73 to 15.25)
52 8/229 (3.49) 1/137 (0.73) 1/99 (1.01) 5.17 (2.39 to 9.59)
Other 25/1820 (1.37) 7/1103 (0.63) 5/671 (0.75) 2.73 (1.86 to 3.85)
a Women with multiple HPV infections at entry have been assigned to the HPV type highest in the hierarchy as listed in
the table. This hierarchy reﬂects the order of crude CIN3+ rates in round 1 among women who had only one of these
seven HPV infections at entry.
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Appendix 2 PapilloCheck® human papillomavirus
genotyping
With a number of new HPV test kits becoming available, it was possible to undertake a number ofcomparisons with new kits. Some of these kits provide genotyping data as their sole read-out, for
example PapilloCheck® (Greiner) and Linear Array® (Roche), while others provide a generic HR type
read-out, for example Cervista (Hologic). Yet others offer both a generic read-out and limited type-speciﬁc
data, for example M2000 (Abbott) and Cobas 4800 (Roche).
In one comparative testing exercise, PapilloCheck® and M2000 were compared with HC2 in a subset of samples
archived from round 1 with known cytological and histological outcomes. There were 387 cases in which an
adequate cytology grade was available and where it was possible to obtain valid HPV results with all three HPV
tests. These are tabulated according to grade of cytology with footnotes detailing CIN2+ histology outcomes.
It can be seen from Table 48 that among a group of normal cytology (n = 66), of which 50 were HC2 positive
and 16 HC2 negative, there was 46/50 (92%) concordance with HC2 positive and 13/16 (82%) concordance
with HC2 negative for the PapilloCheck® and M2000 tests. The results for 212 borderline/mild cytology
were similar, with 99/105 (94%) and 99/107 (92.5%) agreement between the PapilloCheck® and M2000
for HC2 positive and HC2 negative, respectively (Table 49). In 109 samples with moderate dyskaryosis or
worse, there was 92/96 (95.8%) and 13/13 (100%) for these tests for HC2 positive and HC2 negative,
respectively (34 CIN2+ lesions identiﬁed among this group: 28 were positive by all three tests, ﬁve were
negative by all three tests and one was positive by PapilloCheck® only) (Table 50). Taken together, there were
110 underlying CIN2+ lesions, of which 95 were positive by HC2 and M2000 and 93 by PapilloCheck®.
In addition, there was one case of invasive carcinoma which was detected by all three assays.
In a second exercise, 378 HC2-positive samples (300 were prospectively obtained in round 3 and 78 were
archived) were co-tested with PapilloCheck® and LA. This was concerned with HPV genotyping. When
HR type positivity overall was compared, there was 303/378 (80%) concordance between LA and
PapilloCheck®. When types 16/18 detection was compared, this rose to 359/378 (94.9%) concordance.
The results for all HR types are shown in Figure 44 with some differences in both directions in some types,
31 and 68 being more obvious among the more HR types.
In a third typing exercise, PapilloCheck® was compared with LBA (Roche). Among 2189 archived
samples which were cytology negative/HPV positive, the HR types from HC2 were detected by LBA
and PapilloCheck® in 63% and 59.8% of cases, respectively (Figure 45). Again, there was some
non-concordance between individual types in both directions, but in the case of types 16, 18 and 52 there
were quite marked differences. Overall, PapilloCheck® identiﬁed fewer types overall (1683) compared with
LBA (1835). Among 1279 abnormal cytology/HC2-positive sample, the concordance was higher, as shown
in Figure 46, with 1173 types detected using PapilloCheck® and 1117 with LBA.
PapilloCheck® was then compared with HC2 in a prospective study of samples received in round 3,
against a HC2 cut-off of RLU/Co 1 and 2. Again, the results (Table 51) are similar for both low-grade and
high-grade cytology; the concordance within borderline/mild/RLU/Co ≥ 1 and ≥ 2 was 92% and 93.5%,
respectively, and for moderate/severe/RLU/Co ≥ 1 and ≥ 2 was 95.5% and 95%, respectively. Among a
prospective screened group of 4282 normal and abnormal samples in round 3, HC2 (RLU 1), HC2 (RLU 2)
and PapilloCheck® were positive in 16.4%, 13.5% and 11.8%, respectively. It is likely that this reﬂects
greater speciﬁcity for HR types with PapilloCheck® and, consequently, slightly reduced sensitivity. These
tests appear to perform similarly and, although small differences are found, these are unlikely to be
signiﬁcant from a clinical point of view. They do have different testing characteristics, some more labour
intensive than others, and more detailed studies are warranted to address cost-effectiveness taking both
costs and clinical utility into account.
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TABLE 48 A comparison between the HPV HC2 assay (Qiagen), PapilloCheck® (Greiner) and M2000 (Abbott) tests:
normal cytology
HC2+ve HC2−ve
TotalPapilloCheck®+ve PapilloCheck®−ve PapilloCheck®+ve PapilloCheck®−ve
M2000+ve 36 (54.5%) 2 (3.0%) 1 (1.5%) 1 (1.5%) 40 (60.6%)
M2000−ve 2 (3.0%) 10 (15.2%) 2 (3.0%) 12 (18.2%) 26 (39.4%)
Total 38 (57.6%) 12 (18.2%) 3 (4.5%) 13 (19.7%) 66a
−ve, negative; +ve, positive.
a Four CIN2+ lesions identiﬁed among this group – all were positive by all three tests.
TABLE 49 A comparison between the HC2 assay (Qiagen), PapilloCheck® (Greiner) and M2000 (Abbott) tests:
borderline/mild cytology
HC2+ve HC2−ve
TotalPapilloCheck®+ve PapilloCheck®−ve PapilloCheck®+ve PapilloCheck®−ve
M2000+ve 94 (44.3%) 2 (0.9%) 6 (2.8%) 2 (0.9%) 104 (49.1%)
M2000−ve 4 (1.9%) 5 (2.4%) 6 (2.8%) 93 (43.9%) 108 (50.9%)
Total 98 (46.2%) 7 (3.3%) 12 (5.7%) 95 (44.8%) 212a
−ve, negative; +ve, positive.
a Thirty-four CIN2+ lesions identiﬁed among this group – 28 were positive by all three tests, ﬁve were negative by all
three tests and one was positive by PapilloCheck® only.
TABLE 50 A comparison between the HPV HC2 assay (Qiagen), PapilloCheck® (Greiner) and M2000 (Abbott) tests
HC2+ve HC2−ve
TotalPapilloCheck®+ve PapilloCheck®−ve PapilloCheck®+ve PapilloCheck®−ve
M2000+ve 92 (84.4%) 4 (3.7%) 1 (0.9%) 0 (0%) 97 (89.0%)
M2000−ve 0 (0%) 0 (0%) 0 (0%) 12 (11.0%) 12 (11.0%)
Total 92 (84.4%) 4 (3.7%) 1 (0.9%) 12 (11.0%) 109a
−ve, negative; +ve, positive.
a Seventy-two CIN2+ lesions identiﬁed among this group – 60 were positive by all three tests, four were negative by all
three tests and three were positive by HC2 and M2000 but negative by PapilloCheck®. In addition, one sample was
graded invasive by histology and was positive by all three tests.
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FIGURE 44 Linear array vs. PapilloCheck® genotyping results on HC2-positive screening samples (n = 378).
HPV positive
any type
0%
10%
20%
30%
40%
50%
60%
70%
80%
HR HPV
positive
LR only
HPV positive
LBA
PapilloCheck®G
en
o
ty
p
e
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FIGURE 46 Line blot assay vs. PapilloCheck® on HC2-positive/abnormal cytology samples.
TABLE 51 Human papillomavirus-positive rates with PapilloCheck® and HC2 assays
HR PapilloCheck® (%) HC2/1RLU (%) HC2/2RLU (%)
Borderline/mild cytology 47 49 45
Moderate/severe cytology 90 93.40 92.80
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Appendix 3 Key tables reproduced using the
second definition of round 3
TABLE 52 Human papillomavirus prevalence by round and age at round
Age at round (years) Round 1, HPV+/total (%) Round 2, HPV+/totala (%) Round 3, HPV+/totala (%)
19–24 1036/2600 (39.85) 118/360 (32.78) 20/57 (35.09)
25–29 717/2589 (27.69) 215/844 (25.47) 219/859 (25.49)
30–39 1161/7633 (15.21) 372/3251 (11.44) 354/2739 (12.92)
40–49 533/6096 (8.74) 229/4093 (5.59) 273/3596 (7.59)
50–59 290/4351 (6.67) 134/3126 (4.29) 101/1629 (6.20)
60–64 76/1240 (6.13) 45/1075 (4.19) 15/328 (4.57)
65–70 11/401 (2.74) 6/93 (6.45)
Total 3813/24,510 (15.56) 1124/13,150 (8.55) 988/9301 (10.62)
a Total = non-missing HPV results.
TABLE 53 Cytological abnormality and HPV status in round 2
Cytological
abnormality –ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45,
n (%)
Other HC2+ve,
n (%) Total, n (%)
Negative 11,732 (93.4) 140 (1.1) 110 (0.9) 579 (4.6) 12,561 (100)
Borderline 246 (64.7) 39 (10.3) 19 (5.0) 76 (20.0) 380 (100)
Mild 45 (26.3) 40 (23.4) 19 (11.1) 67 (39.2) 171 (100)
Moderate 0 9 (42.9) 3 (14.3) 9 (42.9) 21 (100)
Severe+ 3 (17.6) 11 (64.7) 2 (11.8) 1 (5.9) 17 (100)
Total 12,026 (91.5) 239 (1.8) 153 (1.2) 732 (5.6) 13,150 (100)
–ve, negative; +ve, positive.
TABLE 54 Cytological abnormality and HPV status in round 3
Cytological
abnormality –ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45,
n (%)
Other HC2+ve,
n (%) Total, n (%)
Negative 8156 (92.0) 126 (1.4) 62 (0.7) 524 (5.9) 8868 (100)
Borderline 127 (58.5) 15 (6.9) 15 (6.9) 60 (27.6) 217 (100)
Mild 25 (15.9) 36 (22.9) 22 (14.0) 74 (47.1) 157 (100)
Moderate 2 (7.1) 12 (42.9) 3 (10.7) 11 (39.3) 28 (100)
Severe+ 3 (9.7) 13 (41.9) 6 (19.4) 9 (29.0) 31 (100)
Total 8313 (89.4) 202 (2.0) 108 (1.2) 678 (7.3) 9301 (100)
–ve, negative; +ve, positive.
DOI: 10.3310/hta18230 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 23
117
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 55 CIN2 and CIN3 by randomisation arm and round
Concealed, n (%) Revealed, n (%) Total, n (%)
Round 1 (entry)
CIN2 53 220 273
CIN3 81 233 314
CIN2+ 134 (2.19) 453 (2.46) 587 (2.39)
Total women 6124 18,386 24,510
Round 2
CIN2 13 44 57
CIN3 14 31 45
CIN2+ 27 (0.76) 75 (0.69) 102 (0.71)
Total women 3536 10,800 14,336
Round 3
CIN2 9 34 43
CIN3 10 29 39
CIN2+ 19 (0.77) 63 (0.86) 82 (0.84)
Total women 2460 7321 9781
TABLE 57 Round 3 CIN2+ rate by presence of round 2 cytology and HPV status/cytology at entry [proportion (%)]
Round 3
Concealed arm Revealed arm
HPV– HPV+ Subtotal HPV– HPV+ Subtotal
With round 2
Normal 2/1163 (0.2) 5/127 (3.9) 7/1290 (0.5) 12/3479 (0.3) 3/419 (0.7) 15/3898 (0.4)
Abnormal 1/111 (0.9) 0/73 1/184 (0.5) 0/308 4/248 (1.6) 4/956 (0.7)
Total 3/1274 (0.2) 5/200 (2.5) 8/1474 (0.5) 12/3787 (0.3) 7/667 (1.0) 19/4454 (0.4)
Without round 2
Normal 5/791 (0.6) 3/111 (2.7) 8/902 (0.9) 14/2248 (0.6) 21/316 (6.6) 35/2564 (1.4)
Abnormal 0/42 3/42 (7.4) 3/84 (3.6) 3/176 (1.7) 6/127 (4.7) 9/303 (3.0)
Total 5/833 (0.6) 6/153 (3.9) 11/986 (1.1) 17/2424 (0.7) 27/443 (6.1) 44/267 (1.5)
TABLE 56 CIN2+ rate by round and HPV status/cytology at entry [proportion (%)]
Concealed arm Revealed arm
HPV– HPV+ Subtotal HPV– HPV+ Subtotal
Round 2
Normal 4/2835 (0.4) 13/293 (4.4) 17/3128 (0.5) 23/8739 (0.3) 28/891 (3.1) 51/9630 (0.5)
Abnormal 1/242 (0.4) 9/166 (5.4) 10/408 (2.5) 4/713 (0.6) 20/457 (4.4) 24/1170 (2.1)
Total 5/3077 (0.2) 22/459 (4.8) 27/3536 (0.8) 27/9452 (0.3) 48/1348 (3.6) 75/10,800 (0.7)
Round 3
Normal 7/1954 (0.4) 8/238 (3.4) 15/2192 (0.7) 56/5727 (0.5) 24/735 (3.3) 50/6462 (0.8)
Abnormal 1/153 (0.7) 3/115 (2.6) 4/268 (1.5) 3/484 (0.6) 10/375 (2.7) 13/859 (1.5)
Total 8/2107 (0.4) 11/353 (3.1) 19/2460 (0.8) 15/2192 (0.7) 4/268 (1.5) 19/2460 (0.8)
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Appendix 4 National Screening Committee’s
criteria for appraising the viability, effectiveness and
appropriateness of a screening programme
The criteria, which are set out below, are based on the classic criteria ﬁrst promulgated in a WorldHealth Organization report in 1966 but take into account both the more rigorous standards of evidence
required to improve effectiveness and the greater concern about the adverse effects of health care;
regrettably, some people who undergo screening will suffer adverse effects without receiving beneﬁt from
the programme.
These criteria have been prepared taking into account international work on the appraisal of screening
programmes, particularly that in Canada and the USA. It is recognised that not all of the criteria and
questions raised in the format will be applicable to every proposed programme, but the more that are
answered will obviously assist the NSC to make better evidence-based decisions.
All of the following criteria should be met before screening for a condition is initiated.
The condition
The condition should be an important health problem.
The epidemiology and natural history of the condition, including development from latent to declared
disease, should be adequately understood and there should be a detectable risk factor, or disease marker,
and a latent period or early symptomatic stage.
All of the cost-effective primary prevention interventions should have been implemented as far
as practicable.
The test
There should be a simple, safe, precise and validated screening test.
The distribution of test values in the target population should be known and a suitable cut-off level
deﬁned and agreed.
The test should be acceptable to the population.
There should be an agreed policy on the further diagnostic investigation of individuals with a positive
test result and on the choices available to those individuals.
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The treatment
There should be an effective treatment or intervention for patients identiﬁed through early detection, with
evidence of early treatment leading to better outcomes than late treatment.
There should be agreed evidence-based policies covering which individuals should be offered treatment
and the appropriate treatment to be offered.
Clinical management of the condition and patient outcomes should be optimised by all health-care
providers prior to participation in a screening programme.
The screening programme
There must be evidence from high-quality randomised controlled trials that the screening programme is
effective in reducing mortality or morbidity. Where screening is aimed solely at providing information to
allow the person being screened to make an ‘informed choice’ (e.g. Down’s syndrome or cystic ﬁbrosis
carrier screening), there must be evidence from high-quality trials that the test accurately measures risk.
The information that is provided about the test and its outcome must be of value and readily understood
by the individual being screened.
There should be evidence that the complete screening programme (test, diagnostic procedures, treatment/
intervention) is clinically, socially and ethically acceptable to health professionals and the public.
The beneﬁt from the screening programme should outweigh the physical and psychological harm (caused
by the test, diagnostic procedures and treatment).
The opportunity cost of the screening programme (including testing, diagnosis, treatment, administration,
training and quality assurance) should be economically balanced in relation to expenditure on medical care
as a whole (i.e. value for money).
There must be a plan for managing and monitoring the screening programme and an agreed set of quality
assurance standards.
Adequate stafﬁng and facilities for testing, diagnosis, treatment and programme management should be
made available prior to the commencement of the screening programme.
All other options for managing the condition should have been considered (e.g. improving treatment,
providing other services) to ensure that no more cost-effective intervention could be introduced or current
interventions increased within the resources available.
Evidence-based information, explaining the consequences of testing, investigation and treatment, should
be made available to potential participants to assist them in making an informed choice.
Public pressure for widening the eligibility criteria for reducing the screening interval, and for increasing the
sensitivity of the testing process, should be anticipated. Decisions about these parameters should be
scientiﬁcally justiﬁable to the public.
APPENDIX 4
120
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Reading list
Department of Health. Screening of Pregnant Women for Hepatitis B and Immunisation of Babies at Risk.
London: Department of Health; 1998 (Health Service Circular: HSC 1998/127).
Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Public Health Paper Number 34.
Geneva: WHO; 1968.
Cochrane AL, Holland WW. Validation of screening procedures. Br Med Bull 1971;27:3.
Sackett DL, Holland WW. Controversy in the detection of disease. Lancet 1975;2:357–9.
Wald NJ, editor. Antenatal and Neonatal Screening. Oxford: Oxford University Press; 1984.
Holland WW, Stewart S. Screening in Healthcare. The Nufﬁeld Provincial Hospitals Trust; 1990.
Grey JAM. Dimensions and Definitions of Screening. Milton Keynes: NHS Executive Anglia and Oxford,
Research and Development Directorate; 1996.
DOI: 10.3310/hta18230 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 23
121
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.

Appendix 5 Patient information sheet:
Manchester, Salford, Trafford and Ashton,
Leigh & Wigan primary care trusts
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Appendix 6 Patient information sheet: Stockport
primary care trust
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Appendix 7 Consent form
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Appendix 8 Supplementary tables
TABLE 58 Cytological abnormality and HPV status in round 1 by randomisation arm
Cytological
abnormality
Concealed arm, n (%) Revealed arm, n (%)
HPV– HPV+ Subtotal HPV– HPV+ Subtotal
Negative 4787 (89.7) 551 (10.3) 5338 (100) 14,367 (89.6) 1675 (10.4) 16,042 (100)
Borderline 309 (69.3) 137 (30.7) 446 (100) 923 (68.7) 420 (31.3) 1343 (100)
Mild 69 (29.4) 166 (70.6) 235 (100) 196 (30.5) 447 (69.5) 643 (100)
Moderate 4 (6.0) 63 (94.0) 67 (100) 34 (16.7) 170 (83.3) 204 (100)
Severe+ 2 (5.3) 36 (94.7) 38 (100) 6 (3.9) 148 (96.1) 154 (100)
Total 5171 (84.4) 953 (15.6) 6124 (100) 15,526 (84.4) 2860 (15.6) 18,386 (100)
TABLE 59 Cytological abnormality and HPV status in round 2 by randomisation arm
Cytological
abnormality
Concealed arm, n (%) Revealed arm, n (%)
HPV– HPV+
HPV
missing Subtotal HPV– HPV+
HPV
missing Subtotal
Negative 3128 (93.3) 224 (6.7) 363 3715 9519 (93.2) 697 (6.8) 1066 11,282
Borderline 72 (64.4) 38 (34.6) 28 138 193 (63.9) 109 (36.1) 48 350
Mild 6 (12.2) 43 (87.8) 10 59 41 (27.5) 108 (72.5) 34 183
Moderate 0 8 (100) 3 11 1 (4.2) 23 (95.8) 4 28
Severe+ 1 (20.0) 4 (80.0) 0 5 3 (17.6) 14 (82.4) 2 19
Total 3207 (91.9) 317 (9.0) 404 3928 9757 (91.1) 951 (8.9) 1154 11,862
TABLE 60 Cytological abnormality and HPV status in round 3 by randomisation arm
Cytological
abnormality
Concealed arm, n (%) Revealed arm, n (%)
HPV– HPV+
HPV
missing Subtotal HPV– HPV+
HPV
missing Subtotal
Negative 1855 (92.8) 145 (7.2) 106 2106 5543 (91.8) 498 (8.2) 314 6355
Borderline 27 (54.0) 23 (46.0) 1 51 87 (57.6) 64 (42.4) 8 150
Mild 4 (11.8) 30 (88.2) 3 37 17 (16.2) 88 (83.8) 10 115
Moderate 1 (14.3) 6 (85.7) 1 8 1 (6.72) 14 (93.3) 1 16
Severe+ 1 (6.7) 5 (83.3) 0 6 1 (5.3) 18 (94.7) 1 20
Total 1888 (90.0) 209 (10.0) 111 2208 5649 (89.2) 682 (10.8) 334 6665
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TABLE 62 Cytological abnormality and HPV status in round 1 by age (years) at round 1 sample
Cytological abnormality HPV–, n (%) HPV+, n (%) HPV missing Subtotal, n (%)
Age 20–24
Negative 1424 (73.1) 523 (26.9) N/A 1947 (100)
Borderline 110 (38.5) 176 (61.5) N/A 286 (100)
Mild 25 (9.8) 230 (90.2) N/A 255 (100)
Moderate+ 5 (4.5) 107 (95.5) N/A 112 (100)
Total 1564 1036 N/A 2600
Age 25–29
Negative 1711 (82.0) 375 (18.0) N/A 2086 (100)
Borderline 126 (52.7) 113 (47.3) N/A 239 (100)
Mild 28 (17.4) 133 (82.6) N/A 161 (100)
Moderate+ 7 (6.8) 96 (93.2) N/A 103 (100)
Total 1872 717 N/A 2589
Age 30–39
Negative 5951 (89.9) 679 (10.2) N/A 6630 (100)
Borderline 417 (70.4) 175 (29.6) N/A 592 (100)
Mild 94 (36.6) 163 (63.4) N/A 257 (100)
Moderate+ 10 (6.5) 144 (93.5) N/A 154 (100)
Total 6472 1161 N/A 7633
Age 40–49
Negative 5117 (93.7) 343 (6.3) N/A 5460 (100)
Borderline 359 (84.1) 68 (15.9) N/A 427 (100)
Mild 71 (50.7) 69 (49.3) N/A 140 (100)
Moderate+ 16 (23.2) 53 (76.8) N/A 69 (100)
Total 5563 533 N/A 6096
Age 50–59
Negative 3822 (94.1) 238 (5.9) N/A 4060 (100)
Borderline 192 (89.3) 23 (10.7) N/A 215 (100)
Mild 40 (70.2) 17 (29.8) N/A 57 (100)
Moderate+ 7 (36.8) 12 (63.2) N/A 19 (100)
Total 4061 290 N/A 4351
Age 60–65
Negative 1129 (94.3) 68 (5.7) N/A 1197 (100)
Borderline 28 (93.3) 2 (6.7) N/A 30 (100)
Mild 7 (87.5) 1 (12.5) N/A 8 (100)
Moderate+ 1 (16.7) 5 (83.3) N/A 6 (100)
Total 1165 76 N/A 1241
N/A, not applicable.
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TABLE 63 Cytological abnormality and HPV status in round 2 by age (years) at round 2 sample
Cytological abnormality HPV–, n (%) HPV+, n (%) HPV missing, n Subtotal, N
Age 22–24
Negative 226 (75.8) 85 (24.2) 100 451
Borderline 9 (32.1) 19 (67.9) 5 33
Mild 4 (12.9) 27 (87.1) 2 33
Moderate+ 0 8 (100) 0 8
Total 279 139 107 525
Age 25–29
Negative 703 (81.3) 162 (18.7) 167 1032
Borderline 18 (34.6) 34 (65.4) 18 70
Mild 5 (11.4) 39 (88.6) 11 55
Moderate+ 0 11 (100) 2 13
Total 726 246 198 1170
Age 30–39
Negative 3022 (91.0) 299 (9.0) 463 3805
Borderline 88 (61.1) 56 (38.9) 24 168
Mild 13 (18.8) 56 (81.2) 15 84
Moderate+ 0 22 (100) 4 26
Total 3134 433 516 4083
Age 40–49
Negative 4063 (95.3) 202 (4.7) 384 4649
Borderline 96 (85.0) 17 (15.0) 21 134
Mild 17 (42.5) 23 (57.5) 14 54
Moderate+ 4 (40.0) 6 (60.0) 1 11
Total 4180 248 420 4848
Age 50–59
Negative 3128 (96.3) 119 (3.7) 212 3459
Borderline 41 (71.9) 16 (28.1) 7 64
Mild 7 (53.8) 6 (46.2) 2 15
Moderate+ 0 2 (100) 1 3
Total 3176 143 222 3541
Age 60–68
Negative 1454 (96.4) 54 (3.6) 93 1601
Borderline 13 (72.2) 5 (27.8) 1 19
Mild 1 (100) 0 0 1
Moderate+ 1 (100) 0 1 2
Total 1469 59 95 1623
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TABLE 64 Cytological abnormality and HPV status in round 3 by age (years) at round 3 sample
Cytological abnormality HPV–, n (%) HPV+, n (%) HPV missing, n Subtotal, N
Age 24
Negative 9 0 0 9
Borderline 1 0 0 1
Mild 0 3 0 3
Moderate+ 0 1 0 1
Total 10 4 0 14
Age 25–29
Negative 537 (79.8) 136 (20.2) 26 699
Borderline 15 (45.5) 18 (54.5) 2 35
Mild 4 (11.1) 32 (88.9) 1 37
Moderate+ 0 12 (100) 1 13
Total 556 198 30 784
Age 30–39
Negative 2156 (91.2) 207 (8.8) 128 2491
Borderline 28 (41.2) 40 (58.8) 2 70
Mild 4 (7.7) 48 (92.3) 5 57
Moderate+ 2 (9.5) 19 (90.5) 0 21
Total 2190 314 135 2639
Age 40–49
Negative 3007 (93.7) 203 (6.3) 167 3377
Borderline 47 (67.1) 23 (32.9) 3 73
Mild 12 (30.0) 28 (70.0) 7 47
Moderate+ 1 (10.0) 9 (90.0) 1 11
Total 3067 263 175 3508
Age 50–59
Negative 1348 (94.5) 79 (5.5) 72 1499
Borderline 19 (79.2) 5 (20.8) 2 26
Mild 1 (12.5) 7 (87.5) 0 8
Moderate+ 1 (33) 2 (67) 0 3
Total 1369 93 74 1536
Age 60–70
Negative 341 (95.0) 18 (5.0) 27 386
Borderline 4 (80.0) 1 (20.0) 0 5
Mild 0 0 0 0
Moderate+ 0 0 1 1
Total 345 19 28 392
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TABLE 65 CIN2+ rate by cytology HPV (RLU/Co≥ 1) status and age at round
Age at round
(years)
Cytology at round and HPV status at round, n (%)
Normal cytology Borderline/mild cytology Moderate+ cytology
HPV– HPV+ HPV– HPV+ HPV– HPV+
Round 1
25–34 0/4481 11/747 (1.5) 9/385 (2.3) 90/461 (19.5) 2/9 (22.2) 151/193 (78.2)
35–49 0/8298 8/650 (1.2) 8/710 (1.1) 40/260 (15.4) 6/24 (25.0) 79/100 (79.0)
≥ 50 0/4951 2/306 (0.7) 3/267 (1.1) 2/43 (4.7) 0/8 12/17 (70.6)
Round 2
25–34 0/1890 11/308 (3.6) 2/66 (3.0) 26/137 (19.0) 0/0 19/26 (73.1)
35–49 1/5909 (0.02) 3/355 (0.8) 4/171 (2.3) 12/88 (13.6) 1/4 (25.0) 8/13 (61.5)
≥ 50 0/4582 1/173 (0.6) 0/62 2/27 (7.4) 0/1 1/2 (50.0)
Round 3
25–34 1/1354 (0.1) 1/255 (0.4) 0/29 16/89 (18.0) 0/0 12/20 (60.0)
35–49 1/4346 (0.02) 0/321 2/81 (2.5) 14/100 (14.0) 1/3 (33.3) 9/20 (45.0)
≥ 50 0/1689 1/97 (1.0) 0/24 1/13 (7.7) 0/1 2/2 (100)
TABLE 66 CIN3+ rate by cytology, HPV (RLU/Co≥ 1) status and age at round
Age at round
(years)
Cytology at round and HPV status at round, n (%)
Normal cytology Borderline/mild cytology Moderate+ cytology
HPV– HPV+ HPV– HPV+ HPV– HPV+
Round 1
25–34 0/4481 2747 (0.3) 2385 (0.5) 38/461 (8.2) 1/9 (11.1) 100/193 (51.8)
35–49 0/8298 4650 (0.6) 2/710 (0.3) 14/260 (5.4) 2/24 (8.3) 56/100 (56.0)
≥ 50 0/4951 0/306 0/267 0/43 0/8 9/17 (52.9)
Round 2
25–34 0/1890 5/308 (1.6) 0/66 9/137 (6.6) 0/0 13/26 (50.0)
35–49 0/5909 1/355 (0.3) 1/171 (0.6) 6/88 (6.8) 1/4 (25.0) 6/13 (46.2)
≥ 50 0/4582 0/173 0/62 1/27 (3.7) 0/1 0/2
Round 3
25–34 0/1354 0/255 0/29 8/89 (9.0) 0/0 8/20 (40.0)
35–49 0/4346 0/321 1/81 (1.2) 3/100 (3.0) 0/3 6/20 (30.0)
≥ 50 0/1689 0/97 0/24 1/13 (7.7) 0/1 1/2 (50.0)
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TABLE 67 CIN2+ rate by cytology, HPV (RLU/Co≥ 2) status and age at round
Age at round
(years)
Cytology at round and HPV status at round, n (%)
Normal cytology Borderline/mild cytology Moderate+ cytology
HPV– HPV+ HPV– HPV+ HPV– HPV+
Round 1
25–34 0/4616 11/612 (1.8) 13/414 (3.1) 86/432 (19.9) 2/9 (22.2) 151/193 (78.2)
35–49 2/8482 (0.02) 6/466 (1.3) 10/743 (1.3) 38/227 (16.7) 7/25 (28.0) 78/99 (78.8)
≥ 50 1/5078 (0.02) 1/179 (0.6) 3/274 (1.1) 2/36 (5.6) 0/8 12/17 (70.6)
Round 2
25–34 3/1955 (0.2) 8/243 (3.3) 2/73 (2.7) 26/130 (20.0) 0/2 19/24 (79.2)
35–49 2/6002 (0.03) 2/262 (0.8) 4/176 (2.3) 12/83 (14.5) 1/4 (25.0) 8/13 (61.5)
≥ 50 1/4639 (0.02) 0/116 1/64 (1.6) 1/25 (4.0) 0/1 1/2 (50.0)
Round 3
25–34 1/1385 (0.1) 1/194 (0.5) 1/34 (2.9) 15/84 (17.9) 0/1 12/19 (63.2)
35–49 1/4424 (0.02) 0/243 3/88 (3.4) 13/93 (14.0) 2/4 (50.0) 8/19 (42.1)
≥ 50 0/1712 1/74 (1.4) 0/25 1/12 (8.3) 0/1 2/2 (100)
TABLE 68 CIN3+ rate by cytology, HPV (RLU/Co ≥ 2) status and age at round
Age at round
(years)
Cytology at round and HPV status at round, n (%)
Normal cytology Borderline/mild cytology Moderate+ cytology
HPV– HPV+ HPV– HPV+ HPV– HPV+
Round 1
25–34 0/4616 2/612 (0.3) 4/414 (1.0) 36/432 (8.3) 1/9 (11.1) 100/193 (51.8)
35–49 0/8482 4/466 (0.9) 2/743 (0.3) 14/227 (6.2) 2/25 (8.0) 56/99 (56.6)
≥ 50 0/5078 0/179 0/274 0/36 0/8 9/17 (52.9)
Round 2
25–34 2/1955 (0.1) 3/243 (1.2) 0/73 9/130 (6.9) 0/2 13/24 (54.2)
35–49 0/6002 1/262 (0.4) 1/176 (0.6) 6/83 (7.2) 1/4 (25.0) 6/13 (46.2)
≥ 50 0/4639 0/116 0/64 1/25 (4.0) 0/1 0/2
Round 3
25–34 0/1385 0/194 0/34 8/84 (9.5) 0/1 8/19 (42.1)
35–49 0/4424 0/243 2/88 (2.3) 2/93 (2.2) 1/4 (25.0) 5/19 (26.3)
≥ 50 0/1712 0/74 0/25 1/12 (8.3) 0/1 1/2 (50.0)
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TABLE 69 Cytological abnormality and HPV status in round 1
Cytological
abnormality –ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45/52/58,
n (%)
Other HC2+ve,
n (%) Total, n (%)
Negative 19,154 (89.6) 473 (2.2) 476 (2.2) 1277 (6.0) 21,380 (100)
Borderline 1232 (68.9) 179 (10.0) 160 (8.9) 218 (12.2) 1789 (100)
Mild 265 (30.2) 197 (22.4) 148 (16.9) 268 (30.5) 878 (100)
Moderate 38 (14.0) 130 (48.0) 66 (24.4) 37 (13.7) 271 (100)
Severe+ 8 (4.2) 119 (62.0) 45 (23.4) 20 (10.4) 192 (100)
Total 20,697 (84.4) 1098 (4.5) 895 (3.7) 1820 (7.4) 24,510 (100)
–ve, negative; +ve, positive.
TABLE 70 Cytological abnormality and HPV status in round 2
Cytological
abnormality –ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45/52/58,
n (%)
Other HC2+ve,
n (%) Total, n (%)
Negative 12,647 (93.2) 164 (1.2) 208 (1.5) 549 (4.0) 13,568 (100)
Borderline 265 (64.3) 43 (10.4) 33 (8.0) 71 (17.2) 412 (100)
Mild 47 (23.7) 50 (25.3) 33 (16.7) 68 (34.3) 198 (100)
Moderate 1 (3.1) 14 (43.8) 8 (25.0) 9 (28.1) 32 (100)
Severe+ 4 (18.2) 13 (59.1) 4 (18.2) 1 (4.5) 22 (100)
Total 12,964 (91.1) 284 (2.0) 286 (2.0) 698 (4.9) 14,232 (100)
–ve, negative; +ve, positive.
TABLE 71 Cytological abnormality and HPV status in round 3
Cytological
abnormality –ve, n (%)
HPV 16/18,
n (%)
HPV 31/33/45/52/58,
n (%)
Other HC2+ve,
n (%) Total, n (%)
Negative 7398 (92.0) 109 (1.4) 109 (1.4) 425 (5.3) 8041 (100)
Borderline 114 (56.7) 14 (7.0) 22 (10.9) 51 (25.4) 201 (100)
Mild 21 (15.1) 31 (22.3) 32 (23.0) 55 (39.6) 139 (100)
Moderate 2 (9.1) 9 (40.9) 7 (31.8) 4 (18.2) 22 (100)
Severe+ 2 (8.0) 10 (40.0) 6 (24.0) 7 (28.0) 25 (100)
Total 7537 (89.4) 173 (2.0) 176 (2.1) 542 (6.6) 8428 (100)
–ve, negative; +ve, positive.
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Appendix 9 Determining the test probability
matrices for liquid-based cytology in ARTISTIC
The cohort model that is being used to simulate the ARTISTIC trial cohort uses six underlying healthstates (which we call ‘well’, ‘HPV positive’, ‘CIN1’, ‘CIN2’, ‘CIN3’ and ‘cancer’, which we break into HPV
type-speciﬁc states after the ﬁtting process is complete). The model also uses a test-speciﬁc screening
probability matrix (which we call a test probability matrix, or ‘TPM’) to model the outcomes of screening
tests in the given population. As a ﬁrst step in modelling ARTISTIC, we have to decide what reasonable
underlying health states to give our model as initial inputs, together with the cytology TPM to be used for
the screening rounds. We use a Gibbs sampler to simulate from the posterior distribution of the health
state and cytology TPM parameters, using the cytology and HPV data observed at baseline of the ARTISTIC
data. The Gibbs sampler technique is described in more detail in Joseph.26
The Gibbs sampling process requires prior information on the test characteristics for LBC. We use a
previously derived TPM for LBC as the prior for the Gibbs sampler. We can also provide prior information
about the health state of women entering the trial, because the HPV test results at baseline provide
information on the prevalence of HPV infection of women entering the trial. As the combination of health
states and test probability matrices can be used to calculate the cytology test results, we use the observed
cytology test results observed in ARTISTIC at baseline to inform the sampler on whether the combined
health state and test probability matrices are representative of the ARTISTIC cohort.
Let D be a random variable representing the underlying health state of an individual. The health states
used in the cohort model are:
l Well (D = 1)
l HPV (D = 2)
l CIN1 (D = 3)
l CIN2 (D = 4)
l CIN3 (D = 5)
l Undetected cancer (D = 6).
As we have age-group speciﬁc cytology and HPV data, we let
π ij ¼ PðD ¼ jjAge-group ¼ iÞ, i ¼ 1,. . .,5 and j ¼ 1,. . .,6 ð1Þ
be the prevalence of health state j in age-group i. The age groups we consider are:
l 20–24 (i = 1)
l 25–29 (i = 2)
l 30–39 (i = 3)
l 40–49 (i = 4)
l 50–64 (i = 5).
Let T be a random variable representing the result of a cytology test. T can take values:
l negative (T = 1)
l borderline (T = 2)
l mild (T = 3)
l moderate (T = 4)
l severe (T = 5).
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We deﬁne
ηjk ¼ PðT ¼ kjD ¼ jÞ, j ¼ 1,. . .6 and k ¼ 1,. . .,5 ð2Þ
that is to say ηjk is the probability of getting a cytology result k given that the underlying health state is j.
This is the TPM entry in row j and column k.
For the undetected cancer parameters, π:6, the reported cervical cancer rates in England in 200161 are
used, that is to say we take:
π16 ¼ 0.00002561 π46 ¼ 0.00015524
π26 ¼ 0.00009068 π56 ¼ 0.00010882.
π36 ¼ 0.00014691
ð3Þ
We also assume that the probability of being in the Well health state can be fully obtained from the
HPV-negative data in table 7 of Kitchener et al.1
π11 ¼ 0.601 π41 ¼ 0.913
π21 ¼ 0.721 π51 ¼ 0.935.
π31 ¼ 0.847
ð4Þ
Our goal is to sample from the posterior distribution of π ¼ ðπ ijÞ (excluding the Well and Undetected
cancer parameters) and η ¼ ðηjkÞ given the cytology and HPV data,
pðπ,ηjyÞ. ð5Þ
For each age group i, we use a Dirichlet prior for π i ¼ ðπ i2,π i3,π i4,π i5Þ, that is
π i ∼ Dirichletðα i2,. . .,α i5Þ i ¼ 1,. . .,5 ð6Þ
and as we have no speciﬁc information on the π’s, we choose α12 ¼ . . . ¼ α15 ¼ 1 for i = 1,. . .,5. For each
row in the TPM, ηj: we also use a Dirichlet prior,
ηj. ∼Dirichletðα j1,. . .,α j5Þ j ¼ 1,. . .,6 ð7Þ
where the α jk are chosen based on previous cytology TPMs used to model screening in both an Australian
and a UK context.
At each iteration t of the Gibbs sampler, we ﬁrst have to draw πt from the conditional distribution,
pðπjηt−1,yÞ ð8Þ
where ηt−1 is the TPM computed in iteration t – 1. We then have to sample the updated TPM ηt from
pðηjπt,yÞ ð9Þ
Drawing πt from pðπjηt−1,yÞ can be simpliﬁed by introducing the auxiliary variables zijk which represent the
number of women in age group i, whose cytology test is k and underlying health state is j. Before
sampling πt we sample z from
pðzjπt−1,ηt−1,yÞ ð10Þ
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From our assumption on the health state Well, we know that for each age group i and cytology result k,
zi1k is the number of HPV-negative women in age group i with cytology result k. Using the predictive
power of each test result at t – 1,
γ ijk ¼ PðD ¼ jjT ¼ k and age group ¼ iÞ ¼
ηt−1jk π
t−1
ij
∑6j¼ 1η
t−1
jk π
t−1
ij
ð11Þ
it follows that
zi.kjzi1k ∼Multinomialðnik, γ˜.ki Þ ð12Þ
where γ˜.k
i ¼ð γ˜ i2k,. . ., γ˜ i6kÞ and γ˜ ijk ¼
γ ijk
∑6j¼ 2γ
i
j1
, and nik is the number of HPV-positive women in age group i
with cytology result k.
For each age group i, we can sum over k to get the total number of women in each health state,
x ij ¼ ∑
5
k¼1
zijk ð13Þ
that is to say xij is the number of women in age group i with underlying health state j. Keeping in mind our
assumption on π i1 and π i6, and the Dirichlet priors on π, it follows that
ðπ i2,π i3,π i4,π i5Þ ∼ ð1− π i1− π i6ÞDirichletðx i1 þ 1,. . .,xi5 þ 1Þ ð14Þ
We can then sample from the above to obtain the updated values of π, denoted by πt.
Using the updated values of πt, we now want to sample ηt from
pðηjπt,yÞ ð15Þ
As in the ﬁrst part of the iteration, we introduce the auxiliary variables zijk, which we again draw from
appropriate multinomial distributions. We note that in the calculation of the predictive power of each test
result, we use the updated values of π, that is we draw z from
pðzjπt,ηt−1,yÞ ð16Þ
For each cytology test result, we sum over the age groups to get the total number of women in each
health state with a particular cytology result, that is
wjk ¼ ∑
5
i¼ 1
zijk ð17Þ
wjk is the number of women with underlying health state j and cytology result k. Combining this
information with the Dirichlet priors we assumed for the TPM rows, we can update the ηj. by
sampling from
ηj .∼Dirichletðα j1 þwj1,. . .,α j5 þwj5Þ ð18Þ
This completes one iteration of the Gibbs sampler.
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We run multiple chains and monitor the mixing of the different sequences. We stop the sampler when the
potential scale reduction is near one for all the estimated parameters.
The resultant TPM output from the ﬁtting algorithm was further modiﬁed to match histology outcomes in
ARTISTIC in round 1. The ﬁnal TPM we use in our ARTISTIC simulation is shown below (this matrix was
used to calculate the sensitivity and speciﬁcity of LBC testing as reported in the main body of the report).
TABLE 72 Test probability matrix showing the probability of obtaining a particular cytology test result (%)
Health state Negative Borderline Mild Moderate Severe+
Well 93 6 1 0.2 0.0
HPV (all HPV types) 93 5 1 0.3 0.1
CIN1 (all HPV types) 52 18 23 7 1
CIN2 (all HPV types) 15 18 20 46 26
CIN3 (all HPV types) 13 11 11 65 47
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Appendix 10 Screening behaviour of women in
the ARTISTIC trial
In order to accurately model women in the ARTISTIC trial (in order to validate model outcomes againstARTISTIC outcomes), we must analyse and then model their screening behaviour. This section
summarises this analysis. These screening rates are used in the model to simulate compliance with
trial guidelines.
Background on the trial: all women in the trial attended at least one screening event, their ﬁrst screen,
which occurred upon entry into the trial. Women entered the trial between July 2001 and October 2003.1
Cytology results of all women in the trial were recorded up until July 2009, and histology results were
recorded up until October 2009.62 Thus, women were followed for 6–8 years, depending upon when they
entered the trial.
In this section, we explicitly report the times at which women return for screening based on the results of
their previous screening event.
The times at which women return to screening after a
normal screen
In this section, we will focus on women who have a normal screen at their ﬁrst screening event, and their
rate of return to routine screening.
Table 73 shows the distribution of times a woman returns for a second screen if her ﬁrst screen was
normal (cytologically negative in the concealed arm or both HPV and cytologically negative in the
revealed arm).
A proportion of women who had a normal baseline screen did not return during the trial period for
another screen (26% across all age groups). The proportion of women who never return was higher in the
youngest age group (40%). Of those who did return for a second screen, most return between 36 and
48 months after their ﬁrst screen event.
The times at which women return to screening after
a normal screen: later rounds of the trial
Table 74 shows the distribution of return times for women who had a normal baseline screen and a
normal second screen (i.e. compliance with routine screening in later rounds of the trial).
Table 74 indicates that the proportion of women who return for a third screen after two normal screens is
lower than the proportion who returned for a second screen after a baseline normal screen (an average of
61% did not return for a third screen during the trial period, compared with 26% from Table 73).
However, as the trial ended in 2009, this table does not capture women who returned late for a third
screen, and so it is difﬁcult to compare these rates with those from Table 73. Thus, the rate of
‘non-compliance’ shown in Table 74 is likely to be artiﬁcially high. However, for the purposes of modelling
the trial experience, this analysis informed the attendance assumptions used. Table 74 also shows that only
10% of women aged 50–64 returned after two consecutive normal screens, which is signiﬁcantly lower
than other age groups. In part, this may be due to women ageing beyond 64 years and no longer taking
part in the cervical screening programme.
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The compliance with follow-up of cytology-negative
and human papillomavirus-positive women in the
revealed arm of the trial
Guidelines on cytology-negative/HPV-positive women in the revealed arm of the trial: women who tested
cytology negative but HPV positive in the revealed arm of the trial were recommended to attend a
HPV-only screen 12 months later. If they were HPV negative at this second screen, they were returned to
routine screening. However, women who remained HPV positive at this time could choose to either attend
colposcopy or return in another 12 months for a repeat HPV test. If a woman opted to attend for another
repeat HPV test, then she was referred to colposcopy if HPV positive. Table 75 shows the distribution of
return times in women who were cytologically negative and HPV positive at baseline. In this section, we
consider only women in the revealed arm of the trial.
TABLE 73 Distribution of return times for women in ARTISTIC with a negative result
Age
(years)
0–12
months
(%)
12–24
months
(%)
24–36
months
(%)
36–48
months
(%)
48–60
months
(%)
60+
months
(%)
Never
return (%) Total (n)
20–29 0 1 10 29 10 10 40 3185
30–39 1 1 17 38 9 8 25 5701
40–49 0 1 24 40 8 6 21 4850
50–64 0 1 34 33 6 3 22 4768
Total 0 1 22 36 8 6 26 18,504
TABLE 74 Distribution of return times in women who have two consecutive normal screening events in the trial
Age
(years)
0–12
months
(%)
12–24
months
(%)
24–36
months
(%)
36–48
months
(%)
48+
months
(%)
Never
return (%) Total (n)
20–29 1 2 11 31 2 52 2175
30–39 1 1 14 36 2 46 3790
40–49 1 1 11 31 2 54 2830
50–64 1 1 2 4 2 90 1506
Total 1 1 10 25 2 61 10,301
TABLE 75 Distribution of return times in women who were cytology negative and HPV positive at baseline
(revealed arm only)
Age
(years)
6–12 months
(%)
12–18 months
(%)
18–30 months
(%)
Cytology
(%)
30+ months
(%) Total (n)
20–29 9 31 7 9 44 682
30–39 14 37 6 11 31 506
40–49 20 36 3 11 30 270
50–64 24 43 3 7 22 217
Total 14 35 6 10 35 1675
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The compliance with follow-up of cytology-negative and
human papillomavirus-positive women in the
revealed arm of the trial: later rounds of the trial
Table 76 shows the rate at which women who tested cytology negative and HPV positive returned for
screening in the revealed arm. We considered only women who were not already in follow-up, as women
being monitored for previous abnormalities may have different management. We determined that a
woman was not in follow-up at a screening event if at least 30 months had lapsed since her last screening
event, and if she had no known CIN2+ histology results throughout the trial. Table 76 shows the rate
of return to screening in women who were not in follow-up and had a cytologically negative and
HPV-positive screen.
The compliance with follow-up of borderline and
mild cytology test results
We investigated the rate of return to screening in women who had a cytological low-grade abnormality at
their baseline screen. The national guidelines (prior to 2003) recommended that women who have a
low-grade abnormality return for follow-up cytology 6 months later. The observed distribution of return
times in the ARTISTIC trial is shown in Table 77.
Those who tested either borderline or mild at baseline had very similar rates of follow-up, with about 80%
returning for cytology screening within 12 months, and about 10% not returning within 24 months for
follow-up. Again, we can see that the women in the youngest age group had slightly lower compliance rates
than the overall average. A very small proportion of women attended colposcopy after the ﬁrst low-grade
cytology. These women may have already been in follow-up management prior to trial enrolment.
The compliance with follow-up of borderline and
mild cytology test results later in the trial
After 2003, the national guidelines changed so that women who test mild are referred for colposcopy
rather than returning for further follow-up. Thus, the trial guidelines also changed accordingly. We wished
to consider the return to screening in women who tested mild or borderline, but we wished to consider
only women who are being routinely screened (as opposed to women who are in follow-up for a previous
event). As discussed previously, a woman was not in follow-up at a screening event if at least 30 months
had lapsed since her last screening event, and if she had no known CIN2+ histology results throughout the
trial. Table 78 shows the rate of return to screening in women who tested borderline or mild and were not
in follow-up at the time.
TABLE 76 Return for follow-up after a routine screen that is cytology negative and HPV positive in later rounds
Age
(years)
6–12 months
(%)
12–18 months
(%)
18–30 months
(%)
Cytology
(%)
30+ months
(%) Total (n)
20–29 7 10 2 17 70 397
30–39 4 15 1 11 69 292
40–49 9 15 1 14 58 170
50–64 6 27 1 9 56 125
Total 4 15 1 15 66 984
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Table 78 shows that about 75% of women who tested borderline returned for a follow-up screen within
24 months, 9% returned for a colposcopy and 17% did not return for any follow-up within 24 months.
Compared with those who tested borderline at baseline (see Table 77) there is a slightly lower compliance
rate with cytology follow-up and a slightly higher rate of colposcopy attendance, possibly because women
were encouraged to go for colposcopy earlier than usual in order to get complete trial data.1
Table 78 also shows the rate of return to screening in women who tested mild at a routine screen. Only
56% returned for colposcopy, 40% returned for cytology follow-up and 13% did not return for follow-up
within 24 months of the mild result.
TABLE 77 Distribution of return times in women who tested borderline or mild at entry
Age
(years)
0–6 months
(%)
6–12 months
(%)
12–18 months
(%)
18–24 months
(%)
24+ months
(%)
Colposcopy
(%)
Total
(n)
Borderline
20–29 21 54 8 4 12 1 519
30–39 25 59 4 3 7 3 588
40–49 24 63 4 2 5 2 425
50–64 29 60 4 2 3 3 213
Total 24 58 5 3 8 2 1745
Mild
20–29 20 51 6 4 13 6 412
30–39 25 52 5 2 8 9 256
40–49 25 61 2 1 5 5 138
50–64 31 62 2 0 4 2 55
Total 23 53 5 2 10 6 861
TABLE 78 Distribution of return times later in the trial in women who tested borderline/mild at a routine screen
Age
(years)
0–6 months
(%)
6–12 months
(%)
12–18 months
(%)
18–24 months
(%)
24+ months
(%)
Colposcopy
(%)
Total
(n)
Borderline
20–29 15 46 5 5 21 8 125
30–39 21 51 4 2 15 7 148
40–49 18 47 10 1 13 10 87
50–64 26 43 3 3 17 9 35
Total 19 48 6 3 17 9 395
Mild
20–29 8 22 2 0 8 61 93
30–39 8 22 3 0 9 59 73
40–49 22 23 6 0 8 41 31
50–64 43 33 0 0 0 24 6
Total 11 22 3 0 8 56 203
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Appendix 11 Screening and diagnostic
test characteristics
Liquid-based cytology parameters
Inadequate sample rates for LBC are based on 2007–8 statistics from the Cervical Screening Programme in
England.33 A range was considered in sensitivity analysis based on the previous work.12,19
With regard to the sensitivity of LBC, in the base case it was assumed that test positivity rates for CIN2+
were equivalent to those from a multicentre screening study (HART) conducted in UK.29 ARTISTIC cytology
test characteristics were not assumed for the national evaluation (although they were used for the
validation of the model outcomes) because ARTISTIC did not recruit nationally, and it is possible that
cytology in the baseline round of ARTISTIC was inﬂuenced by the retraining associated with the recent
introduction of LBC to the NHS Cervical Screening Programme at the time of the trial commencement.2
Although HART was conducted a number of years prior to ARTISTIC, and did not involve LBC, it did recruit
across a wider range of centres and thus is more likely to be representative of the performance of cytology
across England. The use of HART data to represent LBC test accuracy was considered to be appropriate
because the sensitivity of LBC and conventional cytology for detection of CIN2+ have been shown in
meta-analysis to be close-to-equivalent,30 and the inadequate smear rate for LBC (which is known to be
much lower than the rate for conventional cytology in England) was speciﬁcally modelled using other data
sources, as detailed above.
The test positivity rates derived from HART data for cytology for CIN2+ and CIN3+ were 76.7% and
75.9%, respectively, at a borderline dyskaryosis smear threshold, and 70.1% for both CIN2+ and CIN3+,
at a mild dyskaryosis smear test threshold. With regard to the speciﬁcity of LBC, the positivity rate for CIN1
was assumed to be 37.6% at a borderline dyskaryosis smear threshold and 28.0% at a mild dyskaryosis
smear threshold.
Alternative sets of test characteristics for LBC, encompassing the range used for the ARTISTIC modelling,
were investigated in sensitivity analysis.
The least favourable LBC performance considered in the sensitivity analysis assumed that the positivity rate
for CIN2+ and CIN 3+ were 53% and 55%, respectively, at a borderline dyskaryosis smear threshold, and
46% and 49%, respectively, at a mild dyskaryosis smear threshold, consistent with the ﬁnding of a
meta-analysis of international literature.31 The most favourable LBC performance considered in the
sensitivity analysis used the test characteristics of manually read LBC in England in the MAVARIC study.19
TABLE 79 Modelled inadequate rate of LBC
Parameter Base-case value (%) Range for sensitivity analysis (%)
Inadequate rate of LBC 3 2.6–4.1
DOI: 10.3310/hta18230 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 23
149
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Kitchener et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Human papillomavirus test parameters
The HPV test positivity rates for histologically veriﬁed CIN1 and for histologically conﬁrmed CIN2+ and
CIN3+ (and the range for sensitivity analysis) were derived from a number of sources to give a range of
assumptions. These included a major meta-analysis of HPV testing,31 the HART study29 and the ATHENA
trial.32 The accuracy of HPV testing was based on extensive data in the literature on HC2 testing, which
was used in ARTISTIC and HART. The use of these test characteristics does not necessarily lead to the
assumption that the speciﬁc platform was used, but that HC2 or alternative platforms with equivalent
performance were used. For some strategies the use of new automated test platforms with partial
genotyping for HPV 16/18 was assumed (sometimes referred to as ‘genotyping’ here).
For HPV testing, in the base case it was assumed that the test positivity rates for CIN2 and CIN3+ were
95.5% and 95.7%, respectively. With regard to speciﬁcity, the test positivity rate for CIN1 was assumed to
be 84.2%. In the base case we assumed that the test threshold was such that the test performance was
equivalent to HC2 at a 2 pg/ml threshold, as this has been proposed for use in primary screening in
England. However, sensitivity analysis encompassed the possibility that a test with performance equivalent
to that of HC2 with a threshold of 1 pg/ml performance was used.
In the base-case scenario, HPV test was assumed to be associated with no inadequate rate. A 1%
inadequate rate was investigated in sensitivity analysis, to encompass the possibility that a technology with
an ‘inadequate’ output is used.
TABLE 80 Modelled positivity rate of LBC
Histology
threshold
Sensitivity analysis value (%)
Base-case value (%)
Least favourable case LBC
performance
Most favourable case LBC
performance
At borderline
threshold
At mild
threshold
At borderline
threshold
At mild
threshold
At borderline
threshold
At mild
threshold
CIN2+ 76.7 70.1 53.0 45.2 79.0 67.5
CIN3+ 75.9 70.1 55.0 49.0 87.2 77.7
TABLE 81 Modelled test characteristics of HPV test
Model health state Gold standard used Baseline (%) Range for sensitivity analysis (%)
Well PCR testing for HPV 1.4 1.4–4.2
HPV infected (no CIN) PCR testing for HPV 82.1 49.7–92.5
CIN1 Histology 84.15 76.3–84.3
CIN2 Histology 95.5 94.7–97.1
CIN3+ Histology 95.7 93.6–97.6
PCR, polymerase-chain reaction.
The health-state speciﬁc positivity rate is assumed to be the same for partial genotyping, assuming relevant health state is
related to the HPV infections tested via partial genotyping.
TABLE 82 Modelled inadequate rate of HPV test
Parameter Base-case value (%) Range for sensitivity analysis (%)
Inadequate rate of HPV test 0 0–1
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Relative performance of liquid-based cytology and
primary human papillomavirus testing
In the base-case scenario, the relative sensitivity of HPV versus cytology for CIN2+ and CIN3+, derived
from the above parameters, was equivalent to 1.25 and 1.26, respectively, at a borderline dyskaryosis
smear threshold, and 1.36 for both CIN2+ and CIN3+ at a mild dyskaryosis smear threshold, which is
consistent with the ﬁnding of a meta-analysis of international literature on the test accuracy of HPV test.63
In sensitivity analysis, in order to assess the most extreme scenarios for the relative performance of LBC
and HPV testing, we chose test characteristics for LBC and HPV from the above values such that the
relative sensitivity was maximised (‘most favourable’ scenario for primary HPV screening) and also
minimised (‘least favourable’ scenario for primary HPV screening) (Table 83).
Colposcopy parameters
The model assumed an age-speciﬁc probability that the colposcopy will be unsatisfactory; data were
derived from a large colposcopy dataset collected in Victoria, Australia.18,20
A TPM was used to specify the relationship between the women’s underlying natural history health state
and the colposcopy result. This TPM was used to specify the probability that abnormal result would obtain
at colposcopy evaluation according to the women’s underlying health state. The matrix was derived from a
large colposcopy data set in Victoria, Australia18,20 and data from the HPV Sentinel Sites study.12
In the sensitivity analysis, a best-case scenario was evaluated which assumed that colposcopy is capable of
detecting cervical abnormalities in all women presenting with CIN2+. The worst-case scenario
assumed a lower positivity rate for all health state based on the test characteristic of colposcopy used in
prior work.18,20
TABLE 83 Modelled relative sensitivity of HPV testing vs. LBC
Sensitivity
At base case
Best-case scenario
assumption
Worse-case scenario
assumption
CIN2+ CIN3+ CIN2+ CIN3+ CIN2+ CIN3+
HPV+ve/cytology borderline 1.25 1.26 1.84 1.77 1.19 1.07
HPV+ve/cytology mild 1.36 1.36 2.15 1.99 1.39 1.20
+ve, positive.
TABLE 84 Modelled test characteristic of colposcopy
Health state
Probability of having abnormal result at colposcopy evaluation (%)
Base case Range for sensitivity analysis
Normal 73.8 50.2–73.8
HPV 73.8 50.2–73.8
CIN1 79.2 76.5–79.2
CIN2 90.8 88.3–100.0
CIN3+ 90.8 88.3–100.0
Cancer 100.0 100.0
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Appendix 12 Compliance with screening and
management recommendations
Routine screening attendance
For strategies that simulate current practice, we used registry data from Oxfordshire to estimate the
cumulative rescreened proportion at various times after a negative smear for women who appeared on
the register.33 We used age-speciﬁc data on the percentage of eligible women who attended at least once
in a 5-year period in England (2007–8)12,34 to adjust these data and derive age- and interval-speciﬁc
probabilities of women attending for routine screening. This allows the model to take into account
non-attendance, early rescreening, late rescreening, and screening in ages outside the target age range
for screening.
For the primary screening strategies that simulate 6-yearly and 5-yearly screening, the proportion of
women rescreened at the sixth year after the last negative test was assumed to be the same as the
observed proportion for current practice after the third year following a negative cytology test, or ﬁfth year
in women older than 50 years.
In the sensitivity analysis, we explored a higher compliance scenario for strategies involving HPV as the
primary test. We made the assumption that continue to use call-and-recall for 5- and 6-yearly screening
intervals, and we did not examine lower screening attendance rates in sensitivity analyses. In this case,
we assumed that the cumulative proportion of women rescreened within 6 years (or within 5 years for
strategies that simulate 5-yearly screening) was the same as the cumulative proportion currently rescreened
within 5 years (Figures 47 and 48).
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FIGURE 47 Modelled cumulative proportion of women with a negative index test reattending for screening
(aged younger than 50 years at the time of the index test).
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Other compliance assumptions
Attendance rates for women with other types of recall codes were based on earlier studies, including data
from the HPV Sentinel Sites,12 and on routinely collected screening data for England (2007–8).33
In sensitivity analysis, we explored a scenario where all women (other than those recommended to return
at the routine interval) attended their appointment for colposcopy or a follow-up test at the recommended
time (perfect compliance with follow-up). This allowed an exploration of whether or not any observed
differences in strategies may have been inﬂuenced by the follow-up management rather than the primary
screening recommendations (Table 85).
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FIGURE 48 Modelled cumulative proportion of women with a negative index test reattending for screening
(aged 50+ years at the time of the index test).
TABLE 85 Modelled compliance rate to colposcopy referral and follow-up
Parameter
Base-case
value (%)
Range for sensitivity
analysis (%)
Compliance with colposcopy recommendation33 84 84–100a
Compliance with 6-month follow-up visit recommendation64 85 60–100a
Compliance with 12-month follow-up visit recommendation64 83 60–100a
Compliance with 24-month intermediate risk follow-up visit recommendationb 80a 60–100a
Compliance with 12-month intermediate risk follow-up visit recommendationb 80a 60–100a
a Assumption.
b For HPV-positive women with a negative cytology result in primary HPV screening.
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Appendix 13 Cost assumptions
All costs used in the model were inﬂated to the 2010 ﬁnancial year value using the HCHS pay-and-priceindex.37 A NHS perspective was utilised for the costing analysis.
Sample collection
Inﬂated costs from the HPV pilot study were used.65 This cost item was applied in the model with each
screening episode involving a clinic visit (Table 86).
Human papillomavirus testing
Costs of HPV testing both for general HR types and speciﬁcally for genotypes 16/18 were obtained from
four manufacturers. Manufacturers were asked to supply information about machine time, stafﬁng
requirements, assay capacity, annual capacity of equipment and indicative costs per test. Costs of staff
time were based on multiplying the staff time per test by the lowest grade of staff recommended to
undertake the activity from the agenda for change costing schedule. Manufacturers were asked to supply
indicative costs for conducting both HR testing only (without speciﬁc testing for HR) and type 16/18
testing. Indicative costs per test are likely to vary signiﬁcantly depending on the total volume of tests
undertaken. Suppliers were asked to provide indicative prices for two costing scenarios: primary HPV
testing and reﬂex testing of cytology samples on the basis of being awarded a national contract. Costs
provided included the service contract for maintenance and rental of equipment based on a 5-year
contract. For the purposes of this study it was assumed that equipment was used at maximum capacity.
If HPV testing were introduced, it is likely that there would be changes to the conﬁguration of laboratories
and transportation system for collecting samples. As a simpliﬁcation these costs were not included in this
analysis. To retain conﬁdentiality between suppliers over indicative contract prices, costs are not presented
for individual manufacturers/systems and, instead, a mean and range are presented across the suppliers
including both staff and consumable/equipment costs.
An average across manufacturer supplied prices was considered for the unit cost of HPV testing and
genotyping in the base case.
The base-case scenarios assumed the HPV test technology used for primary HPV testing would
provide the test outcome against HPV 16/18 infections as well as all HR type infections simultaneously.
Therefore, HPV 16/18 typing was assumed to incur zero additional cost in the baseline scenario. An
additional £5.29 cost for HPV 16/18 was explored in sensitivity analysis.
TABLE 86 Cost of sample collection
Cost item Value (£) (range for sensitivity analysis)a Source
Sample collection 17.31 (16.11–18.91) Inﬂated cost obtained from LBC/HPV pilot study12
a Cost has been inﬂated to present the value in 2010 ﬁnancial year (2009–10).
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Cytology
The cytology costs were based on the reanalysis of the manual arm of the MAVARIC data.19 This indicated
that the costs of cytology testing differ considerably depending on the ﬁnal cytology results (Table 88).
Sample transportation
If primary HPV testing was introduced, it is likely that there would be changes in the sample transport
system, and in the volumes of HPV tests performed and transported (Table 89).
TABLE 87 Cost of HPV testing
Cost item
Value (£) (range for
sensitivity analysis)a Source
Primary HR HPV testing 9.38 (4.5–9.38) Manufacturer average as per value used.
Range informed by data from HPV sentinel sites report for full
batches (high end)
HPV 16/18 test
(additional cost)
0 (0–5.29) Manufacturer average
Reﬂex HR HPV testing
(comparator 1 only)
12.72 (8.13–21.32) Manufacturer average. Range informed by data from
HPV Sentinel Sites report for smaller batches
a Cost has been inﬂated to present the value in 2010 ﬁnancial year (2009–10).
TABLE 88 Cost of cytology testing
Cost item
Value (£) (range for
sensitivity analysis)a Source
Negative or inadequate 5.45 (5.36–5.54) Cost based on reanalysed cost data collected by MAVARIC study
LG cytology 15.40 (15.13–15.65) Cost based on reanalysed cost data collected by MAVARIC study
HG cytology 15.56 (14.38–16.74) Cost based on reanalysed cost data collected by MAVARIC study
HG, high-grade; LG, low-grade.
a Cost has been inﬂated to present the value in 2010 ﬁnancial year (2009–10).
TABLE 89 Cost of sample transport
Cost item
Value (£) (range for
sensitivity analysis)a Source
Transport – sample to lab 0.45 (0–2.81) Cost obtained from HPV sentinel sites report (distances up
to 50 km). This cost is applied to samples requiring additional
triage testing in current practice screening strategy
Transport – lab to lab
(for HPV triage)
3.64 (1.06–6.00) Cost obtained from HPV sentinel sites report. This cost was applied
in the comparator to allow for implementation where LBC and HPV
testing occur in separate laboratories, following a ‘hub and spoke’
model. Includes staff time required for identifying samples requiring
additional triage testing, packing, and reporting
Transport – LBC
triage in same lab
1.06 (0.67–3.64) Cost obtained from HPV sentinel sites report. Administrative
costs within the lab relating to identifying samples requiring
additional triage testing. This cost is applied to samples requiring
cytology triage in strategies 1 and 2, as it is assumed in these
scenarios that all labs will perform HPV testing if it is the primary
screening test. Range encompasses the costs associated with
performing HPV and LBC in different labs
a Cost has been inﬂated to present the value in 2010 ﬁnancial year (2009–10).
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Diagnostic and treatment for cervical
intraepithelial neoplasia
The unit cost for having a colposcopy, biopsy, conisation and large loop excision of the transformation
zone (LLETZ) was obtained from Martin-Hirsch35 and Sherlaw-Johnson et al.36 (Table 90) (inﬂated to
2010 values). For sensitivity analysis, we used a ± 20% range for each cost.
Cancer treatment
The stage-speciﬁc cancer treatment cost was obtained from Martin-Hirsch et al.35 and inﬂated to the
ﬁnancial year of interest. We used ± 20% of the cancer treatment costs for sensitivity analysis (Table 91).
TABLE 90 Cost of colposcopy, biopsy, conisation and LLETZ
Cost item Value (£) (range for sensitivity analysis)a Source
Colposcopy 146.51 (117.21–175.81) Martin-Hirsch35
Biopsy 77.60 (62.08–93.12) Sherlaw-Johnson36
Conisation 370.80 (296.64–444.95) Martin-Hirsch35
LLETZ 370.80 (296.64–444.95) Martin-Hirsch35
a Cost has been inﬂated to the value in 2010 ﬁnancial year (2009–10).
TABLE 91 Cost of cancer treatment
Cost item Value (£) (range for sensitivity analysis)a Source
Stage 1 invasive cancer 3138.76 (2511.01–3766.52) Martin-Hirsch35
Stage 2 invasive cancer 5013.00 (4010.4–6015.6) Martin-Hirsch35
Stage 3 invasive cancer 14,157.73 (11,326.18–16,989.27) Martin-Hirsch35
Stage 4 invasive cancer 14,399.98 (11,519.99–17,279.98) Martin-Hirsch35
a Cost has been inﬂated to the value in 2010 ﬁnancial year (2009–10).
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Appendix 14 Quality-adjusted life-year weights
The model assumes that healthy women without cervical cancer have a health state utility QALY scoreof 1. Screening, diagnostic procedures, treatment for precancerous lesions and treatment for cancer are
assumed to be associated with a decrease in women’s health state utility (QALY) weight for that year.
The QALY weights used for screening associated health states for QALY set 1 were derived from a study
conducted at metropolitan Sydney, NSW, which measured QALY weights via a two-stage standard
gamble.38 A two-stage standard gamble approach was used instead of a time trade-off and was justiﬁed
in that study on the basis that the standard gamble approach is appropriate for outcomes that involve risk
or uncertainty.38 This set of weights assigned some disutility to the experience of being screened, even if
the test result was negative (based on the results of the study).
Quality-adjusted life-year weight set 2 was obtained from previously published weights,40,41 which were
not obtained in context of health-state preference assessment speciﬁcally for primary HPV testing. This set
of weights did not assign any disutility to the experience of being screened per se.
Women with cancer detected in the model were assumed to have a cervical-cancer-stage- and
time-since-diagnosis-speciﬁc mortality rate for a period of 5 years after the cancer was diagnosed. QALY
weights assigned for cancer patients during this period were obtained from published studies by Elbasha
et al.39 and Goldie et al.40 Women who survive 5 years after cancer diagnosis were assumed to become
‘cancer survivors’. It was further assumed that the quality of life of cancer in this group is the same
as in the general population (i.e. QALY weight = 1) (consistent with some other published studies19,66).
Table 92 summarises the QALY scores used.
TABLE 92 Pathway-based QALY weights set 1 for precancerous cervical lesions and associated investigations
Health state
Duration
(years)
Health-state
preference score Source
Cytology normal and HPV negative/no HPV test
(‘experience of being screened even if the result is negative’)
1 0.9967 Simonella38
Cytology normal and HPV positive 1 0.9733 Simonella38
Cytology abnormal and HPV negative/no HPV testa 1 0.9735 Simonella38
Cytology abnormal and HPV positive 1 0.9733 Simonella38
Colposcopy examination with/without biopsy but do not
required treatment for pre-cancerous lesionb
1 0.9724 Simonella38
Treatment for pre-cancerous lesionc 1 0.9704 Simonella38
Cancer
Stage 1 5 0.76 Elbasha et al.39
Stage 2 5 0.67 Elbasha et al.39
Stage 3 5 0.56 Goldie et al.40
Stage 4 5 0.48 Goldie et al.40
Cancer survivor 1
a Based on the value of low-grade cytology from Simonella.38
b Based on the value of low-grade cytology with colposcopy normal and high-grade cytology with CIN1.38
c Based on the value of high-grade cytology with CIN2 or 3.38
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TABLE 93 Quality-adjusted life-year weights set 2 for precancerous cervical lesions and associated investigations
Health state Duration (years)
Health-state
preference score Source
False positive 1 0.92 Insinga et al.41
CIN1 1 0.89 Insinga et al.41
CIN2 1 0.88 Insinga et al.41
CIN3 1 0.89 Insinga et al.41
Cervical cancer
Stage 1 5 0.76 Elbasha et al.39
Stage 2 5 0.67 Elbasha et al.39
Stage 3 5 0.56 Goldie et al.40
Stage 4 5 0.48 Goldie et al.40
Cancer survivor 1
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Appendix 15 Vaccination coverage
Annual vaccine coverage in England by age group for the years 2010–11 was obtained from theDepartment of Health42 and is shown in Table 94. Alternative lower (70%) and higher (95%)
vaccination coverage rates in the ongoing vaccination cohort (12- to 13-year-olds) were investigated in
sensitivity analysis.
TABLE 94 Vaccination coverage and completion for routine and catch-up cohorts in the UK
Age (years) Base-case dose 3 coverage rate
12–13 84.2
13–14 80.9
14–15 84.4
15–16 75.7
16–17 70.8
17–18 48.1
18–19 38.9a
19–20 47.4a
12–20 65.8 b
a Data in these rows were taken from 2009–10 estimates. All other entries use 2010–11 estimates.
b Obtained using 2009–10 and 2010–11 estimates.
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Appendix 16 Sexual behaviour data for the
population model
As HPV is a sexually transmitted virus, data on sexual behaviour surveys were used to inform the modelof HPV transmission in England. We use a transmission model which simulates heterosexual interaction
between men and women in England to inform our natural history model of the rate of HPV transmission
in England.
This model was developed for the ARTISTIC project with the aim of generating sexual activity inputs for
our HPV transmission model that are compatible with sexual behaviour survey data. This includes, in
particular, data presented in terms of fractions of the population age groups who have had speciﬁed total
lifetime numbers of sexual partners, and percentages who have ever been sexually active by age group.
The survey providing the target data for the model in this ARTISTIC context was the UK’s NATSAL II,25
incorporating data collected during 2000 and 2001.
Inputs to the method are probabilities of having different numbers of new sexual partners per year of age,
and these are speciﬁed as a range of values rather than a single value. The fractions speciﬁed for 0 partners
in an age year are treated as the fraction of the already sexually active population who have 0 new partners
in that year. For higher numbers of partners, they represent the fraction of people remaining, after lower
partner numbers are accounted for, who have that number of new partners within a year. For example,
suppose that the model has already allocated 70% of people aged 20 years to have either no or one new
partner in the year, and that the range of probabilities speciﬁed for people aged 20 to have two new
partners is from 30% to 50%. The model will randomly generate a probability in this range – for example,
40% – and apply it to the fraction remaining who have not been allocated to a number of partners yet.
In this case, of the 100% – 70%= 30% of the 20-year-old population who have two or more new partners,
40% of them – that is to say, 12% of 20-year-olds – will have two new partners.
The model differentiates between people who have not yet had any sexual partners and those who are
already sexually active. For these two groups, the probability ranges for having no new partners are
speciﬁed separately. For the fraction of previously inactive people who will acquire partners within an age
year, the same partner number probabilities are applied as for the already active population, scaled to
account for the fact that the newly active group will not have partners in the next year.
The input data are divided into processing blocks (e.g. ages 20–24 years and between three and ﬁve new
partners per year). For each such block, a minimum and maximum probability is speciﬁed. When the
model is run, a random probability is generated from within this range for each age and number of new
partners in the processing block. This probability is then applied as described in the previous paragraphs.
Once this has been done for the whole processing block, one or more test statistics are calculated and
compared against the speciﬁed acceptable ranges. If a ﬁt is obtained, processing moves on to the next
block. If not, the block is recalculated up to a speciﬁed number of times. If none of these retries succeeds,
the entire scenario is regenerated from the beginning. If a set number of restarts is exceeded, processing
terminates. Male and female behaviours are calculated independently.
The model provides an option to hold sexual activity proportions equal to those of a lower age group and
simply multiply average partner numbers for an activity group by an age-dependent constant (similar to
the method used by Choi et al.67). We used this option for higher age groups (35+ years) for which
NATSAL II data are either not available, or not internally consistent when viewed as representing the
behaviour of a single age cohort over time.
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Once a scenario ﬁnishes, the model uses the annual partner number probabilities calculated to determine
the proportions of people who fall into speciﬁed average partner number per annum ranges for speciﬁed
age groups. It also calculates the actual average number of partners for people in each such group. These
values form the sexual behaviour inputs for the HPV transmission model. The model can be set to generate
thousands of such scenarios, in order to produce a spread of acceptable sexual behaviour scenarios that ﬁt
the target conditions.
Model sets which ﬁt the NATSAL II data were then used to generate predictions of the age-speciﬁc
prevalence of oncogenic HPV in cytologically normal women,25 and this was compared with, and ﬁtted to,
the corresponding data from ARTISTIC.
Two groups of sets of sexual behaviour inputs were produced for use in sensitivity analysis. Sets in the ﬁrst
group ﬁtted data from NATSAL II on the proportion of individuals ever sexually active, and the age-speciﬁc
HPV prevalence observed in ARTISTIC. Sets in the second group also ﬁtted additional aspects of NATSAL II
(number of partners in the previous 12 months), but ﬁt less well to the HPV prevalence observed in
ARTISTIC. This enabled us to explore both uncertainty in the sexual behaviour data, and potential
differences between the behaviour of women enrolled in ARTISTIC and in the wider population of
England, including cohort effects.
Model ﬁt to the NATSAL II data is shown in Figures 49 and 50. We attempt to reconcile the number of
reported sexual partners in a 1-year period for men with the number of reported sexual partners over a
1-year period for women. The model is run under a range of different scenarios. The model results are
shown in the graphs as box plots, with the median and interquartile ranges shown across all scenarios
tested. The NATSAL II data ranges are shown as the shaded regions underlying the model results for each
age group and each number of sexual partners.
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FIGURE 49 The proportion of females who have 0, 1, 2, 3–4 or 5–9 new sexual partners in the last 12 months for each
age group. (a) Aged 16–17 years; (b) aged 18–19 years; and (c) aged 20–24 years.
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FIGURE 50 The proportion of males who have 0, 1, 2, 3–4 or 5–9 new sexual partners in the last 12 months for each
age group. (a) Aged 16–17 years; (b) aged 18–19 years; and (c) aged 20–24 years.
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Appendix 17 Sensitivity analysis
The large number of primary HPV screening strategies, including the variants, provides a form ofsensitivity analysis for our analysis, as many possible screening and triage options are considered.
Additional sensitivity analysis reported here allowed us to determine which parameters are inﬂuential in
our model.
The input parameters for our model were carefully determined from data on screening attendance rates,
and screening management has been determined carefully using national guidelines on screening and
colposcopy management in England. Extensive validation of the model has also been performed against
England-wide data on cancer rates, HPV prevalence and numbers of screening tests. In addition to these
careful choices of model input parameters and model structure, we also perform an extensive sensitivity
analysis in this section. In sensitivity analyses, we investigate how varying some parameters in the model
changes outputs on costs and effectiveness as predicted by the model. We performed sensitivity analysis
on strategies one and two, as well as these strategies with the variants of 12-monthly follow-up intervals
and 5-yearly screening for both unvaccinated and vaccinated cohorts. The results are presented in a
tornado diagram, showing the relative change in incremental discounted cost of the strategy compared
with current practice and also the relative change in the incremental discounted life-years of the strategy
compared with current practice under each of the sensitivity analysis assumptions.
One-way sensitivity in unvaccinated cohorts
The tornado diagrams for unvaccinated cohorts are shown in Figures 51 and 52. The tornado diagrams
shown in these ﬁgures indicate that for each strategy considered, the most inﬂuential changes on cost and
life-years were changes to cytology and HPV test characteristics, and changes in compliance rates with
colposcopy and follow-up rates. Both cost and life-years were most sensitive to changes in the cytology
and HPV test characteristics. These results indicate that if cytology testing is substantially more sensitive
than assumed in the base case, and/or if HPV testing is substantially less sensitive, then current practice
can be more effective than strategies 1 and 2 for the variants considered in this sensitivity analysis. Under
these conditions, the primary HPV screening strategies are also less costly than current practice.
Compliance with colposcopy follow-up also signiﬁcantly changes the cost and effectiveness of each of the
primary HPV screening strategies when compared with current practice. As expected, higher rates of
compliance with colposcopy and follow-up improve the effectiveness of primary HPV screening strategies
when compared with current practice management. Higher compliance rates also increase the cost of
primary HPV screening strategies when compared with current practice.
Increasing the rate at which women in routine screening return for their next 5- or 6-yearly screen
increases the costs to some extent; however, it has a smaller effect on the life-years saved when compared
with current practice across all strategies considered (current practice did not change the screening rates
for routine screeners in this comparison).
Managing women who do not comply with colposcopy referral, or follow-up less aggressively, results in a
decrease in effectiveness of HPV screening strategies when compared with current practice in some of the
strategies considered. Increasing the rate of progression of CIN3 to cancer had a signiﬁcant effect on
the predicted life-years in many strategies.
Increasing the rate of receiving an inadequate HPV test result increases the cost of primary HPV
screening strategies by a small amount compared with current practice. Increasing the rate of an
inadequate cytology test decreases the cost of primary HPV screening strategies when compared with
current practice.
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Probabilistic sensitivity analysis for cost assumptions
The PSAs for each of the strategies are shown in Figure 63 for unvaccinated cohorts and Figure 64 for
vaccinated cohorts. These results indicate that primary HPV screening strategies are cost saving when
compared with current practice for each of the combinations of cost assumptions, except for some of the
cost scenarios for strategy 3 and 4 and their variants.
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FIGURE 64 Probabilistic sensitivity analysis on unit cost assumptions on the predicted strategy-specific screening
associated lifetime cost in a vaccinated setting. The discounted lifetime cost and life-years associated with current
screening practice screening was used as the comparator. FU, follow-up.
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FIGURE 63 Probabilistic sensitivity analysis on unit cost assumptions in an unvaccinated population. The discounted
lifetime cost and life-years associated with current screening practice was used as the comparator. FU, follow-up.
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Probabilistic sensitivity analysis for sexual
behaviour assumptions
A PSA was conducted to examine the impact of the detailed sexual behaviour assumptions used by the
model. This is because, as described in Appendix 16, the NATSAL II data were reported in such a way that
there were a range of possible values identiﬁed for the parameters directly input to the model. A total
of 200 model input parameter sets were identiﬁed which fulﬁlled two criteria: (i) the predicted HPV
prevalence was consistent with the prevalence observed in the ARTISTIC trial (i.e. within 95% CI of
observed data at most ages), and (ii) the partnership assumptions were consistent with the ﬁndings of the
NATSAL 2000 survey. These model input sets were included in a PSA for the main strategies S1, S2, S3
and S4 to identify any effect of sexual behaviour assumptions on the main ﬁndings of the analysis.
The predicted HPV prevalence for unvaccinated women for the ﬁtted model input sets are shown in
Figure 65. The ﬁndings of the PSA for each of the strategies are shown in Figure 66 for unvaccinated
cohorts. These results indicate that variations in sexual behaviour assumptions do not substantially alter the
predicted lifetime cost saved and life-years saved associated with the primary HPV screening strategies,
or the relative costs and effects of the main strategies in relation to each other.
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FIGURE 66 Probabilistic sensitivity analysis on sexual behaviour assumptions in an unvaccinated population.
The discounted lifetime cost and life-years associated with current screening practice was used as the comparator.
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FIGURE 65 Human papillomavirus prevalence predicted by scenario assessed in the PSA on sexual
behaviour assumptions.
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Appendix 18 Model predictions of the
ARTISTIC trial
In this appendix, we present model outputs for predictions of the number of CIN cases by age group.Figure 67 shows the number of histology-detected CIN2+ cases for each age group and each trial arm.
The results are presented as a percentage of the total number of women who entered the trial in the
corresponding age group and trial arm for both the model (solid green diamonds) and the ARTISTIC trial
(hollow blue squares). The horizontal axis shows the time since ﬁrst screen in the trial, so that women are
all synchronised at time 0. Across all age groups, we observed that in the ﬁrst 6 months, there are a large
number of histologically detected CIN2+ cases, reﬂecting the screening and follow-up of the bulk of
women. There is a drop in the number of detected CIN2+ cases at 12 months, a second increase at
18 months, and then the observed CIN2+ cases smoothed out as the trial continued. The ﬁrst spike in
CIN2+ cases at 6 months was likely due to the fact that all women who entered the trial attended
screening upon entry into the trial (screening is ‘synchronised’ at baseline), and women who have a high
grade upon entry will have a colposcopy within 6 months of their ﬁrst screen. Women who tested mild/
borderline are recommended to return for a follow-up test in 6 months. However, many do not return
until 12 months, and those who are referred for colposcopy at this time may take another 6 months to
attend. Thus, the second ‘spike’ at 18 months likely represents women who were referred for colposcopy
at their follow-up screen. The rate at which women attended colposcopy stabilised later during follow-up.
The model results compared well with the ARTISTIC data. Both the model and the data exhibited the same
features, with a spike in the number of CIN2+ cases at 6 and 18 months after the initiation of the
simulation. The number of observed CIN2+ cases smoothed out and decreased at later times in both the
model results and the observed data. It is particularly encouraging because the results were being
compared at 6-monthly intervals, indicating that the model is accurately capturing events on relatively
small timescales. We also note that the good comparison between the model results and the ARTISTIC
data during later times in the trial provides a high level of conﬁdence that the natural history model is
capturing the true prevalence of CIN2+ in the population.
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FIGURE 67 CIN2+ cases expressed as a percentage of the total number of women who entered the trial in the
corresponding trial arm and age group. The model results are shown as the solid green diamonds and the data
are shown as the hollow blue squares. The value ‘n = ‘ in each graph represents the number of women who entered
the trial in the respective age group and trial arm.
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Histology detected CIN2+ cases: modelled versus observed
CIN2+ cases by rounds
As the model produced outputs in 6-monthly intervals, there was not a direct relationship between the
round deﬁnitions used in ARTISTIC reports and the model time steps. We therefore processed the model
output to produce results on CIN2+ cases by round, in a process analogous to the original analysis
of trial data. The output has been processed to best match the deﬁnition of a round from the ARTISTIC
trial reports.
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FIGURE 68 The number of histologically detected CIN2+ cases by round and by age group for the concealed arm
(a) and the revealed arm (b) of the trial. The model output is shown as the solid green diamonds and the ARTISTIC
data are presented as the hollow blue diamonds. Lines are drawn through consecutive data points. Bars on the
ARTISTIC data points (hollow blue diamonds) represent ± 95% CIs.
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FIGURE 69 The number of ‘< CIN2’ cases expressed as a percentage of the starting number of women in the
corresponding age group and trial arm. The model results are shown as the solid green diamonds and the data
are shown as the hollow blue squares. Each point represents the number of ‘< CIN2’ histology results that occurred
in that 6-monthly interval. The value ‘n = ‘ in each graph represents the number of women who entered the trial
in the respective age group and trial arm.
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Histology-detected < CIN2 cases
The model results compared reasonably well with the data, implying that the natural history model is
capturing the prevalence of low-grade cervical abnormalities. The comparison also indicated that the
model is capturing the rate at which women return for follow-up colposcopies after a histology of < CIN2.
For each age group and trial arm, there is an initial ‘spike’ in the number of detected cases at 6 months,
followed by a drop in the number of detected cases and then another increase at 18 months. These
features were observed when we considered the number of CIN2+ cases at 6-monthly intervals in
Figure 67. As with the results for the number of CIN2+ cases, the ﬁrst spike in the number of detected
cases likely represents the number of women who tested high grade on their ﬁrst screen and attended
colposcopy within 6 months. The second spike at 18 months captures women who were referred for
colposcopy after their follow-up screen. After about 42 months, the rate of women attending colposcopy
plateaus, a feature we also observed when considering the number of CIN2+ cases.
Overall, the model results compared well with the ARTISTIC data throughout the trial and the number of
‘< CIN 2’ cases detected by the model compared well with the number of cases as detected in the trial. For
older women (ages 40–49 years and 50–64 years), the model underestimated the number of cases
detected when compared with the data for the ﬁrst 36–42 months of the trial (particularly in the
concealed arm of the trial), although the model results compared well with the data at later times in
the trial.
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Appendix 19 Guidelines for the economic analysis
There are several checklists available to ensure that a thorough and accurate economic analysis hasbeen performed. We chose to use the guide on health economic modelling as described in Rudmik and
Drummond,53 and also the ISPOR guidelines for modelling as described in Caro et al.68
Drummond checklist
We have evaluated our work against the Drummond checklist,69 which we provide in Table 95.
TABLE 95 Drummond checklist69
1. Was a well-deﬁned question posed in answerable form?
i. Did the study examine both costs and effects of the service(s) or programme(s)?
The study examines the incremental cost, incremental life-years saved and incremental QALYs saved of Cervical Screening
Programme in England under various primary HPV screening scenarios, compared with current practice. The study also
reports on predicted health outcomes (number of women with histologically-confirmed high-grade lesions, number of
cervical cancer cases, etc.) and predicted resource utilisation (number of screening tests, diagnostics and treatment
procedures, etc.) associated with strategies included in the evaluation
ii. Did the study involve a comparison of alternatives?
The study compared the current cervical screening programme in England with 20 different primary HPV testing strategies
that contain differences in screening interval, screening and follow-up managements for women testing HPV positive.
Details of the alternatives strategies are described in section Methods, Economic analysis, Primary HPV screening strategies
iii. Was a viewpoint for the analysis stated and was the study placed in any particular decision-making context?
The study aimed to inform the policy decision maker about the cost-effectiveness of primary HPV screening compared with
the current cervical screening programme in England. Health-services perspective was used in the economic evaluations,
taking into account the health services cost associated with population-based screening, management, diagnosis,
follow-up and cervical pre-cancer and cancer treatment. The viewpoint of this study is stated in the section titled
Methods for the evaluation
2. Was a comprehensive description of the competing alternatives given (i.e. can you tell who did what to whom, where,
and how often)?
i. Were there any important alternatives omitted?
We considered 20 different primary HPV screening strategies, taking into account important factors such as duration of
follow-up in women testing HPV positive, duration of routine screening interval and the use of genotyping to identify
women with HR HPV types. We believe we have investigated a large range of possible strategies and taken into account
important factors that may influence cost-effectiveness of cervical screening in England
ii. Was (should) a do-nothing alternative be considered?
The aim of this study is to evaluate the incremental cost, effectiveness and incremental cost-effectiveness of
switching from the current cervical screening programme in England, which has been in place for many years, into
a primary HPV screening setting. In this case, a do-nothing alternative could be defined as the current practice scenario, which
was the comparator for all scenarios evaluated
continued
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3. Was the effectiveness of the programme or services established?
i. Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reﬂect what would happen
in regular practice?
No. A modelling approach has been taken to estimate the cost and effectiveness of the current cervical screening programme
and various hypothetical scenarios of primary HPV screening
ii. Was effectiveness established through an overview of clinical studies?
Clinical studies were used to inform the model, e.g. the ARTISTIC trial was used to validate the natural history model
iii. Were observational data or assumptions used to establish effectiveness? If so, what are the potential biases in results?
A modelling approach has been taken to estimate the cost and effectiveness of the current cervical screening programme
and various hypothetical scenarios of primary HPV screening. Observational data from the ARTISTIC trial were used to
establish effectiveness of the model at predicting rates of detected CIN cases. Extensive observational data from the national
programme in England and other countries was also used to calibrate and validate the model’s predictions; any potential
biases associated with the model assumptions have been discussed extensively in the report
All targets related to screening outcomes (e.g. histological-detected disease) would have the potential to show bias if
they were treated as natural history states. However, we avoided this problem by explicitly modelling the screening
attendance, screening and diagnostic test accuracy and the underlying HPV infections and CIN prevalence (by modelling the
sexual behaviour in England and the natural history)
4. Were all the important and relevant costs and consequences for each alternative identiﬁed?
i. Was the range wide enough for the research question at hand?
The primary HPV screening strategies included in the evaluations has covered a wide range of variations in the screening and
follow-up design to determine optimal screening and follow-up management. Strategies which combine primary cytology
testing in younger women and HPV testing in older women were also included in the evaluation. The evaluation has taken
into account the recommended management for screening, follow-up, diagnostic and treatment recommendations by the
NHS, the screening and diagnostic tests characteristics and screening behaviour as observed in England. We carefully
considered best parameter values for costs of cytology testing, HPV test, clinic visit for sample collection, delivery of the sample
from clinic to lab, colposcopy examination, biopsy procedures, treatment procedures for precancerous lesions and cancer
treatment procedures. To our knowledge, no similar modelled analysis of primary HPV screening has been conducted in any
setting to comparable levels of detail
For the comparator and each alternative strategy included in the evaluation, the model predicts the annual cervical screening
associated programme cost and resource utilisation in England as well as the discounted cost and effectiveness per woman in
England. These findings can inform the policy-maker on the strengths and limitations of the large number of primary HPV
screening strategies considered, while taking into account local preferences and limitations
ii. Did it cover all relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those of
patients and third-party payers. Other viewpoints may also be relevant depending upon the particular analysis.)
This economic evaluation was conducted from a health-services provider perspective, which is relevant to the England NHS
Cervical Screening Programme and thus appropriate
iii. Were the capital costs, as well as operating costs, included?
The economic evaluation was conducted from a health-services perspective. Only the health-services cost associated with the
population-based screening, diagnosis, and treatment for CIN and cancer were considered in the evaluation
All costs were allocated on a per-woman basis as appropriate to the scope of the evaluation, which was the entire NHS
Cervical Screening Programme. For example, the HPV test cost was allocated based on a survey of HPV providers and
considered to be the cost of the test provision by the laboratory of the programme. This cost includes components involving
capital cost to the laboratory as part of the test cost. Therefore, our approach is appropriate
TABLE 95 Drummond checklist69 (continued )
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5. Were costs and consequences measured accurately in appropriate physical units (e.g. hours of nursing time, number of
physician visits, lost work-days, gained life years)?
i. Were any of the identiﬁed items omitted from measurement? If so, does this mean that they carried no weight in the
subsequent analysis?
We identified the relevant costs to the NHS Cervical Screening Programme. We have not identified any major relevant
costs that have been excluded. Costs across the screening, diagnostic, treatment for CIN and invasive cancer spectrum have
been fully considered and included in the evaluation
ii. Were there any special circumstances (e.g., joint use of resources) that made measurement difﬁcult? Were these
circumstances handled appropriately?
Because cervical screening may be the secondary reason for consultation, including a full consultation cost for a cervical
screening visit in the evaluation could overestimate the cervical screening cost. To avoid this problem, in this study we used the
sample collection cost estimated by Moss et al. (adjusted to 2010 prices).64 This was based on the time required by the health
care provider to collect a cervical sample from women and included administration and staff costs
6. Were the cost and consequences valued credibly?
i. Were the sources of all values clearly identiﬁed? (Possible sources include market values, patient or client preferences
and views, policy-makers’ views and health professionals’ judgements)
All of the sources of the parameters included in the economic evaluation are provided in the report. The details of the sources
and methods used to derive the parameters for screening and diagnostic test characteristics, compliance with screening
and management recommendations, cost assumptions, QALY weight assumptions, vaccination coverage rate and population
sexual behaviour assumptions are provided
ii. Were market values employed for changes involving resources gained or depleted?
We attempted to include up-to-date values for all cost inputs
HPV primary screening tests were evaluated according to manufacturer-obtained costs. All costs were presented in pounds as
at financial year 2010
iii. Where market values were absent (e.g. volunteer labour), or market values did not reﬂect actual values (such as clinic
space donated at a reduced rate), were adjustments made to approximate market values?
All appropriate known values were taken into account
iv. Was the valuation of consequences appropriate for the question posed (i.e. has the appropriate type or types of
analysis – cost-effectiveness, cost–beneﬁt, cost–utility – been selected)?
Both cost-effectiveness analysis and cost–utility analysis were conducted to evaluate to measure the strategies associated
cost per life-years gained and cost per QALY gained. The two analyses allowed the study to simultaneously measure the
effect of the strategies on the direct clinical outcome as well as gains in the patient’s quality of life from reduced morbidity
and mortality
However, the cost–utility analysis using QALYs was found to be sensitive to the QALY weights assumptions and findings varied
greatly when using different QALY weight assumptions. Due to the uncertainties associated with the QALY weights
assumptions and because there is a paucity of data to inform the choice of QALY weights (health-state utilities) for HPV testing
when it is used as primary screening test and for the subsequent referral and management process, the primary outcome
for the study was considered to be life-years saved. This is appropriate to the analysis performed and takes into account the
availability of relevant data
continued
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7. Were costs and consequences adjusted for differential timing?
i. Were costs and consequences that occur in the future ‘discounted’ to their present values?
Yes. The cost, life-years and quality adjusted life-years occurred in the future are discounted by 3.5% per annum to their
present value
ii. Was there any justiﬁcation given for the discount rate used?
Yes. The 3.5% discount rate is recommended made by the National Institute for Health and Care Excellence based on the
recommendations of the UK Treasury
8. Was an incremental analysis of costs and consequences of alternatives performed?
i. Were the additional (incremental) costs generated by one alternative over another compared to the additional effects,
beneﬁts, or utilities generated?
Incremental cost-effectiveness ratios (using both life-years gained and QALY gained) among different primary HPV
testing strategies were evaluated. The findings are summarised in Tables 35 and 39. Figures 31–33, 37–40 show the
cost-effectiveness planes of the primary HPV testing strategies and comparators while life-years, QALY gained with different
QALY weights assumptions were used as the strategy’s effectiveness measurement
9. Was allowance made for uncertainty in the estimates of costs and consequences?
i. If data on costs and consequences were stochastic (randomly determined sequence of observations), were appropriate
statistical analyses performed?
Allowance was made for uncertainty in the estimation and both one-way and probabilistic sensitivity analysis techniques were
used and extensively employed
ii. If a sensitivity analysis was employed, was justiﬁcation provided for the range of values (or for key study parameters)?
One-way sensitivity analysis and PSA were performed to assess the robustness of model predictions
The parameters included in one-way sensitivity analyses were the relative test performance of cytology and HPV, colposcopy
test accuracy, inadequate rate of cytology and HPV test, compliance rate to routine screening recommendations, colposcopy
referral and follow-up referral, management of women who do not comply with colposcopy referral, proportion of HPV 16/18
infections among all type HPV infections in the population and the aggressiveness of disease natural history assumptions.
The range of the cytology and HPV test characteristics were informed by literature review as described in the report. Details
of the other parameters included in one-way sensitivity analysis are provided in Appendix 10–12
The model assumptions on the baseline and range for screening associated cost assumptions were based on the findings of
LBC/HPV pilot study and MAVARIC study. The unit cost of HPV testing used for primary HPV testing and genotyping were
assumed to be the average of four HPV test manufacturers. The baseline and range assumed for the diagnostic, precancerous
treatment and cancer treatment cost were obtained from Martin-Hirsch et al.35 and Sherlaw-Johnson et al.36 All cost data were
inflated to 2010 financial year value and details are provided in Appendix 13. The range of values used is justified in the report
A probabilistic sensitivity analysis was on a range of feasible sexual behaviour assumptions also conducted in this evaluation.
We conducted a separate modelling exercise to seek for sexual behaviour model input assumptions that are consistent with
the findings of NATSAL II survey and that the predicted HPV prevalence based on that sexual behaviour assumption is
consistent with the ARTISTIC trial findings. Thus, the range of assumptions included in the sensitivity analysis was justified.
This exercise resulted a set of assumptions fitted with these two targets and were used for the probabilistic analysis. Details
of the method used to generate the sexual behaviour model inputs assumptions were described in Appendix 16
iii. Were the study results sensitive to changes in the values (within the assumed range for sensitivity analysis, or within
the conﬁdence interval around the ratio of costs to consequences)?
The one-way sensitivity analyses found that the predicted incremental cost and incremental effectiveness of primary HPV
screening strategies were both sensitive to the relative test performance assumed for cytology test and HPV testing. In the case
if cytology testing is significantly more sensitive than baseline test characteristics, while HPV testing is less sensitive, then
current practice can be more effective than strategies considered in this sensitivity analysis. However under these conditions,
many of the primary HPV screening strategies are predicted to cost less than current practice. The model predictions are
also sensitive to the compliance with colposcopy referral and cytology/HPV follow-up referrals. Higher rates of compliance
improve the effectiveness and at the same time, increase the cost of primary HPV screening strategies when compared
with current practice management. These findings are described in detail in the report
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Excluding strategy 4 (co-testing) and its variants, all primary HPV testing strategies were found to be cost saving
compared with current practice under all sets of cost assumptions and strategy variants considered in the vaccinated cohort.
In unvaccinated cohorts, S2 and S3 (and S4) with 12 months’ follow-up of HPV-positive, triage-negative women were
found to be more costly than current practice under some, but not all, sets of cost assumptions (very few sets of assumptions
for S2)
Other parameters in the one-way sensitivity analysis, and sexual behaviour assumptions included in the probabilistic sensitivity
analysis, were found to have marginal impact on the model predicted outcome within the assumed ranges included for
the analyses
More details of the sensitivity analyses findings are described in Appendix 17
10. Did the presentation and discussion of study results include all issues of concern to users?
The presentation and discussion of study results considered a range of issues of concern to users including predicted health
outcomes, resource utilisation, life-years and QALYs saved, costs (including overall costs), practicalities and a discussion of
the results in both unvaccinated and vaccinated cohorts. Therefore, we believe that the major issues of concern to users
were addressed in this extensive report
i. Were the conclusions of the analysis based on some overall index or ratio of costs to consequences
(e.g. cost-effectiveness ratio)? If so, was the index interpreted intelligently or in a mechanistic fashion?
The conclusion of the analysis was made based on the overall predicted cost and effectiveness of each strategy compared with
current practice outcomes. Ratios of cost-effectiveness were not used as main outcomes because most strategies were
both less costly and more effective than current practice outcomes, and therefore we presented costs and effects in
disaggregated terms. We justified this in the text of the report
The index was interpreted with the presentation of disaggregated results and extensive discussion of the findings relevant to
the evaluation. See the scientific summary for an overview
ii. Were the results compared with those of others who have investigated the same question? If so, were allowances
made for potential differences in study methodology?
As described in the discussion section of the report, other economic evaluations of primary HPV screening have been
conducted in the Netherlands,56 Germany,57 Norway58 and Canada.59 However, the results on cost-effectiveness would vary
across settings, due to differences in the current practice management in different settings (screening recommendations
and local behaviour with compliance), test characteristics for cytology and HPV testing and local prices for cytology tests, HPV
tests and diagnostic and treatment services. In addition to these differences, we believe that our detailed consideration of
modelling screening management as observed in England, use of ARISTIC data for validation, the large number of primary
HPV screening strategies considered and our explicit and detailed consideration of the effects of HPV vaccination, mean that
this work provides a comprehensive and major new insight into the cost-effectiveness of HPV screening strategies in England
We were also unable to identify any equivalently detailed evaluations that took into account the effect of HPV vaccination as
detailed in this report
iii. Did the study discuss the generalisability of the results to other settings and patient/client groups?
The study did discuss the generalisability of the results. The results cannot always be directly comparable with other settings.
Other countries may have different screening regimes currently in place, and therefore the results of primary HPV screening
strategies would need to be evaluated against a different comparator. In addition, sexual behaviour, vaccination uptake,
compliance with routine screening and follow-up management, and costs of screening tests and treatment can vary greatly
from setting to setting, and therefore the results presented in the report should be restricted to England. That said, the
promising conclusion that primary HPV screening strategies are more effective and less costly should encourage other
countries to perform similar evaluations to investigate the potential benefits of changing from primary cytology to primary HPV
screening management strategies
iv. Did the study allude to, or take account of, other important factors in the choice or decision under consideration
(e.g. distribution of costs and consequences, or relevant ethical issues)?
continued
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Yes. The economic evaluation has identified an element important to the practical realisation of primary HPV screening, which
needs to be considered to ensure that implementation of primary HPV screening does not result in a loss of screening
effectiveness compared with current screening practice. The findings of the current analysis emphasise that in order for
primary HPV screening to maintain its effectiveness overall, considerable attention needs to be paid to the optimal
management of HPV-positive/cytology-negative women (i.e. an intermediate risk group not immediately referred to
colposcopy). Because triage testing with cytology has imperfect sensitivity, some women in this group will be at risk of
progression. Delay in follow-up in this group would result in a higher proportion of women with disease progression.
Furthermore, compliance with follow-up in this group is extremely important. In addition, the overall findings of the report
considered not only the findings of the cost-effectiveness analysis, but also those of the clinical evaluation, and the
practicalities involved in implementing primary HPV screening in England
v. Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme
given existing ﬁnancial or other constraints, and whether any freed resources could be redeployed to other
worthwhile programmes?
The economic evaluation has estimated the annual screening associated cost and annual number of cytology tests, HPV tests,
colposcopy examinations, histology evaluations, treatment for cervical precancerous lesions that would occurred in
England for current practice and for each of the primary HPV screening strategies included in the evaluations. The study
has discussed the feasibility of implementing primary HPV screening and the practical issues related to screening strategies
that incorporated genotyping for HPV 16/18 and direct referral of women positive for these HPV types to colposcopy
according to these estimates. See the Scientific Summary and the Discussion section in the report for details
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Appendix 20 Standard checklist for reporting
studies of diagnostic accuracy
Section and topic Item no. On page no.
TITLE/ABSTRACT/
KEYWORDS
1 Identify the article as a study of diagnostic accuracy (recommend MeSH
heading ‘sensitivity and speciﬁcity’)
vii
INTRODUCTION 2 State the research questions or study aims, such as estimating
diagnostic accuracy or comparing accuracy between tests or across
participant groups
1
METHODS
Participants 3 The study population: the inclusion and exclusion criteria, setting and
locations where data were collected
5
4 Participant recruitment: was recruitment based on presenting symptoms,
results from previous tests, or the fact that the participants had received
the index tests or the reference standard?
5, 6
5 Participant sampling: was the study population a consecutive series of
participants deﬁned by the selection criteria in items 3 and 4? If not,
specify how participants were further selected
5, 6
6 Data collection: was data collection planned before the index test and
reference standard were performed (prospective study) or after
(retrospective study)?
10
Test methods 7 The reference standard and its rationale 5
8 Technical speciﬁcations of material and methods involved including how
and when measurements were taken, and/or cite references for index
tests and reference standard
11, 12
9 Deﬁnition of and rationale for the units, cut-offs and/or categories of the
results of the index tests and the reference standard
11, 12
10 The number, training and expertise of the persons executing and reading
the index tests and the reference standard
5, 8
11 Whether or not the readers of the index tests and reference standard
were blind (masked) to the results of the other test and describe any other
clinical information available to the readers
8
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy,
and the statistical methods used to quantify uncertainty (e.g. 95%
conﬁdence intervals)
10
13 Methods for calculating test reproducibility, if done N/A
RESULTS
Participants 14 When study was performed, including beginning and end dates
of recruitment
25
15 Clinical and demographic characteristics of the study population (at least
information on age, gender, spectrum of presenting symptoms)
28
16 The number of participants satisfying the criteria for inclusion who did or
did not undergo the index tests and/or the reference standard; describe
why participants failed to undergo either test (a ﬂow diagram is strongly
recommended)
28
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Section and topic Item no. On page no.
Test results 17 Time-interval between the index tests and the reference standard, and any
treatment administered in between
28
18 Distribution of severity of disease (deﬁne criteria) in those with the target
condition; other diagnoses in participants without the target condition
25–30
19 A cross tabulation of the results of the index tests (including indeterminate
and missing results) by the results of the reference standard; for
continuous results, the distribution of the test results by the results of the
reference standard
25–87
20 Any adverse events from performing the index tests or the reference
standard
N/A
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty
(e.g. 95% conﬁdence intervals)
10
22 How indeterminate results, missing data and outliers of the index tests
were handled
10
23 Estimates of variability of diagnostic accuracy between subgroups of
participants, readers or centres, if done
N/A
24 Estimates of test reproducibility, if done N/A
DISCUSSION 25 Discuss the clinical applicability of the study ﬁndings 89–95
N/A, not applicable.
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